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Abstract 
The NMDA Receptor Transmembrane Region in Receptor Function and Inhibition 
 
Madeleine Ruth Wilcox, PhD 
 
University of Pittsburgh, 2019 
 
 
 
 
NMDA Receptors (NMDARs) are glutamate- and glycine- gated ion channels present at 
most excitatory synapses in the mammalian brain. NMDARs are typically composed of four 
subunits, two GluN1 and two GluN2, which each contain a transmembrane domain (TMD). The 
TMDs of all four subunits assemble to form the NMDAR ion channel, which opens in response to 
agonist binding in the extracellular region. The TMD is critical to ion permeation and channel 
block of NMDARs and small alterations in the TMD can have powerful effects on receptor 
function. This dissertation discusses work by myself and my coauthors centered around the 
NMDAR TMD. My coauthors and I first examined the functional effects of mutating a tryptophan 
residue present at homologous sites in the GluN1 and GluN2 subunit TMDs. We discovered that 
the conserved tryptophan modulates NMDAR function in a subunit-dependent manner. We next 
explored the kinetics of NMDAR recovery from inhibition by the therapeutically relevant 
NMDAR open channel blockers memantine and ketamine. Examination of the kinetics of 
NMDAR unblock by memantine and ketamine led us to conclude that memantine, but not 
ketamine, inhibits NMDARs through an additional mechanism that is distinct from traditional open 
channel block. Building on data from the Johnson lab and others, we characterized a little-studied 
mechanism of NMDAR inhibition by memantine. Our data suggest that memantine can inhibit 
NMDARs by entering the plasma membrane and transiting to the NMDAR ion channel through a 
membrane-to-channel fenestration. We revealed that several NMDAR blockers in addition to 
memantine inhibit NMDARs through the same fenestration-dependent mechanism. 
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1.0 General Introduction to Chemical Excitatory Neurotransmission 
Every thought we think and sensation we experience arises from the nervous system. The 
nervous system contains billions of neurons: specialized cells that transmit information throughout 
the body. Neurons communicate with one another to give rise to both conscious and unconscious 
aspects of being. Synapses, which allow efficient chemical transmission of information between 
neurons, can form where the axon of one neuron meets the dendrite of another. Axon terminals 
release chemical signals called neurotransmitters from the presynaptic region onto dendrites in the 
postsynaptic region. Postsynaptically, dendrites contain many neurotransmitter receptors across 
the synaptic cleft from the axon terminal, prepared to react to presynaptic signals. Binding of 
released neurotransmitters to postsynaptic neurotransmitter receptors can initiate depolarizing 
electrical potentials in the postsynaptic cell that spread into the neuronal cell body. These 
depolarizing potentials can initiate a propagating action potential that causes the release of 
neurotransmitters from the depolarized cell’s axon terminals. This mechanistic loop of neuronal 
communication is at the heart of all experience. 
Neurotransmitter binding to postsynaptic receptors causes receptors to open and pass ions 
across the cellular membrane. Numerous neurotransmitter receptors are present in the postsynaptic 
region, including ionotropic glutamate receptors (iGluRs). iGluRs are ligand-gated ion channels 
that open in response to glutamate binding. When iGluR channels are open, cations can flow 
through them to transport messages across membranes. iGluRs mediate fast excitatory 
transmission in the brain and are present at most excitatory synapses in the mammalian central 
nervous system (CNS).  
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There are three main classes of iGluRs: kainate receptors, alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) 
receptors. AMPA receptors (AMPARs) and NMDA receptors (NMDARs) are found ubiquitously 
in the brain, while kainate receptors (KARs) have a more restricted expression pattern. NMDARs, 
AMPARs and KARs have been implicated in synaptic plasticity, which is thought to be one of the 
most important substrates of learning and memory. NMDARS have many unique and 
physiologically important characteristics among iGluRs that make them paramount to the initiation 
of many types of synaptic plasticity. The work discussed in this dissertation focuses predominantly 
on NMDARs. 
1.1 Physiological Roles of NMDA Receptors 
Upon activation, NMDARs pass positively charged ions including Ca2+, Na+, and K+ 
through their pores. Ca2+ is a central signaling molecule in the CNS and acts to regulate many 
cellular processes (Traynelis et al., 2010b). Intracellular Ca2+ is maintained at low concentrations 
by physiological buffers, ion pumps and exchangers. When Ca2+ enters the cell through channels 
or receptors, it can cause various changes in cell status. While most AMPARs and KARs have low 
permeability to Ca2+, NMDAR Ca2+ permeability is relatively high. NMDARs are inhibited by 
membrane voltage (Vm)-dependent Mg
2+ block at cellular resting potentials. By combining 
agonist-dependent entry of Ca2+ into cells with Vm-dependent Mg
2+ block, NMDARs act as 
“coincidence detectors”. Significant ion flux occurs only when agonist binds and relief of Vm-
dependent Mg2+ block occurs. NMDARs activate when two co-agonists, glutamate and glycine (or 
D-serine), bind (Traynelis et al., 2010b). Since the glycine binding sites are often occupied by 
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ambient glycine, glutamate binding is typically the limiting step in NMDAR activation 
(McNamara and Dingledine, 1990). Therefore, the ion channels (pores) of postsynaptic NMDARs 
open when glutamate is released from presynaptic terminals. Relief of Vm-dependent Mg
2+ block 
requires depolarization of the postsynaptic cell, which can occur with postsynaptic activity. Thus, 
NMDARs pass ions, including the important signaling ion Ca2+, during simultaneous pre- and 
post-synaptic activity. 
1.2 NMDARs in Learning and Memory 
The coincidence detecting capability of NMDARs is crucial to their function in long-term 
potentiation (LTP) and long-term depression (LTD) of synaptic efficacy, which are important for 
many types of memory. NMDARs allow significant Ca2+ into cells when presynaptic stimulation 
is coupled with postsynaptic depolarization (Nicoll, 2017). This pairing of conditions mimics the 
physiological requirements for NMDARs to pass significant current: (1) binding of glutamate, and 
(2) relief of Mg2+ block. These conditions are typically induced experimentally by a strong tetanus 
(e.g. 100 Hz for 1 s). The large influx of Ca2+ through NMDARs during a tetanus activates 
postsynaptic Ca2+-dependent proteins that promote an increase in synaptic strength through 
numerous proposed mechanisms including AMPAR phosphorylation (Lee, 2006), insertion of 
AMPARs into the postsynaptic density (PSD) (Luscher and Malenka, 2012) and modulation of 
protein transcription (Sacktor, 2008). These processes increase synaptic efficacy and sustain it over 
a long period of time (i.e. LTP). In addition to LTP, LTD is critical for learning and memory. 
NMDAR-dependent LTD is typically induced through low-frequency presynaptic stimulation that 
does not induce large postsynaptic depolarization (Luscher and Malenka, 2012). This allows for 
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glutamate binding to NMDARs without significant Mg2+ unblock, which leads to a small amount 
of Ca2+ influx through NMDARs (due to incomplete Mg2+ block of NMDARs). Repeated low-
level Ca2+ influx through NMDARs leads to AMPAR removal from the PSD, reducing synaptic 
efficacy (Nicoll, 2017).  
1.3 NMDARs in Disease 
Due to the critical role of NMDARs in the mammalian CNS, alterations in NMDAR 
function often induce or exacerbate pathogenesis. In recent years, mutations in NMDAR subunits 
have been linked to numerous neurodevelopmental (Burnashev and Szepetowski, 2015, Chen et 
al., 2017, Fedele et al., 2018, Vyklicky et al., 2018, Yuan et al., 2014) and seizure disorders (Addis 
et al., 2017, Gao et al., 2017, Vyklicky et al., 2018, Yuan et al., 2014) in humans. NMDAR 
dysfunction is implicated in many disorders including Parkinson’s Disease (Oh et al., 1998, Calon 
et al., 2002, Nash and Brotchie, 2002, Tikhonov et al., 2006), fragile X syndrome (Toft et al., 2016, 
Lau and Tymianski, 2010), and stroke (Wu and Tymianski, 2018, Li and Wang, 2016). 
Involvement of NMDARs in several prevalent conditions is detailed below to illustrate the 
importance of NMDARs in disease. 
 Alzheimer’s disease  
 Alzheimer’s disease is the sixth leading cause of death in the United States (US). In 2018, 
long-term care and hospice services for Alzheimer’s disease patients cost the US an estimated 
$277 billion (Alzheimer’s Association (2018)). While NMDARs are critical for synaptic plasticity, 
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overactive NMDARs cause excessive Ca2+ influx and excitotoxicity. Excitotoxicity is central to 
the pathogenesis of Alzheimer’s disease. NMDAR localization (synaptic vs. extrasynaptic) also 
seems to play a role in Alzheimer’s disease pathogenesis. Activation of synaptic NMDARs is 
linked to cell survival, while activation of extrasynaptic NMDARs is associated with cell death 
and correlates with the pathological changes that occur in Alzheimer’s disease (Hardingham and 
Bading, 2010, Wang and Reddy, 2017). Increases in extracellular glutamate have also been shown 
to occur in Alzheimer’s disease and may contribute to overactivation of NMDARs and cell death 
(Wang et al., 2013). Additional evidence indicates that a oligomers and overexpression of tau 
protein, which are consistently tied to pathogenesis in Alzheimer’s disease, cause dysregulation of 
NMDARs (Wang and Reddy, 2017, Liu et al., 2019, Zhao et al., 2017). In a sort of vicious cycle, 
activation of extrasynaptic NMDARs drives tau overexpression, which subsequently promotes the 
activity of GluN2B-containing receptors (Liu et al., 2019). a oligomers have been shown to 
activate NMDARs in neurons (Ferreira et al., 2012) and heterologous expression systems (Texido 
et al., 2011, Domingues et al., 2007). a oligomers have also been shown to induce synaptic 
depression, promoting LTD and preventing LTP, which may contribute to dementia in 
Alzheimer’s disease (Liu et al., 2019).  
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Memantine is an NMDAR inhibitor and a Food and Drug Administration (FDA)-approved 
treatment for moderate-to-severe Alzheimer’s disease (Thomas and Grossberg, 2009). Evidence 
suggests that memantine preferentially inhibits NMDARs exposed to high intracellular Ca2+, which 
may partially explain its clinical efficacy (Glasgow et al., 2017). Additionally, memantine 
preferentially inhibits GluN2C and GluN2D-containing receptors in physiological Mg2+ 
(Kotermanski and Johnson, 2009). GluN2C and GluN2D-containing receptors in the cortex are 
preferentially expressed on adult interneurons (Rudolf et al., 1996, Yamasaki et al., 2014, 
Standaert et al., 1996), which suggest that memantine may act through promoting cortical 
disinhibition (Povysheva and Johnson, 2016). 
 Schizophrenia 
Schizophrenia is a disabling mental condition that affects nearly 1% of the world’s 
population (Balu, 2016) and is influenced by both environmental and genetic factors (Moran et al., 
2016). NMDAR dysfunction has long been implicated in the development of schizophrenia 
pathology. Mutations in NMDARs and PSD proteins are linked to heritable schizophrenia 
(Harrison and Weinberger, 2005, Kirov et al., 2012) and hypofunction of NMDARs is proposed 
to be critical to schizophrenic pathogenesis (Snyder and Gao, 2013). The NMDAR hypofunction 
hypothesis of schizophrenia is supported by numerous findings. Administration of several 
NMDAR open-channel blockers including ketamine and phencyclidine (PCP) to healthy 
individuals results in psychotomimetic (schizophrenia-like) symptoms (Javitt and Zukin, 1991, 
Krystal et al., 1994). Low doses of NMDAR inhibitor that do not produce psychotomimetic effects 
in healthy individuals reproduce other physiological changes seen in schizophrenia such as eye-
tracking abnormalities and increased subcortical dopamine release (Radant et al., 1998, Kegeles 
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et al., 2000). Inhibition of NMDARs by PCP causes schizophrenia-associated neurochemical 
alterations in animal models of schizophrenia (Morris et al., 2005) and NMDAR dysregulation is 
frequently observed in postmortem tissue of schizophrenic individuals (Snyder and Gao, 2013). 
  Depression 
Major depression is among the most ubiquitous mental disorders in the United States. 
Excessive NMDAR activation is implicated in depression, and several classes of NMDAR 
inhibitors have shown efficacy in depression treatment (Ates-Alagoz and Adejare, 2013). Glycine-
site antagonists, allosteric NMDAR inhibitors, and open-channel blockers including ketamine 
have been suggested to improve depressive symptoms in pre-clinical studies (Kiss et al., 2012, 
Maj et al., 1994, Paul et al., 1992, Maj et al., 1992, Trullas and Skolnick, 1990). Despite potential 
unwanted side effects at therapeutic doses (e.g. psychotomimetic effects, see Section 1.3.2), 
mounting evidence suggests that ketamine is effective in the treatment of depression (Schwartz et 
al., 2016, Duman, 2018). The FDA recently approved a ketamine-containing nasal spray for 
treatment-resistant depression (2019). However, it is unclear whether ketamine’s efficacy stems 
from inhibition of NMDARs or separate effects (Duman, 2018, Zanos et al., 2016).  
1.4 Properties of NMDARs 
All functional NMDARs are composed of four subunits (i.e. “tetrameric”). Two of the four 
subunits in functional NMDARs are GluN1 subunits, which bind glycine. The other two subunits 
can be any combination of the GluN2(A-D) or GluN3(A-B) subunits. GluN2 subunits bind 
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glutamate, while GluN3 subunits bind glycine. Therefore, GluN1/3 receptors (receptors containing 
two GluN1 and two GluN3 subunits) are glycine-gated, and GluN1/2 receptors (receptors 
containing two GluN1 and two GluN2 subunits) are glycine-and-glutamate-gated. NMDARs that 
contain two GluN1 subunits and two of the same GluN2 or GluN3 subunits are referred to as 
diheteromers (e.g. GluN1/2A), while NMDARs that contain two GluN1 subunits and two different 
GluN2 or GluN3 subunits are called triheteromers (e.g. GluN1/2A/3A). This dissertation focuses 
specifically on GluN1/2 diheteromers and does not include significant discussion of triheteromeric 
or GluN3-containing NMDARs. However, the topics discussed in this work may have important 
implications for triheteromeric and GluN3-containing NMDARs. Recently, new expression 
techniques have assisted research into triheteromeric NMDARs (Hansen et al., 2014, Stroebel et 
al., 2014). For review, see Stroebel et al (Stroebel et al., 2018).  
 GluN1 subunit expression  
NMDAR subunit expression varies throughout development. GluN1 mRNA expression 
begins as early as embryonic day (E) 14 in rats, peaks around the third postnatal week, and then 
declines slightly into adulthood (Monyer et al., 1992). GluN1 is present in 8 splice variants: 
GluN1-1a, GluN1-1b, GluN1-2a, GluN1-2b, GluN1-3a, GluN1-3b, GluN1-4a and GluN1-4b 
(Dingledine et al., 1999). GluN1 splice variants have different combinations of three alternatively 
spliced exons: exon 5 in the amino terminal domain (NTD) and exons 21 and 22 in the C-terminal 
Doman (CTD), referred to as C1 and C2 cassettes, respectively (Figure 1). Exon 22 contains an 
alternative splice site that can lead to splicing out part of exon 22 and the inclusion of the C2’ 
cassette. The eight GluN1 splice variants are diagrammed in Figure 1. The “a” label indicates exon 
5’s absence, and “b” indicates its presence (Dingledine et al., 1999). GluN1 splice variants that 
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lack exon 5 (GluN1-a) are expressed widely throughout the brain, while GluN1 splice variants that 
include exon 5 (GluN1-b isoforms) are restricted to specific areas including the sensorimotor 
cortex and thalamus. The GluN1-2a and GluN1-2b are also widely expressed throughout the brain, 
while the GluN1-1a and GluN1-2b isoforms are in rostral brain and GluN1-4a and GluN1-4b 
isoforms are in caudal brain. GluN1-3 expression it is barely detectable at birth and remains at low 
levels in cortex and hippocampus into adulthood (Ewald and Cline, 2009). Splice variants can 
imbue NMDARs with unique properties including susceptibility to NMDAR modulators (see 
Section 1.6).  
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Figure 1 GluN1 splice variants 
 
Diagram of the eight GluN1 splice variants and their corresponding names. GluN1 splice 
variant expression varies with developmental stage and brain region, and can influence NMDAR 
properties, along with the GluN2 or GluN3 subunits present in an intact receptor. Figure adapted 
from (Dingledine et al., 1999).  
 GluN2 subunit expression 
Like GluN1 splice variant expression, GluN2 subunit expression varies with brain region 
and developmental stage (Monyer et al., 1994). GluN2B and GluN2D receptor mRNAs are present 
prenatally in rat CNS. GluN2B mRNA expression peaks around postnatal day (P) 12, GluN2D 
expression peaks around P7, and both decline as the animal reaches adulthood. Expression of 
GluN2A mRNA begins postnatally, with significant expression apparent by P7. GluN2A 
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expression increases into animal adulthood, when it plateaus. Similarly, GluN2C mRNA 
expression begins shortly after birth and increases until it reaches a plateau in mature animals. 
GluN2C and GluN2D expression are more spatially restricted than GluN2A and GluN2B, with 
GluN2C present mainly in the cerebellum and GluN2D present mainly in the midbrain. However, 
GluN2C and GluN2D receptors are present in interneuron subtypes in the adult hippocampus 
(Monyer et al., 1994). 
 NMDAR structure 
In the intact NMDAR, GluN1 and GluN2 or GluN3 subunits are arranged in an alternating 
arrangement (Figure 2A) with GluN1 subunits across from one another and GluN2 subunits across 
from one another (Karakas and Furukawa, 2014, Riou et al., 2012). Each subunit contains an 
extracellular NTD and agonist binding domain (ABD), a transmembrane domain (TMD), and 
intracellular CTD (Figure 2B,C). 
The TMD of each subunit is structured similarly, with three transmembrane helices (M1, 
M3, M4), and a re-entrant loop (M2) that lines the ion channel (Figure 2B,C). The M3 regions 
compose the channel gate and M2 regions form the ion selectivity filter. The M2 and M3 regions 
together form the ion conduction pathway in NMDARs. The M1 and M4 regions sit external to 
M2 and M3 regions (see Section 1.5 for more information on the TMD). 
The ABD lies atop the TMD, while the NTD is the most extracellular portion of the 
receptor. The ABD and NTD in intact NMDARs are each composed of four subunits in a “dimer 
of dimers” organization (Traynelis et al., 2010b). Interestingly, domain swapping occurs between 
the NTD and ABD: the subunits composing dimers in the ABD are different from those composing 
dimers in the NTD, though each layer maintains a GluN1-GluN2-GluN1-GluN2 arrangement 
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(Karakas and Furukawa, 2014, Lee et al., 2014). The NTD of each subunit is composed of an upper 
(R1) and lower (R2) lobe that, together, resemble a clamshell. The S1 and S2 amino acid segments 
form most of the upper (D1) and lower (D2) lobe, respectively, of the clamshell-like LBD. S1 
connects to the M1 domain and S2 forms a large loop that joins the M3 and M4 regions (Figure 
2B) (Traynelis et al., 2010b).  
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Figure 2 Structure of NMDARs 
 
A, diagram of an NMDAR composed of two GluN2 and two GluN2 subunits showing the 
alternating GluN1-GluN2-GluN1-GluN2 arrangement of subunits. B, blow-up of cross section 
showing two GluN2 subunits in the membrane. NTD, amino terminal domain; ABD, agonist 
binding domain; TMD, transmembrane domain; CTD, C-terminal domain. Within the TMD, 
transmembrane helices M1, M3, and M4, and re-entrant loop M2 are shown. M2 regions from all 
four subunits line the pore in intact NMDARs. S1 connects to M1 and forms most of the lower 
lobe of the ABD. S2 connects to M3 and forms most of the upper lobe of the ABD. R1 and R2 are 
the upper and lower lobes of the NTD, respectively. C, crystal structure of GluN1/2B NMDAR 
(PBD 4PE5) with receptor domains labelled. The M3 bundle crossing within the TMD (proposed 
channel gate) is also labelled. The crystal structure does not contain the CTD. Image in B was 
adapted from (Siegler Retchless et al., 2012); image in C was adapted from (Glasgow et al., 2015). 
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  Subtype dependence of NMDAR properties 
The GluN2 subunits present in an intact NMDAR imbue receptors with specific properties. 
Many of the properties of NMDARs can be categorized into “gating and ligand-binding properties” 
and “channel properties” (Figure 3). Gating and ligand-binding properties include the probability 
of the receptor being open (Popen), agonist potency, Zn
2+ sensitivity, proton sensitivity, and 
ifenprodil sensitivity (Zn2+, proton, and ifenprodil sensitivity are discussed in detail in section 1.6). 
Channel properties include Mg2+ sensitivity, selective permeability to Ca2+, single-channel 
conductance and inherent membrane voltage (Vm) dependence of gating.  
 Gating and ligand binding properties 
Gating and ligand binding properties vary with the GluN2 subunits present in the intact 
NMDAR (Figure 3B). GluN1/2A receptors have the highest maximal Popen, about 0.5, GluN1/2B 
receptors have a maximal Popen of about 0.1, GluN1/2C and GluN1/2D receptors have a maximal 
Popen of about 0.01 (Wyllie et al., 1998, Erreger et al., 2005, Chen et al., 1999, Dravid et al., 2008b, 
Gielen et al., 2009, Yuan et al., 2009, Glasgow et al., 2015). Glutamate potency increases from 
GluN1/2A to GluN1/2D receptors (glutamate EC50 GluN1/2A = 3.3 M; GluN1/2B = 2.9 M; 
GluN1/2C = 1.7 M; GluN1/2D = 0.51 M) (Traynelis et al., 2010b). Glycine potency varies 
similarly between receptor subtypes (glycine EC50 GluN1/2A = 1.1 μM; GluN1/2B = 0.72 μM; 
GluN1/2C = 0.34 μM; GluN1/2D = 0.13 μM) (Traynelis et al., 2010b). Subtype dependence of 
glutamate and glycine potency and maximal probability of being open (max Popen) are influenced 
by the GluN2D NTD and NTD-LBD linker (Figure 3A) (Yuan et al., 2009, Gielen et al., 2009). 
The weighted time constant (w) of deactivation following rapid glutamate removal also varies 
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significantly with the identity of the GluN2 subunits. GluN1/2A receptors have the fastest w (~50-
130 ms), followed by GluN1/2B and GluN1/2C (~300-400 ms), and GluN1/2D subunits (>1 
second) (Yuan et al., 2009, Monyer et al., 1992, Vicini et al., 1998, Wyllie et al., 2013, Monyer et 
al., 1994). The w of NMDARs plays an important role in determining the time course of excitatory 
post synaptic potentials (EPSCs), along with total charge transfer when NMDARs are activated 
(Lester et al., 1990, Tovar and Westbrook, 2012, Dingledine et al., 1999). 
 Channel properties 
NMDARs can be split into two categories with regard to channel properties: GluN1/2A-
like and GluN1/2D-like (Figure 3B). GluN1/2B receptors, which have similar channel properties 
to GluN1/2A receptors, are considered GluN2A-like; GluN1/2C receptors, which have similar 
channel properties to GluN1/2D receptors, are considered GluN1/2D-like. GluN1/2A-like 
receptors show higher potency of Mg2+ block (IC50 at -65 mV ~45 M) than GluN1/2D-like 
receptors (IC50 at -65 mV ~200 M) (Siegler Retchless et al., 2012). Siegler Retchless et al. 
examined the relative Ca2+ permeability of NMDAR subtypes by calculating reversal potentials in 
various concentrations of extracellular Ca2+. Ca2+ permeability was found to be greater in 
GluN1/2A-like receptors than GluN1/2D receptors (Burnashev et al., 1995, Schneggenburger, 
1996). GluN1/2A-like and GluN1/2D-like receptors show differences in single channel 
conductance (Burnashev et al., 1995, Schneggenburger, 1996, Siegler Retchless et al., 2012). 
GluN1/2D-like receptors show a main conductance state ~35 pS and subconductance state of ~20 
pS while GluN1/2A-like receptors show a main conductance single-channel conductance of ~50 
pS, with a ~40 pS subconductance (Siegler Retchless et al., 2012, Stern et al., 1992, Stern et al., 
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1994, Wyllie et al., 1996). Inherent Vm dependence of gating occurs in NMDARs and was found 
to be larger in GluN1/2A and GluN1/2B receptors compared to GluN1/2D receptors (Siegler 
Retchless et al., 2012, Clarke et al., 2013, Clarke and Johnson, 2008). Siegler Retchless et al. 
identified a site in GluN2 subunits, called the “GluN2 S/L site” that dictates the subtype 
dependence of channel properties including single-channel conductance, Ca2+ permeability, Mg2+ 
inhibition (Figure 3A). Subsequent work revealed that the subtype dependence of inherent Vm 
dependence of gating also depends on the GluN2 S/L site (Clarke et al., 2013). The GluN2 S/L 
site is a serine (S) in GluN2A and GluN2B receptors, and a leucine (L) in GluN2C and GluN2D 
receptors. Astoundingly, mutation of the GluN2 S/L site in GluN2A receptors (GluN2A(S632)) to 
leucine results in a nearly complete switch of GluN2A-like channel properties to GluN2D-like 
channel properties.  
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Figure 3 NMDAR structure and subtype dependent function 
 
A, cartoon of NMDAR GluN1/2 receptor in membrane (top). Bottom, schematic of a single 
GluN2 subunit with the GluN2 S/L site, NTD – ABD linker, and ion channel labelled. B, table of 
subtype-dependent NMDAR gating and ligand-binding properties, which are GluN2 NTD-
dependent, and subtype-dependent channel properties, which depend on the GluN2 S/L site. Figure 
adapted from (Glasgow et al., 2015). 
1.5 The Structural and Functional Role of the TMD 
As outlined in Section 1.4.3, the TMD contains three transmembrane helices M1, M3 and 
M4, and a re-entrant loop M2 that lines the ion channel (Figure 1A-C, Figure 4). The TMD is 
central to NMDAR function and its structural components contribute to receptor gating, Mg2+ 
block, and Ca2+ permeability. 
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 Determinants of gating 
 The M3 transmembrane helices from each subunit in an assembled receptor form a 
“bundle crossing” near the extracellular side of the membrane (Figure 3C, 4A). The M3 bundle 
crossing is thought to act as the channel gate. When the tips of the M3 regions are huddled together 
near the extracellular side of the membrane, they form a physical block between the extracellular 
space and the ion channel (Song et al., 2018). The M3 regions splay apart during receptor 
activation and allow access between the extracellular solution and the channel. The M3 regions 
are linked to the ABD through a short linker, which plays an important role in coupling agonist 
binding with channel opening. 
The M3s house an important amino acid motif, SYTANLAAF, that is almost fully 
conserved in animal iGluRs (Hansen et al., 2018). This highly conserved region is located near the 
bundle crossing in intact receptors. Mutation of the eighth residue in the nine-residue 
SYTANLAAF motif, Alaine (A), to threonine (T) (“A8T”) in the 2 glutamate receptor was found 
to cause lurching ataxic movements in mice containing a single copy (called “lurcher” mice) 
(Phillips, 1960, Zuo et al., 1997). Mice homozygous for the A8T mutation died at birth. The A8T 
mutation was found to cause constitutive (i.e. agonist-independent) activation of 2 receptors that 
resulted in cerebellar neurodegeneration and ataxia (Zuo et al., 1997). Similarly, modification of 
several locations in the SYTANLAAF motif in NMDARs generate constitutively open channels 
(Sobolevsky et al., 2007, Kashiwagi et al., 2002, Jones et al., 2002, Yuan et al., 2005, Beck et al., 
1999). The extreme conservation of the SYTANLAAF motif, along with decoupling of agonist 
binding and gating in NMDAR SYTANLAAF mutant receptors suggest that this motif is critical 
for normal NMDAR function. Recent evidence suggests that the SYTANLAAF motif may interact 
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with the pre-M1 (Figure 4B,C) and pre-M4 regions located just extracellular to the TMD to 
influence gating (Chen et al., 2017, Fedele et al., 2018). 
Work by Amin et al. has revealed that the M4 segment also plays an important role in 
receptor gating. A conserved glycine on the extracellular side of the M4 region was found to be 
crucial for receptor activation, serving as a hinge that allows pore opening (Amin et al., 2018). In 
GluN1 and GluN2 subunits, mutations at the conserved glycine increased mean closed times and 
altered receptor deactivation. In a separate study, Amin et al. conducted a tryptophan scan of the 
GluN1 and GluN2A M4 regions. The introduction of a large, bulky tryptophan at many regions in 
the M4 resulted in substantially altered gating, and mutation of residues at the extracellular end of 
the M4 resulted in receptors that failed to gate altogether. This suggests that the M4 region 
participates in important gating interactions (Amin et al., 2017).  
Investigation of NMDAR inhibition by ethanol suggested that intersubunit interfaces in the 
TMD are important for gating. Ethanol modulates NMDAR gating (Peoples et al., 1997, Wright 
et al., 1996). Ren et al. identified residues along the GluN1 M3 – GluN2A M4 and GluN1 M4 – 
GluN2A M3 interfaces that are critical to ethanol sensitivity (Ren et al., 2012). Functional residue 
interactions that influence ethanol sensitivity and receptor deactivation were found between the 
GluN1(G638) and GluN2A(M823), GluN1(F639) and GluN2A(M823), GluN1(M818) and 
GluN2A(P636), and GluN1(L819) and GluN2A(F636) positions. The last pair was also found to 
influence desensitization. Similarly, six pairs of residues at the GluN1 M3 – GluN2B M4 and 
GluN1 M4 – GluN2B M3 interfaces were found to influence ethanol sensitivity in GluN1/2B 
receptors (Zhao et al., 2016). Additionally, work by Buck et al. suggested a role for GluN1 M2 – 
GluN2 M3 interface in NMDAR gating. Mutation of GluN1(W611), predicted to face the GluN2 
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M3 region (Siegler Retchless et al., 2012), to leucine caused increased channel mean open time 
(Buck et al., 2000).  
 
 
Figure 4 Arrangement of TMD regions 
 
A, TMD of NMDAR from PDB 4TLM (Lee et al., 2014) with residues missing in the TMD 
modeled (Amin et al., 2017). GluN1 subunits are in blue and magenta; GluN2B subunits are in red 
and green. “Bundle crossing” where M3 regions come together near the extracellular (ABD-
proximal) end of the TMD of the membrane is shown from the side. B, View of organization within 
the GluN2B TMD showing the relative arrangement of the M1-M4, pre-M1 and pre-M4 regions. 
C, View of organization within the GluN1 TMD showing the relative arrangement of the M1-M4, 
pre-M1 and pre-M4 regions. Figure adapted from Pang et al (Pang and Zhou, 2017). 
 Determinants of Mg2+ block and Ca2+ permeability 
The M2 reentrant loop is composed of a helical segment and an extended region. The 
extended region greatly influences ion permeation and block in NMDARs. The extended region 
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of each subunit contains a residue called the Q/R/N site, which is a critical determinant of Ca2+ 
permeability (Burnashev et al., 1992a, Burnashev et al., 1992b, Egebjerg and Heinemann, 1993), 
single-channel conductance (Swanson et al., 1997, Swanson et al., 1996, Traynelis and Wahl, 
1997), and channel block of iGluRs (Burnashev et al., 1992b, Mori et al., 1992, Kashiwagi et al., 
2002, Bowie and Mayer, 1995). NMDARs have an asparagine at the Q/R/N site, called the N-site 
in NMDARs. The asparagines at the N-site in GluN1 and GluN2 subunits, and at the neighboring 
N+1 site in GluN2 subunits, have been shown to be critical for Mg2+ block and Ca2+ permeability 
(Burnashev et al., 1992b, Kashiwagi et al., 2002, Kuner and Schoepfer, 1996, Mesbahi-Vasey et 
al., 2017).  
In addition to residues in the selectivity filter, non-pore-lining residues are important for 
Mg2+ bock. The GluN2 S/L site that dictates subtype-dependence of channel properties (Figure 
2A, Section 1.4.6) is located on the GluN2 M3 region facing toward the GluN1 M2. It was initially 
surprising that a single residue facing away from the pore could be the key determinant of subtype-
dependent channel properties. Siegler Retchless et al. sought to understand the mechanism through 
which the GluN2 S/L site mediated its effects. The results of mutant cycle analysis revealed that 
the residue at the GluN2A S/L site (GluN2A(S632)) interacts with a tryptophan (GluN1(W608)) 
predicted to lie across the intersubunit interface to influence Mg2+ IC50. The tryptophan at position 
GluN1(608) is conserved at the homologous location in GluN2A-D subunits, suggesting that 
maintaining tryptophan at this site is functionally important. Interestingly, mutation of the 
homologous tryptophan in GluN2B (GluN2B(W607)) nearly abolishes Mg2+ block. Williams et 
al. found that mutation of GluN2B(W607) to non-aromatic residues (residues excluding 
phenylalanine and tyrosine) resulted in reduced Mg2+ potency, increased Ba2+ permeation, and 
increased Mg2+ permeation (Williams et al., 1998). Kashiwagi et al. observed that mutation of 
 22 
GluN2B(W607) to non-aromatic residues influenced pore block by drugs in addition to Mg2+ 
(Kashiwagi et al., 2002). Evidence suggests that GluN2B(W607) plays a role in supporting 
NMDAR channel structure that can only be fulfilled by an aromatic residue (McMenimen et al., 
2006). Recently, GluN2B(W607C) was identified as a disease-associated mutation in human 
NMDARs that causes decreased Mg2+ block of NMDARs in addition to decreased surface 
expression and agonist potency (Vyklicky et al., 2018). Structural and modeling evidence indicate 
that GluN2B(W607) likely faces toward the GluN1 M3 region, suggesting that M2 – M3 interfaces 
between adjacent subunits are important for channel permeation and block (Vyklicky et al., 2018, 
Mesbahi-Vasey et al., 2017, Song et al., 2018, Fedele et al., 2018). 
Much like Mg2+ block, Ca2+ permeation is influenced by residues in addition to the N and 
N+1 sites at the selectivity filter. Residues in the GluN1 subunit form an interesting amino acid 
motif (DRPEER) that lies just extracellular to the channel gate in assembled receptors (see Section 
1.5.2). Residues within the DRPEER motif are important influencers of Ca2+ permeability. The 
DRPEER amino acid motif is thought to bind Ca2+ in the external vestibule and promote its entry 
into the pore (Watanabe et al., 2002). Neutralization of the negatively charged residues aspartate 
(D) and glutamate (E) results in NMDARs with reduced Ca2+ permeability without affecting block 
by Mg2+ (Watanabe et al., 2002). Recently, a conserved glycine residue, which is linked to genetic 
disorders when mutated, was also shown to be critical to Ca2+ permeability (Amin et al., 2018). 
The conserved glycine lies near the extracellular region of the M4 helix in GluN1 and GluN2 
subunits and its mutation caused reduced Ca2+ influx by preventing the expansion of the selectivity 
filter. 
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1.6 Modulators of NMDAR Function 
Numerous modulators of NMDAR function exist, and act through several different 
pathways. Orthosteric antagonists, commonly referred to as competitive antagonists, bind in the 
NMDAR agonist binding pockets to inhibit the receptor. Positive allosteric modulators (PAMs) of 
NMDARs enhance the activity of the receptor through binding to non-orthosteric sites (Hackos 
and Hanson, 2017). Negative allosteric modulators (NAMs) decrease the activity of the receptor 
through binding to non-orthosteric sites. A recurring theme in NMDAR modulation is the 
receptor’s immense allostery, which allows functional communication between distant regions. 
Further, stereotyped configurations of receptor domains, particularly the NTD and ABD, seem to 
consistently affect NMDAR function. Several intriguing NMDAR modulators that lend insight 
into NMDAR structure and function are detailed below. 
 Orthosteric antagonists 
Glutamate and glycine site antagonists share structural similarity with glutamate and 
glycine and were very useful in early investigation of NMDAR structure and function. Evidence 
from orthosteric site agonists and antagonists suggests that agonists induce closure of the ABD 
clamshell, whereas antagonists stabilize open-clamshell states (Zhu et al., 2016, Zhou, 2017, 
Paganelli et al., 2013, Romero-Hernandez et al., 2016). LBD clamshell closure may initiate M3 
splaying, causing opening of the bundle crossing. Two well-known orthosteric antagonists are the 
glutamate site antagonist 2-amino-5-phosphonovalerate (APV) and the glycine site antagonist 7-
chlorokynurenic acid (7CK). APV was discovered in the 1980s and used to push forward 
knowledge about the role of NMDARs in LTP, epilepsy, and pain (Davies et al., 1981, Lodge et 
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al., 2019). In 1988, 7CK was developed and found to be a competitive glycine site antagonist 
(Kemp et al., 1988). Both 7CK and APV were used to predict that the NMDAR bound two 
glutamate and two glycine molecules decades before structural information was available 
(Benveniste and Mayer, 1991). 
 Inhibition by protons 
 GluN1-a/2A and GluN1-a/2B receptors are ~50% inhibited by protons at pH 7.3, while 
GluN1-a/2D receptors are ~50% inhibited by protons at pH 7.2. GluN1/2C receptors are less 
sensitive to proton inhibition, and are ~50% inhibited by protons at pH 6.2 (Traynelis et al., 1995). 
In addition to GluN2 subunit identity, GluN1 splice variants influence proton sensitivity. 
Receptors composed of exon 5-containing GluN1 subunits are less sensitive to proton inhibition 
than receptors with exon 5-lacking subunits, showing 50% inhibition of response at pH 6.6 – 6.7 
in GluN1/2A, GluN1/2B, and GluN1/2D receptors. Mutation of residues in exon 5 revealed that 
substitution of lysine 211 greatly reduced the effect of exon 5 on proton inhibition (Traynelis et 
al., 1995). This suggests that exon 5 acts as a pH-sensitive modulator of receptor function.  
Recently, structures of GluN1/2A receptors at pH 6.3 and 7.8 were resolved by cryo-
electron microscopy (cryo-EM) (Zhang et al., 2018). Through comparison of the structures at 
different pH’s the authors concluded that protons act primarily on the NTD. Low pH resulted in 
NTD clamshell closure stemming from increased distance between the R2 lobes (Figure 5). This 
is in agreement with electrophysiological experiments that have linked NTD clamshell closure to 
inhibition and NTD clamshell opening to potentiation (Yuan et al., 2009, Gielen et al., 2008). 
Closure of the NTD clamshell is thought to induce changes in gating through inter and intra-
subunit interfaces with the ABD.   
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Figure 5 pH-dependent changes in the NMDAR NTD 
 
Overlay of NTD structures at pH 6.3 and 7.8. The pH 6.3 structure shows the GluN1 
subunit in pink and the GluN2A subunit in green. The pH 7.8 structure shows the GluN1 and 
GluN2A subunits in gray. The distance between the R2 lobes is larger at pH 6.3 than pH 7.8, 
consistent with clamshell closure. Figure from (Zhang et al., 2018). 
 GluN2A and GluN2B subunit-specific negative allosteric modulators 
Zn2+ selectively inhibits GluN1/2A receptors through an NTD-mediated mechanism 
(Legendre and Westbrook, 1990, Christine and Choi, 1990, Karakas et al., 2009). GluN1-1b/2A 
receptors are inhibited by Zn2+ with lower potency than GluN1-1a/2A receptors. Site-directed 
mutagenesis of exon 5 revealed that lysine 211 mediates the effect of exon 5 on Zn2+ inhibition 
(Traynelis et al., 1995). The same residue was implicated in proton inhibition of NMDARs. Further 
exploration of GluN1 residues outside of exon 5 revealed that several residues important for proton 
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inhibition of NMDARs are also important for Zn2+ inhibition of NMDARs. Therefore, Zn2+ is 
thought to inhibit NMDARs by increasing their pH sensitivity (Choi and Lipton, 1999, Traynelis 
et al., 1995, Zheng et al., 2001). Evidence suggests that Zn2+ binds in the cleft of the GluN2A NTD 
and induces closure of the GluN2A NTD clamshell (Romero-Hernandez et al., 2016, Karakas et 
al., 2009). Stabilization of the closed conformation of the GluN2A NTD induces allosteric changes 
in the ABD that favor channel closure (Gielen et al., 2008, Romero-Hernandez et al., 2016). Of 
note, Zn2+ also causes subtype-independent Vm-dependent inhibition of NMDAR receptors at high 
concentrations (μM) relative to GluN2A-selective inhibition. This is thought to occur through Zn2+ 
occupancy of a binding site in the pore (Mayer and Vyklicky, 1989, Christine and Choi, 1990, 
Legendre and Westbrook, 1990). 
Phenylethanolamines are GluN2B-specific inhibitors that bind in the NTD at the interface 
of the GluN1 R1 and GluN2B R2 lobes (Karakas et al., 2011). Ifenprodil exemplifies the effects 
of phenylethanolamines on GluN1/2B receptors (Gallagher et al., 1996, Williams, 1993). Several 
NMDAR structures with ifenprodil bound have become available in recent years (Karakas et al., 
2009, Karakas and Furukawa, 2014). Analogous to Zn2+ in GluN2A-containing receptors, 
ifenprodil binds in the GluN2B NTD region (Karakas et al., 2009). Comparing ifenprodil-bound 
with the apo NTD structures reveals that ifenprodil causes the NTD R2 domains to splay apart, 
initiating clamshell closure (Tajima et al., 2016). Like Zn2+ inhibition of GluN1/2A receptors, 
ifenprodil inhibition is pH-dependent. Ifenprodil is more potent at lower pH (Pahk and Williams, 
1997), and may enhance the inhibitory effects of protons (Mott et al., 1998). Unlike Zn2+, 
ifenprodil inhibits NMDARs approximately equally in the presence and absence of exon 5.   
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 GluN2B-specific positive allosteric modulators  
Spermine and other polyamines show subtype-dependent potentiation of NMDARs. 
Spermine potentiates NMDAR responses in conditions of saturating glycine (glycine-independent 
potentiation) (Benveniste and Mayer, 1993, Lerma, 1992, Rock and MacDonald, 1992) and also 
in conditions of non-saturating glycine (glycine-dependent potentiation) through different 
mechanisms (Benveniste and Mayer, 1993, McGurk et al., 1990). Glycine-dependent potentiation 
involves an increase in NMDAR affinity for glycine. Glycine-independent potentiation occurs 
only at GluN1/2B receptors that contain exon 5-lacking GluN1 subunits (e.g. GluN1-1a). As with 
inhibition of NMDARs by Zn2+ and ifenprodil, evidence suggests that spermine acts through 
regulating proton inhibition of NMDARs (Traynelis et al., 1995). By shielding negative charges 
present on GluN1 and GluN2B NTD R2 regions, spermine and other polyamines may allow the 
NTD lower lobes to remain close to one another, discouraging NTD clamshell closure (Mony et 
al., 2011). Separate from its mechanism of GluN2B-specific potentiation, spermine also blocks 
NMDARs in a Vm-dependent manner (Araneda et al., 1999, Benveniste and Mayer, 1993). 
 Actions of steroids at NMDARs 
Numerous neurosteroids and steroid precursors exist in the brain and may modulate 
NMDAR function. Pregnenolone sulfate (PS) is a hydrophobic neurosteroid well-known for 
endogenous antagonism of GABAA receptor function (Wang, 2011, Shen et al., 2000, Chen et al., 
2019). Data suggest that PS also has complex and varied effects on NMDARs. PS was initially 
shown to modulate NMDARs in a subtype-dependent manner, potentiating GluN1/2A and 
GluN1/2B receptors and inhibiting GluN1/2C and GluN1/2D receptors (Malayev et al., 2002). The 
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basis of subtype dependence of PS action was proposed to stem from differences in the GluN2 
ABD (Jang et al., 2004, Horak et al., 2006). At GluN1/2A and GluN1/2B receptors, PS increases 
the NMDAR current at saturating agonist concentrations, and increases glutamate and glycine 
potency at subsaturating agonist conditions (Malayev et al., 2002). One publication proposed that 
PS induces Ca2+ influx through GluN1/2A and GluN1/2B receptors in the absence of agonist, 
although the NMDAR dependence of PS-induced Ca2+ influx has not been directly tested 
(Adamusova et al., 2013). Work by Chopra et al. suggests that Ca2+ and the intracellular milieu 
are powerful mediators of PS action. Heterologously expressed GluN1/2A receptors in cells with 
intact intracellular milieu (perforated patch technique) show greater modulation in response to PS 
than dialyzed cells. Interestingly, in both dialyzed and perforated patched cells, GluN1/2A 
receptors responses can be either potentiated or inhibited by the same concentration of PS, 
depending on external Ca2+ concentration (Chopra et al., 2015) .  
Another neurosteroid, pregnanolone sulfate (PAS), inhibits NMDARs in a use-dependent 
and voltage-independent manner (Vyklicky et al., 2015). PAS inhibits NMDARs by increasing 
occupancy of desensitized states (Kussius et al., 2009). A synthetic analog of PAS (PAS-6) and 
similar molecules exhibit unusually slow kinetics of NMDAR inhibition, atypical for molecular 
interactions with the NMDAR in aqueous solution (Borovska et al., 2012). Recovery from 
inhibition by PAS-6-like molecules was accelerated by cyclodextrin, which was used to alter the 
cholesterol content of the plasma membrane (Borovska et al., 2012). Additionally, the membrane 
capacitance was found to increase in response to application of PAS, and return to baseline after 
PAS washout. These experiments suggest that PAS may affect NMDARs by first partitioning into 
the membrane. Other experiments found that binding of negatively charged PAS analogs is 
disrupted by mutations to the SYTANLAAF motif (Vyklicky et al., 2015), suggested binding to 
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regions near the NMDAR bundle crossing. Interestingly, positively-charged PAS analogs show 
Vm-dependent inhibition, much like positively charged open-channel blockers (Vyklicky et al., 
2015).  
Physiological cholesterol modulates NMDARs. Cholesterol depletion from NMDAR-
containing plasma membranes decreased NMDAR Popen and increased entry into desensitized 
states (Korinek et al., 2015, Sibarov et al., 2018). Physiological NMDAR modulation by 
cholesterol and its breakdown products may be quite complex. Cholesterol breakdown product 24-
S-hydroxycholesterol appears to potentiate NMDARs independent of subtype, while 25-S-
hydroxcholesterol antagonizes the effects of 24-S-hydroxycholesterol (Linsenbardt et al., 2014). 
Additionally, although oxysterols are thought to partition into the plasma membrane to act on 
NMDARs, application of oxysterols to the intracellular space was found to have no effect on 
NMDAR function (Linsenbardt et al., 2014). 
 Inhibition by open channel blockers 
Open channel blockers are another class of drugs that inhibit NMDARs. The mechanism 
of action of these molecules is well-described by their name: they enter open NMDAR channels. 
Several open-channel blockers are very useful therapeutically. Memantine is an NMDAR open-
channel blocker widely used for the management of Alzheimer’s disease, and is also being 
explored for treatment of Huntington’s disease and ischemia (Witt et al., 2004, Emre et al., 2010, 
Kafi et al., 2014, Okamoto et al., 2009, Dau et al., 2014). Ketamine, a recently FDA-approved 
treatment for depression, is also an open channel blocker. Open channel blockers are described in 
detail in the next section. 
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1.7 Mechanisms of Open Channel Block 
Open channel blockers are NMDAR inhibitors that bind in the pore, and require opening 
of the NMDAR channel to bind and unbind from their binding site (MacDonald et al., 1991, Wong 
et al., 1986). They are typically thought to reach their binding site from the extracellular space, 
though inhibition by intracellular open-channel blockers is also known to occur (Berretta and 
Jones, 1996). Open channel blockers can be further categorized as “foot-in-the-door” blockers and 
trapping blockers. Foot-in-the-door blockers bind in a manner that occludes the flow of ions while 
preventing channel closure. Examples of NMDAR foot-in-the-door blockers include 9-
aminoacridine (Benveniste and Mayer, 1995), tetrahydroaminoacridine (Vorobjev and Sharonova, 
1994), tetrapentylammonium (Sobolevsky, 2000, Sobolevsky et al., 1999) and bupivacaine 
(Paganelli and Popescu, 2015). Trapping blockers allow channel closure while bound, causing the 
blocker to become trapped inside closed receptors. Examples of well-known and mechanistically 
interesting open channel blockers are described below. 
 Memantine 
Memantine is a rare clinical success story among NMDAR antagonists: it is tolerated very 
well, with few side effects (Muir, 2006, Gladstone et al., 2002). Memantine is typically 
administered orally and has 100% bioavailability (Robinson and Keating, 2006). Memantine is 
excreted intact in urine (Robinson and Keating, 2006), suggesting that memantine itself, rather 
than its breakdown products, mediates therapeutic efficacy. Memantine’s binding site in the pore 
resides near the selectivity filter where 6 asparagine residues are clustered (Kashiwagi et al., 2002, 
Chen and Lipton, 2005, Kotermanski et al., 2009). This binding site is accessible from the 
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extracellular space when agonist is present and the channel is open, and is thought to overlap with 
the Mg2+ binding site (Glasgow et al., 2018, Kotermanski et al., 2009, Kotermanski and Johnson, 
2009). 
Memantine is a partial trapping channel blocker (Blanpied et al., 1997, Kotermanski et al., 
2009, Mealing et al., 1999, Sobolevsky et al., 1998), which means that a fraction of memantine 
unbinds from closed NMDARs. Memantine was shown to have several unique properties, 
including stabilization of Ca2+-dependent desensitized states (Glasgow et al., 2017). This results 
in memantine preferentially inhibiting receptors exposed to high intracellular Ca2+, which may 
contribute to its therapeutic efficacy in Alzheimer’s disease. Although memantine is subtype 
independent in the absence of Mg2+, it inhibits GluN1/2C and GluN1/2D receptors more potently 
than GluN1/2A and GluN1/2B receptors in the presence of physiological Mg2+ (Kotermanski and 
Johnson, 2009). Therapeutic brain concentrations of memantine are low compared to the 
GluN1/2A and GluN1/2B memantine IC50s in the presence of physiological Mg
2+, suggesting that 
some of memantine’s therapeutic actions may be mediated by GluN1/2C and GluN1/2D receptors 
(Povysheva and Johnson, 2016).   
Interestingly, when concentrations of memantine several fold higher than its channel 
blocking IC50 are applied in the absence of agonist and briefly washed away, subsequent agonist 
application shows NMDAR inhibition. NMDAR inhibition following memantine application in 
the absence of agonist has been attributed to the binding of memantine to two sites: the site in the 
pore that gives rise to open-channel block (“the deep site”) and a “superficial site” that is accessible 
in closed receptors (Blanpied et al., 1997, Sobolevsky and Koshelev, 1998, Sobolevsky et al., 
1998, Chen and Lipton, 2005, Kotermanski et al., 2009). Reported memantine IC50 at the 
superficial site is quite high, ranging from 79-179 M (Kotermanski et al., 2009, Blanpied et al., 
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1997). It is currently unclear whether memantine acting through two mechanisms is significant to 
its clinical utility. 
 Ketamine 
Like memantine, ketamine is a clinically useful NMDAR inhibitor. Ketamine has been 
used as a pediatric anesthetic and analgesic (Durrmeyer et al., 2010, Hall and Shbarou, 2009), and 
more recently, as an anti-depressant (Schwartz et al., 2016). However, ketamine administration 
requires physician oversight because it can cause dissociative effects and psychotomimetic 
behavior. Ketamine is suggested to bind near the selectivity filter in the pore, overlapping with the 
Mg2+ binding site (Johnson et al., 2015, MacDonald et al., 1991). However, it is unclear whether 
ketamine’s antidepressant effects are due to NMDAR inhibition or other targets of ketamine or 
ketamine breakdown products (Zanos et al., 2016). 
 MK-801 
MK-801’s open-channel block mechanism was discovered over three decades ago 
(Huettner and Bean, 1988, Foster and Wong, 1987, Wong et al., 1986) and MK-801 has been used 
to block NMDARs in many experiments ever since. Recovery of NMDARs from block by MK-
801 in the presence of agonist was found to be extremely slow at negative voltages (order of 
minutes), making MK-801 useful for “irreversible" NMDAR inhibition on the timeline of many 
experiments. MK-801 unblock occurs much faster at positive voltages (Huettner and Bean, 1988). 
NMDAR recovery from MK-801 inhibition in the presence of agonist was found to be accelerated 
by Mg2+ and memantine, suggesting that the slow unbinding of MK-801 arises partially from the 
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subsequent unbinding and re-binding of MK-801 to the NMDAR (McKay et al., 2013). MK-801 
binds in the pore with its positive charge facing the 6 asparagines (Song et al., 2018, Reynolds and 
Miller, 1988). Recent structural data suggest that during MK-801 pore block, two aromatic rings 
of MK-801 lie near the GluN1 M3 region, close to GluN1(V642), while the methyl substituent lies 
near GluN2B(L640) (Song et al., 2018). Mutation of GluN1(V642) eliminates MK-801 binding. 
MK-801 also inhibits NMDARs from the intracellular space, though at high concentrations 
(mM) relative to the IC50 of external MK-801 (nM). (Berretta and Jones, 1996, Sun et al., 2018). 
MK-801 is seemingly too large to reach its binding site through direct diffusion into the pore from 
the intracellular region, suggesting that NMDAR inhibition by intracellular MK-801 may occur 
through a more complex mechanism. Sun et al. found that the intracellular MK-801 has an affinity 
for NMDARs ~30,000 times less potent than extracellular MK-801, suggesting that it behaves 
very differently from extracellular MK-801 at NMDARs (Sun et al., 2018). 
1.8 Dissertation Contents 
The work discussed in this dissertation centers around the NMDAR TMD. I began work in 
the Johnson lab shortly after the publication of their work on the GluN2 S/L site detailing its critical 
role in influencing subtype-dependent properties (Siegler Retchless et al., 2012). My first project 
in the lab involved exploring the functional role of intersubunit interactions in the TMD, and in 
particular, the role of a conserved M2 tryptophan that, in GluN1, interacts with the GluN2A S/L 
site (Chapter 2). I then performed experiments on the mechanism of “superficial site” block by 
memantine, which were included in a publication by former graduate student Nathan Glasgow 
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(Chapter 3) (Glasgow et al., 2018). Intrigued by the unique mechanism of memantine binding to 
the “superficial site”, I continued to explore non-traditional actions of open-channel blockers 
(Chapter 4). 
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2.0  Role of a Conserved Tryptophan at Intersubunit Interfaces in NMDA Receptors 
2.1 Summary 
My coauthors and I examined the role of a tryptophan residue in NMDA receptors 
(NMDARs) that is conserved in ionotropic glutamate receptor (iGluR) subunits and similar 
proteins. This conserved tryptophan lies at an intersubunit interface in the transmembrane domain 
(TMD). In a previous publication the tryptophan in GluN1 (GluN1(W608)) was found to interact 
with GluN2A(S632) to influence NMDAR subtype-dependent channel properties. We examined 
whether GluN1(W608) and GluN2A(S632) are in close physical proximity, as predicted by 
structural models, by mutating both residues to cysteine and probing for intersubunit disulfide 
linkages. Using Western blot and tandem mass spectrometry, we confirmed that GluN1(W608C) 
and GluN2A(S632C) crosslink, and therefore, are in close proximity. Examining the cysteine 
mutant receptors electrophysiologically, we noted slowed deactivation kinetics in 
GluN1(W608C)/2A receptors. Through mutant cycle analysis we discovered that the GluN1(608) 
and GluN2A(632) positions couple to influence deactivation kinetics. Therefore, intersubunit 
interfaces in the TMD can influence receptor kinetics as well as permeation properties. We next 
examined the homologous tryptophan in GluN2A subunits. Using molecular modeling, we 
predicted that GluN2A(W606) lies across the intersubunit interface from, and in close proximity 
to, GluN1(M634). We mutated GluN1(M634) and GluN2A(W606) to cysteine and examined the 
mutant receptors electrophysiologically. We found that GluN1(M634C) interacts with 
GluN2A(W606C) to influence Mg2+ IC50. However, we found no evidence of biochemical 
crosslinking between GluN1(M634C) and GluN2A(W606C). Last we examined the conserved 
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tryptophan in GluN2B subunits. We examined whether, as in GluN1/2A receptors, a cysteine 
introduced at the site of the conserved tryptophan in GluN2B subunits interacts with 
GluN1(M634C) to influence Mg2+ IC50. Surprisingly, GluN2B(W607C)-containing receptors 
showed potentiation in response to Mg2+ at negative potentials. After compensating for the large 
Mg2+ potentiation in GluN2B(W607C)-containing receptors we identified that block by Mg2+ 
occurs in GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) receptors, though it is less potent 
and less efficacious than in wildtype GluN1/2B receptors. Interestingly, while the 
GluN2B(W607C) mutation increases Mg2+ IC50 in GluN1/2B receptors and the GluN1(M634C) 
mutation does not, the opposite is true at the homologous residues in GluN1/2A receptors. This 
reveals a striking role reversal in the effect on Mg2+ block of mutating GluN1(M634) and the 
GluN2 conserved tryptophan in GluN1/2A and GluN1/2B receptors. Thus, residues at intersubunit 
interfaces in the NMDAR TMD are critical to gating and block, but the effects of interface 
mutations are strongly subtype dependent. 
2.2 Introduction 
NMDA receptors (NMDARs) are ionotropic glutamate receptors (iGluRs) that are central 
to learning and memory (Nicoll, 2017, Li and Tsien, 2009), and also implicated in neurological 
disease and neurodegeneration (Kayser and Dalmau, 2011, Hallett and Standaert, 2004, Zhou and 
Sheng, 2013, Zhang et al., 2016, Balu, 2016). NMDARs are composed of two GluN1 and two 
GluN2(A-D) or GluN3(A,B) subunits (Traynelis et al., 2010b). Each subunit contains an amino-
terminal domain (NTD), agonist binding domain (ABD), transmembrane domain (TMD), and C-
terminal domain (CTD). The NTD and ABD are extracellular, while the CTD is intracellular. 
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Linking extra- and intracellular domains is the membrane-embedded TMD. The GluN1 and GluN2 
subunits share high sequence homology (Monyer et al., 1992) and have very similar structures in 
the TMD (Traynelis et al., 2010b). The TMD of each subunit contains three transmembrane helices 
(M1, M3, M4) and a re-entrant loop (M2) that lines the ion channel. The M2 region is composed 
of an alpha helix and an extended region, which forms the selectivity filter. In the extended region 
of the M2, asparagines (N) at the Q/R/N site and the adjacent N+1 site have been found to be 
critical to block of NMDARs by Mg2+ and other channel blockers (Burnashev et al., 1992b, 
Kashiwagi et al., 2002, Kuner and Schoepfer, 1996, Wollmuth et al., 1998). These asparagines 
have been suggested to coordinate Mg2+ in the channel, giving rise to Vm-dependent Mg
2+ block 
of NMDARs (Mesbahi-Vasey et al., 2017, Burnashev et al., 1992b, Kashiwagi et al., 2002, Kuner 
and Schoepfer, 1996, Wollmuth et al., 1998).  
In the fully assembled NMDAR, subunits are in an alternating GluN1-GluN2-GluN1-
GluN2 conformation (Traynelis et al., 2010b, Karakas and Furukawa, 2014, Lee et al., 2014). 
Therefore, within each receptor there are four intersubunit interfaces in the TMD. At these 
locations, the GluN1 M2 and GluN2 M3, and GluN1 M3 and GluN2 M2 regions come into close 
contact. Several previous studies have explored the roles of residues at these interfaces. Williams 
et al. demonstrated that mutation of a GluN2B tryptophan (W; GluN2B(W607)) to non-aromatic 
residues decreased Mg2+ block, increased Mg2+ permeation, and decreased Ba2+ permeation 
(Williams et al., 1998). Interestingly, mutation of the homologous residue in GluN1 
(GluN1(W608)) and GluN2A (GluN2A(W606)) had little-to-no effect on Mg2+ block. Williams et 
al. speculated that GluN2B(W607) participated in Mg2+ coordination and was positioned at the 
narrow part of the channel constriction. Several years later, Kashiwagi et al. revealed that 
GluN2B(W607) mutations alter NMDAR block by several channel-blocking molecules with 
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binding sites that overlap the Mg2+ binding site, including memantine, MK-801, and TB-3-4 
(Kashiwagi et al., 2002). Like Williams et al. (1998), Kashiwagi et al. suggested that 
GluN2B(W607) may reside at the narrow construction of the channel. However, Kashiwagi et al. 
also speculated that GluN2B(W607) could instead form a structural backbone that influences the 
structure of the pore. In 2006, work by McMenimen et al. confirmed that GluN2B(W607) is 
involved in maintaining the structure of the pore, possibly through interactions with the GluN1 
M3 region (McMenimen et al., 2006).  
Siegler Retchless et al. identified a single GluN2 residue at a TMD intersubunit interface 
that determines the subtype dependence of NMDAR channel properties (Siegler Retchless et al., 
2012). GluN1/2A and GluN1/2B receptors show similar channel properties, including Mg2+ block, 
single channel conductance, and selective permeability to Ca2+. The residue, serine (S) in 
GluN1/2A and GluN1/2B receptors and leucine (L) in GluN1/2C and GluN1/2D receptors (the 
“GluN2 S/L site”), determines whether NMDAR channel properties are “GluN1/2D-like”or 
“GluN1/2A-like” (Siegler Retchless et al., 2012). Siegler Retchless et al. used molecular modeling 
to predict that the GluN2 S/L site faces away from the pore toward the neighboring GluN1 subunit 
and identified nearby residues through which the GluN2 S/L site could mediate its effect. Mutant 
cycle experiments were performed by swapping the residues of interest in the GluN1 and GluN2A 
subunits and examining the Mg2+ IC50s of the resulting subunit combinations. Mutant cycle 
analysis suggested that the GluN2A subunit S/L site (GluN2A(S632)) interacts functionally with 
GluN1(W608) (which is homologous to GluN2A(W606) and GluN2B(W607)) to produce subtype 
dependent Mg2+ block.  
We were intrigued by the conservation of the M2 tryptophan in GluN2, GluN2A, and 
GluN2B receptors (Figure 1A), as well as residue-residue interactions at intersubunit interfaces in 
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the TMD. In this work, we set out to explore NMDAR properties mediated by the conserved 
tryptophan at the TMD intersubunit interface in GluN1, GluN2A, and GluN2B subunits, and to 
identify interacting residues. We used a molecular model of the NMDAR TMD to identify residues 
that may interact with the conserved tryptophan in the GluN1, GluN2A, and GluN2B subunits. 
We then mutated the conserved tryptophan within each subunit, and potential interacting residues, 
to cysteine (C). We examined whether the introduced mutations interact with one another in 
GluN1/2A and GluN1/2B receptors through cysteine substitution and Western blotting, 
electrophysiological mutant cycle analysis, and tandem mass spectrometry. Our results reveal that 
interactions at intersubunit interfaces in the NMDAR TMD are crucial for determining both 
receptor gating and channel properties. 
2.3 Methods 
 Cell culture and transfection 
Experiments were performed on the tsA201 cell line (The European Collection of 
Authenticated Cell Cultures), a variant of the HEK 293 cell line. tsA201 cells were maintained as 
previously described (Glasgow and Johnson, 2014) in DMEM supplemented with 10% fetal 
bovine serum and 1% GlutaMAX (Thermo Fisher Scientific). 1 × 105 cells/dish were plated in 35 
mm petri dishes containing 15 mm glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-
tail collagen (0.1 mg/ml, BD Biosciences). 12–24 h after plating, cells were transiently co-
transfected using FuGENE6 Transfection Reagent (Promega) with mammalian 
expression plasmids that contained cDNAs encoding enhanced green fluorescent protein (EGFP 
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in pRK7) for identification of transfected cells, the rat GluN1-1a subunit (hereafter GluN1; 
GenBank X63255 in pcDNA3.1), the rat GluN2A subunit (GenBank M91561 in pcDNA1), or the 
rat GluN2B subunit (GenBank M91562 in pcDNA1). In some experiments we used cells 
transfected with GluN1 and an EGFP:pIRES:GluN2A construct, which was a kind gift from Dr. 
Kasper Hansen (Hansen, unpublished) (Glasgow et al., 2017). Mutagenized with the Stratagene 
Quik-Change XL sited-directed mutagenesis kit NMDAR subunit cDNAs from isolated colonies 
were sequenced from 100–200 bases upstream to 100–200 bases downstream of each mutation 
(University of Pittsburgh Genomics and Proteomics Core Laboratories). cDNA ratios used in 
transfection were 1:1:1 (EGFP, GluN1, and GluN2A), 1:1 (GluN1 and EGFP:pIRES:GluN2A), or 
1:1:2 (EGFP, GluN1, and GluN2B). Following transfection, 200 μM of the competitive NMDAR 
antagonist D,L-2-amino-5-phosphonopentanoate was added to the media to prevent NMDAR-
mediated cell death. 
 Solutions 
The extracellular bath solution contained (in mM): 140 NaCl, 2.8 KCl, 0.1 CaCl2, 
10 HEPES, 0.1 glycine, 0.01 EDTA, and osmolality adjusted to 290 ± 10 mOsm with sucrose. 
Extracellular solution pH was balanced to 7.2 ± 0.05 with NaOH. Intracellular solution contained 
(in mM) 130 CsCl, 10 HEPES and 10 EGTA with pH balanced to 7.2 ± 0.05 with CsOH and an 
osmolality of 280 ± 10 mOsm. Tris(2-carboxyethyl)phosphine (TCEP; Sigma), L-glutamate 
(Sigma) and MgCl (Sigma) were added to solutions on the day of experiments as indicated. Whole 
cell voltage-clamp recordings were obtained from transfected tsA201 cells 12–48 h after 
transfection. Pipettes were pulled from borosilicate capillary tubing (Sutter Instruments) on a 
Sutter Instruments-Flaming Brown P-97 glass puller and polished using a heated filament to a 
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resistance of 2–5 ΜΩ. Whole-cell recordings were made from cells expressing EGFP identified 
by epifluorescence illumination on an inverted Zeiss Axiovert microscope. Cells were held at a 
membrane potential of −60 mV (corrected for a liquid junction potential of −6 mV) unless 
otherwise indicated (e.g. +50 mV in Figure 6). For experiments in which high concentrations of 
Mg2+ were used ([Mg2+] > 2 mM) the bath was grounded using a flowing KCl bridge. Whole-cell 
currents were recorded using an Axopatch 200B patch-clamp amplifier (Molecular Devices), low-
pass filtered at 5 kHz and sampled at 10 or 20 kHz in pClamp10 (Molecular Devices). Series 
resistance was compensated 80–90% with prediction and correction circuitry in all experiments. 
Solutions were delivered to cells attached to the coverslip using a ten-barrel fast perfusion system 
with 27 ms time constant of solution exchange (Glasgow et al., 2017).  
 Analysis 
All data were analyzed with Clampfit 10.7 (Molecular Devices) or GraphPad Prism 7. For 
experiments in which Mg2+ IC50 was measured, steady-state response to glutamate application 
before and after application of [Mg2+]. Experiments in which recovery was <80% were excluded 
from analysis. 
The weighted time constant of deactivation (w) was calculated by fitting a double 
exponential curve to the deactivation time course following the glutamate wash off after currents 
reached steady-state using the following formula: 
 
 
𝜏𝑤 =  𝜏1(
𝐴1
𝐴1 + 𝐴2
) + 𝜏2(
𝐴2
𝐴1 + 𝐴2
) Equation 1 
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Where A1 and A2 are the amplitudes, and 1 and 2 are time constants, resulting from each 
of two exponential fits. 
IC50 was calculated using the following equation: 
𝐼𝑀𝑔2+
𝐼𝐶𝑜𝑛𝑡𝑟𝑜𝑙
= 𝐴1 +
(1 − 𝐴1)
1 + (
[𝑀𝑔2+]
𝐼𝐶50
)
𝑛 Equation 2 
Where 
𝐼
𝑀𝑔2+
𝐼𝐶𝑜𝑛𝑡𝑟𝑜𝑙
is the normalized steady-state current following application of [Mg2+] 
(concentration of Mg2+) in the presence of agonist, A1 is the value at saturating Mg
2+ and n is the 
Hill coefficient. Data from cells at each [Mg2+] were averaged and a fit was performed to average 
data to obtain the IC50 value. 
The mutant cycle coupling coefficient, , was calculated as follows using 𝜏w: 
Ω =
𝜏𝑤𝐺𝑙𝑢𝑁1(𝑚)/2𝐴 ∗ 𝜏𝑤𝐺𝑙𝑢𝑁1/2𝐴(𝑚) 
𝜏𝑤𝐺𝑙𝑢𝑁1(𝑚)/2𝐴(𝑚) ∗ 𝜏𝑤𝐺𝑙𝑢𝑁1/2𝐴
Equation 3 
Where (m) indicates that a subunit contains a mutated residue. Ω resulting from mutant 
cycle analysis of Mg2+ IC50 was calculated similarly, except using Mg
2+ IC50 values in place of 𝜏w 
values. 
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 Plasma membrane preparation and Western blot 
Cell lysates were prepared from tsA201 cells transfected with the indicated plasmids. A 
plasma membrane protein extraction kit (Abcam) was used to isolate proteins expressed at the cell 
surface. Resolved mixtures were run on a 7.5% polyacrylamide gel, for ~1.5 hours at 100 V before 
transferring to a polyvinylidene difluoride (PVDF) membrane. We blocked membranes with 
proprietary blocking buffer (LI-COR biosciences) for 1 hour at room temperature. Then the 
membrane was incubated with mouse anti-pan-GluN1(1:1000) (Millipore, catalog # 05-432) or 
rabbit anti-GluN2A (1:1000) (Millipore, catalog # 04-901) primary antibody with the proprietary 
blocking buffer at 4°C overnight. We revealed specific bands by incubating with appropriate 
secondary antibody (goat anti-mouse or goat anti-rabbit, from LI-COR Biosciences) conjugated to 
a fluorophore (with excitation wavelength of 680 or 800 nm) for 1 hour at room temperature. 
Membranes were imaged with a LI-COR Odyssey CLx. To compare diheteromer content between 
lanes, densitometry was used to quantify the diheteromer and GluN1 monomer bands and calculated the 
diheteromer/monomer ratio. Densitometry analysis was done in ImageJ 1.50i (National Institutes of 
Health). 
 Mass spectrometry 
Gel bands were washed with 50:50 methanol: 50 mM ammonium bicarbonate twice for 40 
min with gentle agitation (VWR Thermal Shake Touch, 900 rpm). Gel bands were dehydrated by 
adding 500 L acetonitrile for 20 minutes. Acetonitrile was removed and gel bands were dried in 
an Eppendorf 5301 Vacufuge Concentrator for approximately 15 minutes. Trypsin solution (10 L 
at 20 g/mL in 50 mM ammonium bicarbonate) was added to gel bands and incubated on ice for 
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15 minutes, then incubated overnight at 37˚C with gentle agitation (VWR Thermal Shake Touch, 
900 rpm). The pH was adjusted to ~2 (5M HCl) and pepsin solution (10 L at 1 mg/mL in H2O 
(pH~3)) was added. Tubes were incubated overnight at 37˚C with gentle agitation. Digested 
peptides were extracted into supernatant and transferred to VWR non-stick microcentrifuge tubes. 
Digested peptides were further extracted by incubating gel bands twice for 30 minutes in 500 L 
of 0.1 % formic acid in 50:50 acetonitrile:H2O. The resulting supernatant was collected and 
combined with the supernatant collected immediately following the overnight incubation. Digest 
extract solution was dried in an Eppendorf 5301 Vacufuge Concentrator. Dried extract was 
reconstituted in 50 L of 0.1% formic acid in H2O for 30 minutes with gentle agitation. The 
reconstituted peptides were run through liquid chromatography-mass spectrometry (LCMS). 
Electrospray ionization quadrupole time-of-flight mass spectrometry (ESI-Q-TOF MS) was done 
on the extracted peptides and measurements were taken using an Agilent 6530 Q-TOF-MS with 
an Agilent HPLC-Chip II G4240-62006 ProtID-Chip-150. The mobile phase was created by 
combining varying percentages of Solvent A (95 % H2O, 5 % ACN, 0.1 % Formic acid) and 
Solvent B (95 % ACN, 5 % H2O, 0.1 % Formic acid). The nanoflow elution gradient was 
developed as follows at 0.50 µl/min of Solvent A (minute, percent A): 0.00, 95 %; 4.00, 10 %; 
6.00, 70 %; 9.00,: 50 %; 11.50, 95 %; 13.00, 95 %. The mass-to-charge (m/z) ratio range was 200-
1700 m/z for MS analysis and 100-2000 m/z for MSMS analysis. Data were processed using 
Agilent Qualitative Analysis Software 6.0 using the following parameters: 2 missed enzymatic 
cleavages, 20 ppm precursor ion/ 0.1 Da product ion cutoff, and peptide modifications (oxidation 
and acrylamidation). For MS/MS analysis, the extracted peptide samples were run again on the 
Agilent 6530 Q-TOF-MS, targeting the specific m/z ratio, charge, and retention time (RT) of the 
cross-linked peptides identified in MS analysis. Collision-induced dissociation (CID) was used for 
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MS-MS fragmentation following a linear increase in collision energy by m/z using the equation: 
y = 3.7x + 2.5. CID was performed at + 0.2 min from initial MS scan RT of each crosslinked 
precursor ion identified. Measurements were taken in triplicate from distinctive gel bands at 
molecular weights of crosslinked dimers. Precursor/product ion pairing identified in ≥2 of 3 trials 
of mass ions unique to crosslinked diheteromer gel band and not identified in controls (single 
subunit and enzymatic solution gel band) were considered as evidence of diheteromer formation. 
 Statistics 
Statistical tests were performed in GraphPad Prism 7. Student’s t-test and two-way 
ANOVA with Tukey’s post-hoc test were used where indicated and p-values of <0.05 were 
considered statistically significant. Statistical significance of mutant cycles was tested using a two-
way ANOVA with the identity of the residue at each mutated site as factors. A significant 
interaction between factors was taken to reflect significant coupling between the mutated sites. 
Error bars indicate ± standard error of the mean (SEM). Mg2+ IC50 error is the standard error 
reported in the curve fit to determine Mg2+ IC50. 
 Molecular modeling, sequence alignment and image creation 
To identify residues of interested at intersubunit interfaces in the TMD, we utilized the 
published all-atom GluN1/2A TMD model (Mesbahi-Vasey et al., 2017). We achieved the 
sequence alignment shown in Figure 6A using NCBI BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). Images of NMDAR TMD model used in figures were 
created using Pymol software. 
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2.4 Results 
 GluN1(W608C) and GluN2A(S632C) form a disulfide linkage 
We began our exploration of the conserved tryptophan in GluN1, GluN2A, and GluN2B 
subunits (Figure 6) with GluN1(W608). Based on the observation by Siegler Retchless et al. that 
GluN1(W608) and GluN2A(S632) interact to mediate the effects of the GluN2 S/L site, we created 
GluN1(W608C) and GluN2A(S632C) mutants to explore whether the introduced cysteines are in 
close physical proximity, as predicted (Siegler Retchless et al., 2012). We hypothesized that we 
could detect GluN1(W608C) - GluN2A(WS632C) disulfide bond formation in non-reducing 
Western blots by probing for GluN1/2A diheteromers. Cysteine residues near one another share 
the ability to crosslink, resulting in formation of a covalent disulfide bond (Anfinsen and Haber, 
1961). Observation that a disulfide bond can form between a pair of introduced cysteines suggests 
that their α-carbons come within 7 Å of each other (Katz and Kossiakoff, 1986). Based on known 
NMDAR structure, naturally-occurring intersubunit disulfide bonds should not occur in properly-
assembled GluN1/2A receptors. In agreement with this, non-reducing western blots of membrane 
proteins isolated from Xenopus oocytes show no diheteromerization in WT GluN1/2A receptors 
(Talukder and Wollmuth, 2011). Non-reducing western blots of whole-cell extracts in tsA201 and 
HEK293 cells, however, do show faint diheteromer bands in WT GluN1/2A lanes that are 
eliminated by inclusion of a reducing agent in the protein sample (Lee and Gouaux, 2011, Xu et 
al., 2015). Nonfunctional proteins located in ribosomes (Pechmann et al., 2013), likely present in 
whole-cell extracts, could be responsible for the observed inter-subunit disulfide bonds. Therefore, 
we performed Western blots on proteins isolated from the surface of tsA201 cells to obtain a 
sample with minimal misfolded or improperly assembled protein (Riou et al., 2012) expecting that 
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any observed diheteromers would correspond to crosslinking between GluN1(W608C) and 
GluN2A(S632C). To our surprise, even after isolation of the plasma membrane fraction, we 
consistently observed a faint diheteromer signal in WT GluN1/2A lanes. This could arise due to 
imperfect separation of the plasma membrane and cytosolic fractions or may be ascribed to 
association of integral membrane proteins with NMDAR subunits even in the presence of 
detergents. We observed that GluN1(W608C)/2A(S632C) receptors showed a 
diheteromer/monomer ratio (30.7 ± 5.3 %) several-fold larger than in GluN1/2A receptors (8.93 ± 
1.80, p = 0.017), suggesting that crosslinking occurs between GluN1(W608C) and 
GluN2A(S632C) (Figure 7B,C). 
 
Figure 6 A conserved tryptophan in NMDARs 
 
A, a conserved tryptophan (W) emerges from an alignment of p-loops of glutamate receptor 
and K+ channel subunits from a wide range of organisms. KcsA, prokaryotic K+ channel from 
Streptomyces lividans; NaK, bacterial action channel from Bacillus cereus; MlotiK1, prokaryotic 
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K+ channel from Mesorhizobium loti, KvAP archaebacterial K+ channel from Aeropyrum Pernix; 
Ara, glutamate binding protein from the plant Arabidopsis; GluR0, prokaryotic glutamate receptor 
from Synechocystis; Kv1.2, Kir 3.1, Kir 1.3: mammalian K+ channels; delta1, GluK1-4, GluA1-4, 
GluN1, GluN2A-D: mammalian glutamate receptors. B, molecular model of GluN1/2A M2 and 
M3 segments of the TMD (Mesbahi-Vasey et al., 2017) showing the conserved tryptophans. 
GluN1 is green and GluN2A is blue. GluN1(W608) residues are in magenta and GluN2A(W606) 
residues are in yellow. C, same as B, but viewed from below. 
 To further explore whether our Western blot contained diheteromers due specifically to 
crosslinking of GluN1(W608C) and GluN2A(S632C), we performed electrospray ionization 
quadrupole time-of-flight mass spectrometry (ESI-Q-TOF MS) on excised gel slices. ESI-Q-TOF 
MS allowed us to specifically identify mass-shifted diheteromer derived disulfide linked GluN1-
GluN2A peptides arising from the introduced cysteines. Tandem-MS studies were conducted on 
three independently prepared samples. Mass coverage of GluN1(W608C) and GluN2A(632C) 
ranged from 50 – 65% in our trials. Given the potential steric hindrance of the disulfide linkage as 
well as the raggedness of pepsin cleavage (Gorman et al., 2002), results with two missed cleavages, 
as well as oxidation and acrylamidation, were analyzed. Overall, in the three trials 10 different 
precursor ions were identified within 20 ppm mass error of mass-shifted disulfide-linked peptides 
consistent with linked diheteromers. In all cases, tandem MS studies showed a, b, and y product 
ion fragmentation patterns. In 6 of these cases, the intact disulfide linkage, which is labile to 
collision-induced dissociation (which also leads to cleavage of more than one bond) (Clark et al., 
2011), was observed amongst the product ions. A representative MS/MS scan with assigned 
fragmentation pattern is provided in Figure 8. For simplicity only single CID cleavages to either 
the diheteromer or the free GluN1 or GluN2A peptide were assigned. These experiments revealed 
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that a disulfide bond formed between GluN1(W608C) and GluN2A(S632C) in agreement with our 
Western blot results. 
 
Figure 7 GluN1(W608C) and GluN2A(S632C) form a disulfide bond in assembled receptors 
 
A, image of GluN1 (green) and GluN2A (blue) M2 and M3 regions (Mesbahi-Vasey et al., 
2017) showing GluN1(W608) in magenta and GluN2A(S632) in orange. B, Western blot of 
surface NMDARs probed with anti-GluN2A and anti-GluN1. Diheteromer (~300 kDa), GluN1/N1 
dimer (~240 kDa), GluN2A monomer (~175 kDa), and GluN1 monomer bands (~125 kDa) are 
labelled. C, plot of intensity of the diheteromer band divided by the intensity of the GluN1 
monomer band, multiplied by 100, for GluN1/2A and GluN1(W608C)/2A(S632C) receptors (n = 
3 Western blots). 
 50 
 
Figure 8 MS analysis of crosslinked diheteromer 
 
Representative tandem MS-MS fragmentation scan of precursor m/z corresponding to 
crosslinked peptide pair produced from enzymatic double digestion. Fragmented a, b and y product 
ions (labeled 1-6) stemming from the crosslinked peptide pair precursor ion were assigned to 
product ions containing the disulfide crosslink between GluN1 and GluN2 (Diheteromer) as well 
as product ions assigned to individual GluN1 and GluN2 peptides due to CID of the disulfide 
linkage. 
 51 
 GluN1(W608C) and GluN2A(S632C) interact to influence deactivation kinetics 
Next we examined the electrophysiological effects of the GluN1(W608C) and 
GluN2A(S632C) mutations on receptor function. We noticed that GluN1(W608C)/2A receptors 
showed remarkably slow deactivation, similar to that of GluN1/2D receptors (Traynelis et al., 
2010b). In further experiments, we found that the effect of the mutation on deactivation depended 
on the redox state of the receptor: deactivation kinetics were modulated by the membrane-
impermeable reducing reagent TCEP. To examine the effect of the GluN1(W608C) mutation on 
deactivation in a uniform population of NMDARs we measured the time constant of deactivation 
(w) in the presence of 5 mM TCEP. GluN1(W608C)/2A receptors showed drastically slowed 
deactivation (w = 3390 ± 628 ms) compared to WT GluN1/2A receptors (𝜏w = 140 ± 20 ms, p < 
0.0001, one-way ANOVA) in 5 mM TCEP. 𝜏w of GluN1/2A(S632C) receptors was not different 
from WT GluN1/2A receptors (p > 0.99). GluN1(W608C)/2A(S632C) receptors showed 𝜏w slower 
than WT GluN1/2A receptors (1550 ± 180 ms, p = 0.017) but faster than GluN1(W608C)/2A 
receptors (p = 0.004). 
We were intrigued by evidence of proximity between GluN1(W608C) and 
GluN2A(S632C) residues (Figures 7,8) as well as published evidence that GluN1(W608) and 
GluN2A(S632) couple to influence Mg2+ IC50 (Siegler Retchless et al., 2012). We decided to 
examine whether the GluN1(W608) and GluN2A(S632) positions also couple to influence receptor 
gating. Mutant cycle analyses involve comparing the effect of each of two single mutations (e.g. 
GluN1(W608C)/2A and GluN1/2A(S632C) receptors) on a parameter of interest (e.g. w) with 
the effect induced by both mutations simultaneously (GluN1(W608C)/2A(S632C)). If the 
mutated residues do not interact, the fractional change in 𝜏w between GluN1/2A and 
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GluN1(W608C)/2A receptors should be equal to the fold change in 𝜏w between 
GluN1/2A(S632C) and GluN1(W608C)/2A(S632C) receptors. If the mutated residues are 
coupled, the fractional change in 𝜏w between GluN1/2A(S632C) and 
GluN1(W608C)/2A(S632C) receptors will be greater than or less than the fractional change 
between GluN1/2A and GluN1(W608C)/2A receptors. A coupling coefficient, Ω, is often used 
as a measure of residue coupling (equation 3, Methods). If Ω = 1, there is no evidence for residue 
coupling, while Ω < 1 or Ω > 1 suggests that residues are coupled. Based on the average 𝜏w for 
each receptor type, we calculated the Ω value of the GluN1(W608C)/2A(S632C) mutant cycle. 
We found that Ω was greater than 1 (Ω = 2.0), suggesting that the GluN1(608) and GluN2A(S632) 
positions interact to influence deactivation kinetics (Figure 9C). The interaction between the 
GluN1(W608) and GluN2A(S632) was statistically significant (p = 0.0001) using two-way 
ANOVA, supporting the idea that the residues interact to influence receptor deactivation kinetics. 
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Figure 9 GluN1(W608C)/2A receptors show slowed deactivation kinetics; GluN1(W608) 
interacts functionally with Glun2A(S632) to influence receptor gating 
 
A, example trace of GluN1(W608C)/2A receptors showing slow deactivation in response 
to 5 s glutamate (Glu) applications. B, overlay of mutant and WT receptor normalized currents 
showing receptor deactivation. C, mutant cycle analysis diagram based on average 𝜏w of receptors 
(n = 4-5 cells per receptor type). Numbers beside arrows indicate the fold change in 𝜏w between 
the indicated receptors. The mutant cycle 𝜏w value is shown in the center. The interaction between 
the GluN1(608) and GluN2A(632) positions with respect to 𝜏w was tested using two-way ANOVA 
and was found to be statistically significant (p = 0.0001) 
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 GluN2A(W606C) interacts with GluN1(M634C) to influence Mg2+ IC50 
We next examined the role of GluN2A(W606) and residues it may interact with (Figure 
10). Using an all-atom NMDAR TMD model (Mesbahi-Vasey et al., 2017) we noticed \ that 
GluN1(M634) is positioned for interaction with GluN2A(W606) (Figure 10A). Interestingly, 
GluN1(M634) is homologous to GluN2A(S632) (Tikhonov, 2007, Siegler Retchless et al., 2012). 
We mutated GluN2A(W606) and GluN1(M634) to cysteine and examined the resulting receptors 
electrophysiologically (Figure 10). We found that the Mg2+ IC50 was significantly greater for 
GluN1(M634C)/2A receptors (385 ± 224 μM) than for GluN1/2A receptors (69.4 ± 7.1 μM, p = 
0.021) (Figure 10C). We decided to explore whether GluN1(M634C) and GluN2A(W606C) 
interact by performing mutant cycle analysis using Mg2+ IC50 as a readout of potential residue 
coupling. We measured Mg2+ IC50 in GluN1/2A(W606C) and GluN1(M634C)/2A(W606C) 
receptors and found that, while GluN1(M634C)/2A(W606C) receptors showed IC50 (1.45 ± 0.19 
mM) different from GluN1/2A receptors (p < 0.0001), GluN1/2A(W606C) receptors did not (59.2 
± 19.3 μM, p = 0.99). We calculated the mutant cycle Ω using Mg2+ IC50 values and found that Ω 
= 0.23) suggesting that GluN1(M634C) and GluN1A(W606C) interact functionally to influence 
Mg2+ IC50 (Figure 10D)(p = 0.023 by two-way ANOVA). We next examined whether 
GluN1(M634C) and GluN2A(W606C) receptors were in close physical proximity, as predicted by 
the NMDAR TMD model. We isolated plasma membrane receptors and performed non-reducing 
Western blots to examine whether crosslinking occurred between the introduced cysteines. 
Examining surface GluN1/2A and GluN1(M634C)/2A(W606C) receptors for evidence of 
intersubunit crosslinking, we found that diheteromeric signal above WT levels was not present in 
GluN1(M634C)/2A(W606C) lanes. Therefore, the results of the Western blots suggest that 
GluN1(M634C) and GluN2A(W606C) do not form disulfide bonds.  
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Figure 10 GluN1(M634C) and GluN2A(W606C) interact functionally but not biochemically 
 
A, image of GluN1 (green) and GluN2A (blue) M2 and M3 regions (Mesbahi-Vasey et al., 
2017) showing GluN1(M634C) in yellow and GluN2A(W606C) in purple. B, example trace of 
Mg2+ IC50 data from GluN1(M634C)/2A(W606C) receptors with glutamate and increasing 
[Mg2+]s applied as indicated. C, [Mg2+]-inhibition curves for mutant and WT receptors tested for 
mutant cycle (n = 4-5 cells per receptor type). D, mutant cycle analysis diagram based on Mg2+ 
IC50 of receptors. Numbers beside arrows show the fold change in IC50 between the indicated 
receptors. The interaction between the GluN1(634) and GluN2A(606) positions with respect to 
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Mg2+ IC50 was tested using a two-way ANOVA, which revealed a significant interaction (p < 
0.0001).” E, Western blot of surface NMDARs. Left, probed with anti-GluN2A, GluN2A 
monomer bands are apparent at about 160 kDa and faint diheteromer bands are seen in the 
GluN1/2A and GluN1(M634C)/2A(W606C) receptor lanes. Right, same blot probed with anti-
GluN1 showing GluN1/N1 dimers and GluN1 monomers. 
 No evidence of interaction between GluN1(W607C) and GluN1(M634C) to influence 
Mg2+ inhibition 
Based on the similarity of the GluN2A and GluN2B subunits in the M2 and M3 regions, 
we examined electrophysiologically whether the residue in GluN2B homologous to 
GluN2A(W606) (GluN2B(W607)) interacts with GluN1(M634) in GluN1/2B receptors. 
Intriguingly, we noticed potentiation of current when [Mg2+] was applied to cells expressing 
GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) receptors (Figure 11A,B). These 
experiments were done with GluN1-1a/2B receptors (see Methods), which are sensitive to voltage 
and glycine-independent potentiation by Mg2+ (Paoletti et al., 1995, Wang and MacDonald, 1995). 
Mg2+ potentiation of WT GluN1-1a/2B receptors was reported to be maximal (approximately 
three-fold) at 10 mM, the highest [Mg2+] examined, and absent at GluN1-1a/2A receptors (Paoletti 
et al., 1995). While Mg2+ potentiation is voltage-independent, it is occluded by Vm-dependent Mg
2+ 
block in WT GluN1-1a/2B receptors. Therefore, we isolated Mg2+ potentiation by applying Mg2+ 
at +50 mV, where Vm-dependent Mg
2+ block is minimal. We examined whether Mg2+ potentiation 
at GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) receptors differed from potentiation of 
GluN1/2B receptors at +50 mV (Figure 11C). At several Mg2+ concentrations tested, 
GluN1(M634C)/2B(W607C) receptors showed significantly more potentiation than GluN1/2B 
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receptors. It was previously shown that the presence of exon 5 in the GluN1 subunit (e.g. GluN1-
1b) eliminates potentiation of GluN1/2B by Mg2+. We examined Mg2+ potentiation in GluN1/2B 
receptors with NTD-lacking GluN1 subunits (GluN1(∆NTD)). Paoletti et al., 1995, showed that 
exon 5 in the GluN1 NTD controls Mg2+ potentiation. Our data show little-to-no potentiation in 
GluN1(∆NTD)/2B receptors, indicating that the NTD is critical for Mg2+ potentiation.   
To determine whether Mg2+ inhibition occurs in addition to Mg2+ potentiation in 
GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) receptors, we normalized IMg
2+/IControl 
values at -60 mV (IMg
2+/IControl(-60mV)) to IMg
2+/IControl values at + 50 mV (IMg
2+/IControl(+50mV)). 
We found that Vm-dependent Mg
2+ inhibition occurs at GluN2B(W607C)-containing receptors but 
is masked by Mg2+ potentiation (Figure 11D). We fit IMg
2+/IControl(-60mV))/ IMg
2+/IControl(+50mV) 
data from GluN2B(W607C)-containing receptors with Equation 2 to determine Mg2+ IC50. Mg
2+
 
block was incomplete in GluN2B(W607C)-containing receptors. In GluN1/2B and 
GluN1(M634C)/2B receptors, Mg2+ potentiation was either small or absent at the [Mg2+]s used to 
determine the Mg2+ IC50. Therefore, Mg
2+ IC50 values in these receptors were measured using 
unnormalized data collected at -60 mV. Mg2+ IC50s were similar in GluN1/2B (26.9 ± 3.3 μM) and 
GluN1(M634C)/2B (20.1 ± 1.0 μM) receptors (p = 0.99). We found that both GluN1/2B(W607C) 
(264 ± 18 μM, p = 0.0006) and GluN1(M634C)/2B(W607C) receptors (365 ± 180 μM, p < 0.0001) 
showed higher Mg2+ IC50 than GluN1/2B receptors. Using the measured IC50 values, we calculated 
the mutant cycle Ω. We found that Ω = 0.53, and that the interaction between the GluN1(634) and 
GluN2B(607) positions was not significant by two-way ANOVA (p = 0.12). Therefore, we did not 
find evidence that GluN1(M634) and GluN2B(W607) interact to influence Mg2+ IC50.  
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Figure 11 No evidence for interaction of GluN1(M634C) and GluN2B(W607C) to influence 
Mg2+ IC50 
 
A, example trace of responses of GluN1(M634C)/2B(W607C) receptors to varying [Mg2+] 
at -60 mV (dark pink, bottom trace) and +50 mV (light pink, top trace). Traces at -60 mV and +50 
mV are from two different cells. B,C, Plotted response of WT and mutant receptors to varying 
[Mg2+] at -60 mV (B; n=4-8 cells per receptor type) and +50 mV (C; n = 4-5 cells per receptor 
type). C also shows the absence of potentiation in GluN1(∆NTD)/2B receptors. D, IC50 values of 
WT and mutant receptors. GluN1(M634C)/2B and GluN1/2B receptor IC50s were determined from 
recordings at -60 mV, while GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) IC50s were 
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obtained by fitting responses to [Mg2+] at -60 mV normalized to responses to the same [Mg2+] at 
+50 mV. E, mutant cycle analysis diagram based on Mg2+ IC50 of receptors. Numbers beside 
arrows indicate the fold change in IC50 between the indicated receptors. Ω is shown in the center. 
The interaction between GluN1(M634) and GluN2B(W607) with respect to Mg2+ IC50 determined 
using two-way ANOVA was not statistically significant (p = 0.12). 
2.5 Discussion 
In this work we investigated the role of a conserved tryptophan in the TMD of GluN1, 
GluN2A and GluN2B subunits and its interaction with residues predicted to be nearby across the 
intersubunit interface. We began by studying the conserved tryptophan in GluN1 subunits. 
GluN1(W608) was previously shown to couple with GluN2A(S632), predicted to across the 
interface from GluN2A(S632), with respect to Mg2+ IC50 (Siegler Retchless et al., 2012). To test 
whether GluN1(W608) and GluN2A(S632) are in close proximity, we created the GluN1(W608C) 
and GluN2A(S632C) mutations and probed for crosslinking between the introduced cysteines by 
examining diheteromer formation in membrane proteins (Figure 7). Western blotting identified 
diheteromers in both WT GluN1/2A and GluN1(W608C)/2A(S632C) membrane proteins. The 
ratio of diheteromer to GluN1 monomer was significantly higher in GluN1(W608C)/2A(S632C) 
than in WT receptors, suggesting that crosslinking occurred between GluN1(W608C) and 
GluN2A(S632C). We further probed for crosslinking between GluN1(W608C) and 
GluN2A(S632C) using tandem mass spectrometry (Figure 8), which verified that crosslinking 
occurs between GluN1(W608C) and GluN2A(S632C). In accordance with predictions from 
molecular modeling (Siegler Retchless et al., 2012, Mesbahi-Vasey et al., 2017), our data suggest 
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that GluN1(W608) and GluN2A(S632) come into close proximity at the GluN1 M2 – GluN2A M3 
interface. 
The GluN2 S/L site, a position containing a serine (S) in WT GluN2A and GluN2B and 
leucine (L) in GluN2C and GluN2D influences NMDAR subtype-dependence of channel 
properties. We wanted to examine whether residues lining the GluN1 M2 – GluN2A M3 interface 
also influence receptor gating. Indeed, we detected altered gating in GluN1(W608C)/2A receptors 
electrophysiologically. GluN1(W608C)/2A receptors showed extremely slow deactivation 
kinetics. To explore whether GluN1(W608C) interacts with GluN2A(S632C) to affect 
deactivation kinetics we performed mutant cycle analysis using receptor 𝜏w (Figure 9). We 
discovered that positions GluN1(608) and GluN2A(632) interact to influence 𝜏w, suggesting 
functional coupling between these residues with respect to deactivation kinetics. Therefore, we 
suggest that residue-residue interactions at the GluN1 M2 – GluN2A M3 interface influence 
receptor gating as well as NMDAR channel properties (Siegler Retchless et al., 2012).  
We next examined residues predicted to lie across the intersubunit interface from the 
conserved tryptophan in GluN2A (GluN2A(W606)). Using an NMDAR TMD model we identified 
that the residue homologous to GluN2A(S632C), GluN1(M634), lies directly across the GluN1 
M3 – GluN2A M2 interface from GluN2A(W606). To investigate whether the GluN2A(W606) 
interacts functionally with the GluN1(M634) position, we examined GluN1/2A, 
GluN1(M634C)/2A, GluN1/2A(W606C), and GluN1(M634C)/2A(W606C) receptors 
electrophysiologically (Figure 10). We noted altered Mg2+ IC50 in GluN1(M634C)-containing 
receptors and performed mutant cycle analysis using Mg2+ IC50 to examine whether GluN1(M634) 
and GluN2A(W606) interact to influence Mg2+ block. Mutant cycle analysis revealed evidence of 
residue coupling to influence Mg2+ IC50. We conclude that residues at the GluN1(M634) and 
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GluN2A(W606) positions can modulate NMDAR block by Mg2+. Williams et al. observed that 
GluN1/2A(W606L) receptors showed slightly increased Mg2+ IC50 compared to GluN1/2A 
receptors, as well as increased permeability to Mg2+ (Williams et al., 1998). Interestingly, we did 
not observe decreased Mg2+ potency in GluN1/2A(W606C) receptors. The differences in Mg2+ 
block between GluN1/2A(W606L) and GluN1/2A(W606C) receptors may be explained by the 
differing effects produced by insertion of leucine, rather than cysteine, at GluN2A(W606). After 
finding evidence of functional coupling between GluN1(M634C) and GluN2A(W606C), we 
examined the physical proximity of the residues by probing for disulfide bond formation between 
GluN1(M634C) and GluN2A(W606C) in membrane receptors. Western blot experiments did not 
reveal evidence for intersubunit disulfide bond formation between GluN1(M634C) and 
2A(W606C). However, several factors influence whether cysteine residues can crosslink, 
including access to solvent (Wang and Kaltashov, 2015). If the GluN1(M634C) or 
GluN2A(W606C) residues are not solvent-accessible, disulfide bond formation between the 
residues may be inhibited regardless of their physical proximity. Therefore, this result neither 
confirms nor rejects the hypothesis that GluN1(M634C) and GluN2A(W606C) are physically 
close.  
We also examined whether, like GluN2A(W606C), GluN2B(W607C) interacts with 
GluN1(M634C) to influence Mg2+ IC50 (Figure 11). Interestingly, application of Mg
2+ to 
GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) receptors resulted in potentiation of 
responses at -60 mV. Noting that exon 5-lacking WT GluN1/2B NMDARs (like those used here; 
GluN1-1a/2B receptors) are potentiated by Mg2+, we investigated whether increased Mg
2+ 
potentiation could explain the potentiation seen with GluN2B(W607C)-containing receptors at -
60 mV. Mg2+ potentiation of WT GluN1/2B receptors is most apparent at positive potentials, where 
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Vm-dependent Mg
2+ block of receptors is minimal. Therefore, we compared the potentiation by 
Mg2+ of WT GluN1/2B receptors with GluN2B(W607C)-containing receptors at +50 mV. We 
found that Mg2+ potentiation was eliminated in GluN1/2B receptors that lack the GluN1 NTD 
(GluN1(∆NTD)/2B receptors), consistent with Paoletti et al., 1995. GluN1/2B(W607C) and 
GluN1(M634C)/2B(W607C) receptors showed significantly more Mg2+ potentiation than 
GluN1/2B receptors, indicating that that mutation of a GluN2B M2 residue can influence distant 
NTD-mediated phenomena. This result confirms that, as others have noted (Hansen et al., 2018), 
NMDARs are highly allosteric with extensive coupling between its domains. 
 We then determined whether increased Mg2+ potentiation prevented us from observing 
Vm-dependent Mg
2+ block in GluN2B(W607C)-containing receptors at -60 mV. To measure Vm-
dependent Mg2+ block in GluN2B(W607C)-containing receptors, we divided normalized 
responses to [Mg2+] at -60 mV by responses to the same [Mg2+] at +50 mV. We found that 
GluN1/2B(W607C) and GluN1(M634C)/2B(W607C) were maximally ~50% and ~40% inhibited, 
respectively, by Mg2+ at -60 mV. Incomplete block by Mg2+ of GluN1/2B(W607C) and 
GluN1(M634C)/2B(W607C) receptors may be due to increased Mg2+ permeation, which was 
observed in other receptors with mutations at GluN2B(W607) (Williams et al., 1998). We 
calculated Mg2+ IC50 values of GluN1/2B, GluN1(M634C)/2B, GluN1/2B(W607C), and 
GluN1(M634C)/2B(W607C) receptors to examine interaction between GluN1(M634) and 
GluN2B(W607) to influence Mg2+ IC50. The values obtained for Mg
2+ IC50 of GluN1/2A and 
GluN1/2B were within the range of reported values at similar membrane potentials for GluN1/2A 
(Wrighton et al., 2008, Qian et al., 2005, Monyer et al., 1992, Yi et al., 2018, Paoletti and Neyton, 
2007) and GluN1/2B (Williams et al., 1998, Siegler Retchless et al., 2012, Paoletti and Neyton, 
2007). We found that the GluN2B(W607C) mutation resulted in a significantly larger Mg2+ IC50 
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than in GluN1/2B receptors, while the GluN1(M634C) mutation did not affect Mg2+ IC50. The 
interaction between GluN1(M634) and GluN2B(W607) residues to affect Mg2+ IC50 was not 
significant (p = 0.12), suggesting that GluN1(M634C) and GluN2B(W607C) do not couple to 
influence Mg2+ IC50.  
Our examination of the conserved tryptophan in GluN2A and GluN2B subunits reveals 
that the GluN1 M3 – GluN2 M2 interface powerfully influences GluN1/2A and GluN1/2B 
receptors. The GluN2A and GluN2B M1-M4 regions have identical sequences apart from three 
amino acids (Siegler Retchless et al., 2012, Tikhonov, 2007). However, our results suggest that 
the GluN2 conserved tryptophan may play different roles in GluN1/2A and GluN1/2B receptors. 
In GluN1/2A receptors, the GluN2A(W606C) mutation does not alter Mg2+ IC50 and the 
GluN1(M634C) mutation does. In GluN1/2B receptors, the opposite is true: the GluN1(M634C) 
mutation does not affect Mg2+ IC50, while the GluN2B(W607C) does. This “role swapping” of 
homologous residues in the GluN2A and GluN2B subunits suggests that, despite the immense 
similarity between GluN2A and GluN2B subunit TMDs, there are functionally-important 
differences that may influence receptor function.  
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3.0 Effects of Mg2+ on Recovery of NMDA Receptors from Inhibition by Memantine and 
Ketamine Reveal Properties of a Second Site 
Glasgow N.G, Wilcox M.R., Johnson, J.W. (2018). “Effects of Mg2+ on recovery of 
NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.” 
Neuropharmacology 137: 344-358. 
3.1 Overview 
Memantine and ketamine are NMDA receptor (NMDAR) open channel blockers that are 
thought to act via similar mechanisms at NMDARs but exhibit divergent clinical effects. Both 
drugs act by entering open NMDARs and binding at a site deep within the ion channel (the deep 
site) at which the endogenous NMDAR channel blocker Mg2+ also binds. Under physiological 
conditions, Mg2+ increases the IC50s of memantine and ketamine through competition for binding 
at the deep site. Memantine also can inhibit NMDARs after associating with a second site 
accessible in the absence of agonist, a process termed second site inhibition (SSI) that is not 
observed with ketamine. Here we investigated the effects of 1 mM Mg2+ on recovery from 
inhibition by memantine and ketamine, and on memantine SSI, of the four main diheteromeric 
NMDAR subtypes. We found that: recovery from memantine inhibition depended strongly on the 
concentration of memantine used to inhibit the NMDAR response; Mg2+ accelerated recovery from 
memantine and ketamine inhibition through distinct mechanisms and in an NMDAR subtype-
dependent manner; and Mg2+ occupation of the deep site disrupted memantine SSI in a subtype-
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dependent manner. Our results support the hypothesis that memantine associates with but does not 
inhibit at the second site. After associating with the second site, memantine can either slowly 
dissociate directly to the extracellular solution, or transit to the deep site, resulting in typical 
channel block. Memantine's relatively slow dissociation from the second site underlies the 
dependence of NMDAR recovery from inhibition on both memantine concentration and on Mg2+. 
3.2 Introduction 
NMDA receptors (NMDARs) are a class of ionotropic glutamate receptors found at most 
fast excitatory synapses in vertebrate nervous systems (Iacobucci and Popescu, 2017a). NMDARs 
are implicated in many disorders of the central nervous system, driving sustained interest in 
therapeutically targeting NMDARs to treat disease (Paoletti et al., 2013, Parsons and Raymond, 
2014). The clinical utility of two NMDAR channel blockers, memantine and ketamine, lend hope 
that continued development of drugs that modify NMDAR function may lead to new therapies for 
numerous disorders (Abdallah et al., 2015, Johnson et al., 2015, Parsons and Raymond, 2014). 
Despite sharing similar mechanisms of action at NMDARs, memantine and ketamine have 
strikingly divergent clinical profiles (Johnson et al., 2015, Parsons et al., 2007b, Abdallah et al., 
2015). Memantine is approved for the treatment of moderate to severe Alzheimer's disease and is 
clinically well tolerated (Lipton, 2006, Parsons et al., 2007b, Parsons and Raymond, 2014). In 
contrast, ketamine was initially approved as an anesthetic and has shown efficacy as a rapid 
antidepressant and in treatment of pain, but causes psychotomimetic side effects at therapeutic 
doses (Abdallah et al., 2015, Persson, 2013, Krystal et al., 2003). A more thorough understanding 
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of the differential mechanisms of memantine and ketamine action may aid development of novel 
therapeutics for treatment of nervous system disorders.  
NMDARs are glutamate- and glycine-gated ion channels that exhibit unique biophysical 
properties including highly Vm-dependent channel block by physiological concentrations (~1 mM) 
of Mg2+ (Mayer et al., 1984, Nowak et al., 1984). Mg2+ inhibition and other NMDAR biophysical 
properties vary substantially depending on the identity of the GluN2 subunits that constitute the 
receptor (Glasgow et al., 2015, Paoletti et al., 2013). NMDARs are heterotetramers typically 
composed of two GluN1 and two GluN2 subunits. One gene encodes the GluN1 subunit, whereas 
four genes encode four GluN2 subunits: GluN2A, GluN2B, GluN2C, and GluN2D (Iacobucci and 
Popescu, 2017a, Paoletti et al., 2013). The specific combination of subunits that make up an intact 
receptor defines the NMDAR subtype, of which there are many. For example, a GluN1/2A 
receptor subtype refers to an NMDAR that contains two GluN1 and two GluN2A subunits. Here 
we focus on the four GluN1/2 diheteromeric NMDAR subtypes: GluN1/2A, GluN1/2B, 
GluN1/2C, and GluN1/2D receptors. Due to NMDAR subtype-dependent structural differences, 
Mg2+ inhibition varies among NMDAR subtypes (Monyer et al., 1994, Kuner and Schoepfer, 1996, 
Siegler Retchless et al., 2012). Mg2+ exhibits similar inhibition of GluN1/2A and GluN1/2B 
receptors, and similar inhibition of GluN1/2C and GluN1/2D receptors, but Mg2+ inhibits 
GluN1/2A and GluN1/2B receptors more potently than GluN1/2C and GluN1/2D receptors.  
Inhibition of all four GluN1/2 diheteromeric NMDAR subtypes by Mg2+, memantine, and 
ketamine can be reduced or eliminated by mutation of critical asparagine residues at the N-site in 
the M2 pore-lining region of NMDARs (Yamakura et al., 1993, Kashiwagi et al., 2002, Burnashev 
et al., 1992b, Kuner and Schoepfer, 1996). These asparagine residues therefore are thought to play 
an essential role in forming the site, or overlapping sites, where channel blockers bind, referred to 
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here as the deep site. Because Mg2+ competes with organic NMDAR channel blockers for binding 
at the deep site, Mg2+ increases the IC50 of organic channel blockers, including memantine and 
ketamine (Kotermanski and Johnson, 2009, Nikolaev et al., 2012, Otton et al., 2011, Lerma et al., 
1991). At a concentration of 1 mM, Mg2+ increases the memantine and ketamine IC50s for 
inhibition of GluN1/2A and GluN1/2B receptors at -66 mV ~17-fold. However, 1 mM Mg2+ 
increases the memantine and ketamine IC50s for inhibition of GluN1/2C and GluN1/2D receptors 
only ~3-fold because of the lower Mg2+ potency at these NMDAR subtypes (Kotermanski and 
Johnson, 2009). Therefore, in physiological Mg2+, memantine preferentially inhibits GluN1/2C 
and GluN1/2D receptors, an effect proposed to impact strongly the clinical effects of memantine 
(Povysheva and Johnson, 2016). However, NMDAR subtype discrimination by memantine 
decreases with depolarization (Kotermanski and Johnson, 2009), inhibition of GluN1/2A receptors 
increases with increasing intracellular Ca2+ concentration (Glasgow et al., 2017), and low-dose 
memantine inhibition of GluN2A- and GluN2B-containing receptors reduces firing frequency in 
vivo (Szegedi et al., 2010). Thus, inhibition by memantine of all GluN1/2 receptor subtypes is 
likely to play important roles in the clinical actions of memantine. 
Although the effects of Mg2+ on memantine and ketamine IC50s are consistent with a 
competitive binding model, other data suggest a more complex interaction between Mg2+ and 
organic NMDAR channel blockers (Nikolaev et al., 2012). For example, Mg2+ can accelerate 
recovery from inhibition by MK-801 (McKay et al., 2013), an organic NMDAR channel blocker 
with a very slow time course of recovery (Huettner and Bean, 1988); if Mg2+ and MK-801 
exhibited simple competitive binding, Mg2+ should not affect recovery from MK-801 inhibition. 
The effects of Mg2+ on the time course of recovery from inhibition by memantine and ketamine 
have not been explored. Indeed, most basic in vitro investigations of organic NMDAR channel 
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blockers have been conducted in the absence of extracellular Mg2+. As a result, our ability to 
predict how organic NMDAR channel blockers act at NMDARs under physiological conditions, 
which may depend importantly on the effects of a physiological Mg2+ concentration (Gideons et 
al., 2014), is limited. 
There are several differences between memantine and ketamine that may underlie their 
distinct clinical actions including binding to non-NMDAR targets (e.g. (Maskell et al., 2003, Lu 
et al., 2010)) and differences in pharmacokinetics (e.g. (Hesselink et al., 1999, Lord et al., 2013), 
but see (Kotermanski et al., 2013)). In addition to differences in non-NMDAR targets and 
pharmacokinetics, there is a prominent distinction between memantine and ketamine action at 
NMDARs: the ability of memantine (Blanpied et al., 1997, Chen and Lipton, 2005, Kotermanski 
et al., 2009, Sobolevsky and Koshelev, 1998), but not ketamine (Kotermanski et al., 2009), inhibit 
NMDARs via second site inhibition (SSI), a type of inhibition observed following drug association 
with a second site accessible in the absence of agonist. Although the clinical implications of 
memantine action at a second site are not clear, SSI has been suggested to contribute to the clinical 
safety of memantine (Parsons et al., 2007b, Chen and Lipton, 2005, Kotermanski et al., 2009). 
However, the effect of Mg2+ on memantine action at the second site has not been explored. 
Therefore, we investigated the effects of 1 mM Mg2+ both on the time course of recovery from 
inhibition by memantine and ketamine and on memantine SSI. 
 My contribution 
Nathan G. Glasgow is the first author of this work, which is published in 
Neuropharmacology (Glasgow et al., 2018). As the second author, I designed some of the 
experiments in this paper, collected data (Figures 16,18), analyzed and interpreted data, and 
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assisted in writing the manuscript. This work is included as a chapter in my dissertation because it 
provides an informative introduction to SSI (later re-named membrane-to-channel inhibition; 
MCI, in Chapter 4). The findings in chapter 4 were rooted in discoveries that I contributed to in 
this paper.  
3.3 Methods 
 Cell culture and transfection 
Experiments were performed on the tsA201 cell line (The European Collection of 
Authenticated Cell Cultures), which is a variant of the HEK 293 cell line. tsA201 cells were 
maintained as previously described (Glasgow and Johnson, 2014) in DMEM supplemented with 
10% fetal bovine serum and 1% GlutaMAX (Thermo Fisher Scientific), either with or without 100 
IU/ml of penicillin and 100 mg/ml streptomycin (Corning). 1 x 105 cells/dish were plated on 15 
mm glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 mg/ml, BD 
Biosciences) in 35 mm petri dishes. 12 to 24 hours after plating, the cells were transiently 
cotransfected using FuGENE 6 Transfection Reagent (Promega) with mammalian expression 
plasmids that contained cDNAs encoding enhanced green fluorescent protein (EGFP in pRK7) for 
identification of transfected cells, the rat GluN1-1a subunit (hereafter GluN1; GenBank X63255 
in pcDNA3.1), and either the rat GluN2A subunit (GenBank M91561 in pcDNA1), the rat GluN2B 
subunit (GenBank M91562 in pcDNA1), the rat GluN2C subunit (GenBank M91563 in pcDNA1), 
or the rat GluN2D subunit (GenBank L31612 in pcDM8). For some experiments we used cells 
transfected with GluN1 and an EGFP:pIRES:GluN2A construct, which was a kind gift from Dr. 
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Kasper Hansen (Hansen, unpublished). Briefly, EGFP was inserted in pIRES (Clontech) under 
transcriptional control of the CMV promoter, and the open reading frame of rat GluN2A (GenBank 
D13211) was inserted after the IRES sequence. cDNA ratios used were 1:1:1 (EGFP, GluN1, and 
GluN2A); 1:1 (GluN1 and EGFP:pIRES:GluN2A); or 1:1:3 (EGFP, GluN1, and GluN2B, C, or 
D). cDNA for the GluN1(N616R) mutant subunit (residue numbering starting from initiating 
methionine) was a kind gift from Dr. Pierre Paoletti and was transfected at the same ratio as wild-
type GluN1. Immediately after transfection, the culture medium was supplemented with the 
competitive NMDAR antagonists D,L-2-amino-5-phosphonopentanoate (200 μM) and 7-
chlorokynurenic acid (200 μM) to prevent NMDAR-mediated cell death. 
 Solutions 
The extracellular bath solution contained (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, 10 
HEPES, 0.01 EDTA, and 0.1 glycine, balanced to pH 7.2 ± 0.05 with NaOH and osmolality raised 
to 290 ± 10 mOsm with sucrose. L-glutamate, MgCl2, memantine, and (R,S)-ketamine (hereafter, 
ketamine) were added to the extracellular solution as indicated from frozen concentrated stock 
solutions on the same day as experiments. The intracellular pipette solution contained (in mM): 
130 CsCl, 10 HEPES, 10 BAPTA, and 4 MgATP balanced to pH 7.2 ± 0.05 with CsOH; solution 
osmolality was 280 ± 10 mOsm. Frozen aliquots of pipette solution were thawed and kept on ice 
until loaded into pipettes immediately before starting an experiment. 
 71 
 Electrophysiology 
Whole-cell voltage-clamp recordings were performed on transfected tsA201 cells 12 – 72 
hours after transfection. Pipettes were pulled from borosilicate capillary tubing (Sutter 
Instruments) on a Sutter Instruments-Flaming Brown P-97 microelectrode puller and fire polished 
to a resistance of 2 – 5 ΜΩ . Whole-cell recordings were made from cells expressing EGFP 
identified by epifluorescence illumination on an inverted Zeiss Axiovert microscope. Cells were 
held at a membrane potential (Vm) of -65 mV, unless otherwise indicated, corrected for an 
empirically determined liquid junction potential between the extracellular and intracellular 
solution of -6 mV. Whole-cell currents were amplified using an Axopatch 200B patch-clamp 
amplifier (Molecular Devices), low-pass filtered at 5 kHz and sampled at 20 kHz in pClamp10 
(Molecular Devices). Series resistance was compensated 85-90% with the prediction and 
correction circuitry in all experiments.  
Solutions were delivered to coverslip-attached cells through a ten-barrel fast perfusion 
system described previously (Glasgow et al., 2017). We determined the time course of solution 
exchange around whole cells by recording current relaxations following movements between two 
adjacent barrels. The initial barrel contained normal extracellular solution and 1 mM glutamate, 
and the barrel to which test movements were made contained extracellular solution with 50% NaCl 
and 1 mM glutamate. Solution exchange around a whole cell had a 10-90% rise time of 150 ± 35 
ms (mean ± SD) and was well fit by a single exponential with a time constant of 27.4 ± 6.6 ms 
(mean ± SD).  
Accurate measurement of the time course of recovery from inhibition by an inhibitory drug 
requires a rapid decrease of drug concentration to well below its IC50. Effective drug washout can 
require multiple solution exchange time constants, especially with higher drug concentrations. 
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Therefore, some of our measurements of the 𝜏fast of recovery from drug inhibition may have been 
limited by the speed of solution exchange. For example, at a starting concentration of 100 μM 
drug, after 150 ms (~5 time constants) the drug concentration would be ~0.4 μM, which is still 
close to the IC50 for memantine or ketamine (Kotermanski and Johnson, 2009). However, 
measurements of the slow of recovery from drug inhibition should have been unaffected by 
limitations of solution exchange around a whole cell, even at the highest drug concentrations used.   
 Analysis 
All data were analyzed with Clampfit 10.3 or 10.7 (Molecular Devices), or GraphPad Prism 
7. Time course of recovery from inhibition by memantine or ketamine were determined from drug 
concentration-inhibition relation experiments. Briefly, glutamate was applied for 10 – 20 s until 
current reached steady state, then glutamate with 1, 10, 100, or 1000 μM memantine or ketamine 
was applied for 10 – 40 s until a new steady-state current level was reached. Glutamate in the 
absence of drug was then reapplied for 20 – 60 s to allow recovery from inhibition. The time 
necessary to reach a steady level of inhibition and to allow recovery from inhibition depended on 
the NMDAR subtype, as expected for channel blockers. Experiments in which NMDAR-mediated 
current during recovery from inhibition did not reach at least 90% of steady-state NMDAR-
mediated current preceding drug application were excluded from analysis.  
Time course of recovery from memantine and ketamine inhibition was measured by 
performing least-squares fits of single or double exponential functions to current traces using 
Clampfit 10.3 or 10.7. The number of components used in exponential fits was determined by 
visual examination, using the fewest components required to obtain a satisfactory fit. For 
comparison with the time constant () of single exponential fits, a weighted time constant (w) was 
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calculated from the results of double exponential fits using the equation: w = (fast*Afast + 
slow*Aslow)/(Afast + Aslow), where the faster component had time constant fast and amplitude Afast 
and the slower component had time constant slow and amplitude Aslow. To compare amplitudes of 
the fast and slow components across cells irrespective of absolute current amplitude, normalized 
values of Afast and Aslow were calculated by dividing each by (Afast + Aslow).  
SSI was measured using the following SSI protocol: (a) 1 mM glutamate was applied for 
20 s, and control current before SSI (Icontrol1) was measured (see below); (b) normal extracellular 
solution was applied for at least 9 s to allow full deactivation of receptors; (c) memantine in the 
absence of glutamate was applied for 30 s; (d) memantine was washed away by a 1 s application 
of normal extracellular solution; (e) 1 mM glutamate was reapplied for 20 s for GluN1/2A 
receptors and for 40 s for GluN1/2C receptors, and current during SSI (ISSI) was measured; (f) 
normal extracellular solution was applied for at least 40 s; (g) 1 mM glutamate was reapplied for 
20 s and control current after SSI (Icontrol2) was measured. We chose to use a 1 s wash (>30-fold 
longer than the  of solution exchange) in step (d) for ensure complete removal of memantine from 
the extracellular solution while still maintaining substantial SSI ( of recovery from SSI is ~2 s) 
(Kotermanski et al., 2009). 
The minimum fractional response after SSI (minimum ISSI/Icontrol) was measured by 
comparing ISSI to the average of Icontrol1 and Icontrol2 with a point-by-point ratio (Iacobucci and 
Popescu, 2017b) of ISSI/Icontrol, where Icontrol = ((Icontrol1 + Icontrol2)/2) (see Figure 16). Each of the 
currents was aligned to the time of glutamate application. We measured the minimum ISSI/Icontrol 
as the mean of ISSI/Icontrol over a 200 ms window centered on the minimum ratio value. The time 
constant of recovery from SSI (recovery SSI) was measured by fitting a single exponential function 
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to recovery of ISSI/Icontrol (see Figure 16). SSI measurements were excluded if Icontrol2 did not recover 
to at least 80% of Icontrol1.  
Cells with NMDAR currents > 2 nA were excluded from analysis due to large Ca2+-
dependent desensitization. Because of potent Mg2+ inhibition at -65 mV, for recordings in the 
continuous presence of 1 mM Mg2+ we chose cells with large NMDAR responses that exceeded 
our current amplitude cutoff in 0 Mg2+. Therefore, separate cells were used for recordings 
performed in 0 Mg2+ and in the continuous presence of 1 mM Mg2+. 
 Statistics 
All statistical comparisons were performed in GraphPad Prism 7. We compared the  or w 
of recovery from drug inhibition across drug concentrations for each NMDAR subtype and Mg2+ 
concentration by repeated measures one-way ANOVA with Tukey’s post hoc analysis; 
significance values are indicated in text. Individual pair-wise comparisons of the  or w of 
recovery from inhibition by the same drug concentration between 0 and 1 mM Mg2+ were made 
by two-tailed Student’s t-test with the Bonferroni correction; significance values are indicated in 
text. We compared the minimum ISSI/Icontrol across all conditions within each NMDAR subtype by 
one-way ANOVA with Tukey’s post hoc analysis; significance values are indicated in text. We 
compared the  recovery SSI between GluN1/2A and GluN1/2C receptors and within each 
NMDAR subtype between recovery SSI and slow of recovery from memantine inhibition by one-
way ANOVA with Tukey’s post hoc analysis; significance values are indicated in text. All error 
bars indicate ± standard error of the mean (SEM). Current traces for presentation were refiltered 
offline in Clampfit 10.3 or 10.7 at 200 Hz. 
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3.4 Results 
 Recovery from inhibition by memantine, but not ketamine, exhibits strong 
dependence on drug concentration 
To determine whether addition of 1 mM extracellular Mg2+ affects the time course of 
recovery from inhibition by memantine and ketamine, we first measured recovery from inhibition 
by memantine and ketamine in 0 Mg2+. We used 1, 10 and 100 μM memantine or ketamine to 
assess the time course of recovery from inhibition for each drug with the four GluN1/2 
diheteromeric NMDAR subtypes: GluN1/2A, GluN1/2B, GluN1/2C, and GluN1/2D receptors. 
Drug concentrations below 1 μM were not used because the small amount of inhibition prevented 
reliable measurements of recovery from inhibition. We assessed the time course of recovery from 
inhibition by comparing time constants of single () or double exponential (w) fits to current 
relaxations following rapid removal of drug in the continuous presence of agonists (see Methods). 
NMDARs were activated using 1 mM glutamate (applied at times indicated in figures) and 100 
μM glycine (present in all extracellular solutions) to assure that all measurements were performed 
at saturating agonist concentrations (Traynelis et al., 2010a). 
The time course of recovery from memantine and ketamine inhibition exhibited powerful 
NMDAR subtype dependence. At each memantine and ketamine concentration, recovery from 
inhibition was fastest for GluN1/2A receptors, slower for GluN1/2B receptors, and slowest for 
GluN1/2C and GluN1/2D receptors (Figure 12B; Figure 13B; Tables 1 and 2). These results are 
consistent with a defining characteristic of open channel blockers: recovery from inhibition occurs 
only when the channel is open, and thus speed of recovery from inhibition correlates with receptor 
maximal open probability (Popen), which is highest for GluN1/2A, lower for GluN1/2B, and lowest 
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for GluN1/2C and GluN1/2D receptors (Chen et al., 1999, Dravid et al., 2008a, Erreger et al., 
2005, Wyllie et al., 1998). 
We found in 0 Mg2+ that the time course of recovery from memantine inhibition of each 
NMDAR subtype depended strongly on the concentration of memantine used to inhibit the 
response (Figure 12B; Figure 14D; Table 1). Consistent with previous studies (Sobolevsky and 
Koshelev, 1998, Gilling et al., 2007), recovery from inhibition was slower at higher memantine 
concentrations, although we observed greater dependence of recovery time course on memantine 
concentration than reported previously (see Discussion). The 𝜏w of recovery from inhibition with 
100 μM memantine was 11.7-fold slower than with 1 μM memantine for GluN1/2A receptors (p 
= 0.0002), 5.1-fold slower for GluN1/2B receptors (p = <0.0001), 2.5-fold slower for GluN1/2C 
receptors (p = 0.04), and 1.9-fold slower for GluN1/2D receptors (p = 0.002; Figure 12B; Figure 
14D; Table 1). In sharp contrast, we found that the time course of recovery from ketamine 
inhibition was weakly concentration-dependent in GluN1/2A receptors and was not concentration-
dependent in GluN1/2B, GluN1/2C, and GluN1/2D receptors (Figure 13B; Figure 15D; Table 2). 
These data are consistent with previous reports of no concentration dependence of recovery from 
ketamine inhibition (Parsons et al., 1995, MacDonald et al., 1991, Parsons et al., 1996). The 𝜏w of 
recovery from inhibition with 100 μM ketamine was only 1.6-fold slower than with 1 μM ketamine 
for GluN1/2A receptors (p = 0.01), which is ~10-fold less slowing than for memantine for 
GluN1/2A receptors. This small but significant increase could have resulted from limitations in 
the speed of solution exchange on washout of high drug concentrations (see Methods). 
Importantly, both 𝜏slow and Aslow (measurement of which should have been unaffected by speed of 
solution exchange; see Methods) increased substantially across all NMDAR subtypes between 1 
and 100 μM for memantine (Table 1), but not ketamine (Table 2). Therefore, it appears implausible 
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that the robust concentration dependence of the time course of recovery from memantine inhibition 
could have resulted from limitations in the speed of solution exchange.  
 
Figure 12 Time course of recovery from memantine inhibition is strongly concentration 
dependent 
 
A, representative current traces used for measuring the time course of recovery from 
memantine inhibition of GluN1/2A receptors activated by 1 mM glutamate (Glu, black bars) in 0 
Mg2+. Memantine (Mem, red bars) was applied at the indicated concentrations. Traces are from 
the same cell. B, representative current traces illustrating memantine concentration dependence of 
recovery from memantine inhibition for GluN1/2A – GluN1/2D receptors (Ba-Bd). Current traces 
show recovery from memantine (red bars) inhibition in the continuous presence of glutamate 
(black bars) for GluN1/2A receptors (Ba; from cell used for panel A), or from similar experiments 
for GluN1/2B – GluN1/2D receptors (Bb-Bd). Pairs of traces at the indicated memantine 
concentrations are aligned at the time of memantine removal and scaled to the change in current 
 78 
amplitude during recovery from inhibition. Results of exponential fits to recovery from memantine 
inhibition are shown in Figure 14 and Table 1.   
 
Figure 13 Time course of recovery from ketamine inhibition is largely independent of 
concentration 
 
A, representative current traces used for measuring the time course of recovery from 
ketamine inhibition of GluN1/2A receptors activated by 1 mM glutamate (black bars) in 0 Mg2+. 
Ketamine (Ket, blue bars) was applied at the indicated concentrations. Traces are from the same 
cell. B, representative current traces illustrating ketamine concentration independence of recovery 
from ketamine inhibition for GluN1/2A – GluN1/2D receptors (Ba-Bd). Current traces show 
recovery from ketamine (blue bars) inhibition in the continuous presence of glutamate (black bars) 
for GluN1/2A receptors (Ba; from cell used for panel A), or from similar experiments for 
GluN1/2B – GluN1/2D receptors (Bb-Bd). Pairs of traces at the indicated ketamine concentrations 
are aligned at the time of ketamine removal and scaled to the change in current amplitude during 
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recovery from inhibition. Results of exponential fits to recovery from ketamine inhibition data are 
shown in Figure 15D and Table 2. 
Table 1 Components of the time course of recovery from memantine inhibition 
Values represent means ± SEM, n = 5 – 7 cells per condition. Statistical significance of 
comparisons of 𝜏w values is displayed in Figure 14D. 
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Table 2 Components of the time course of recovery from ketamine inhibition 
 
 
Values represent means ± SEM. Some cells displayed recovery from ketamine inhibition well fit 
by a single exponential, whereas other cells required a double exponential fit. Therefore, single 
exponential 𝜏 and double exponential 𝜏w values were combined when calculating the mean time 
constant value, with n = 4 – 7 cells per condition. The mean values for double exponential 
components have n = 2 – 7 cells per condition. Statistical significance of comparisons of 𝜏 and 𝜏w 
 81 
values is displayed in Figure 15D. Mg2+ accelerates recovery from inhibition by memantine and 
ketamine in an NMDAR subtype-dependent manner 
The presence of 1 mM Mg2+ causes an increase in the memantine and ketamine IC50 values 
((Kotermanski and Johnson, 2009); see Introduction). To achieve similar fractional currents at 
each drug concentration in 1 mM Mg2+ as in 0 Mg2+ for GluN1/2A and GluN1/2B receptors, we 
used 10-fold higher memantine and ketamine concentrations (10, 100, and 1000 μM) when 
measuring the time course of recovery from inhibition in 1 mM Mg2+. For GluN1/2C and 
GluN1/2D receptors in 1 mM Mg2+, we used four memantine and ketamine concentrations (1, 10, 
100, and 1000 μM).  
We found that in 1 mM Mg2+, the time course of recovery from memantine inhibition from 
each NMDAR subtype also exhibited strong concentration dependence (Figure 14A-B,D; Table 
1). The 𝜏w of recovery with 1000 μM memantine was 9.5-fold slower than with 10 μM memantine 
for GluN1/2A receptors (p = 0.0005), 5.8-fold slower for GluN1/2B receptors (p = 0.002), 2.4-
fold slower for GluN1/2C receptors (p = 0.02), and 2-fold slower for GluN1/2D receptors (p = 
0.002; Figure 14B,D; Table 1). Recovery from ketamine inhibition was only weakly concentration-
dependent in 1 mM Mg2+ for GluN1/2A receptors, and was concentration independent for 
GluN1/2B, GluN1/2C, and GluN1/2D receptors (Figure15A-B,D; Table 2), similar to results in 0 
Mg2+.  
Interestingly, we found that recovery of GluN1/2A receptors from inhibition by 100 μM 
memantine and of GluN1/2B receptors from inhibition by 10 and 100 μM memantine was 
significantly faster in 1 mM than in 0 Mg2+ (Figure 14C-D; Table 1). Note that for GluN1/2A and 
GluN1/2B receptors, 10 and 100 μM memantine are the highest concentrations at which recovery 
from inhibition in 0 and 1 mM Mg2+ can be compared. In contrast, recovery from memantine 
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inhibition of GluN1/2C or GluN1/2D receptors was not faster in 1 mM than in 0 Mg2+, and 
recovery of GluN1/2C receptors from inhibition by 1 μM memantine was slower in 1 mM than in 
0 Mg2+ (Figure 14C-D; Table 1). Recovery of GluN1/2A receptors from inhibition by 10 μM 
ketamine was significantly slower in 1 mM than in 0 Mg2+; recovery of GluN1/2B receptors from 
inhibition by 10 and 100 μM ketamine was significantly faster in 1 mM than in 0 Mg2+; Mg2+ had 
no effect on recovery from ketamine inhibition of GluN1/2C and GluN1/2D receptors (Figure 
15C-D; Table 2). The mechanism responsible for the small and variable slowing by Mg2+ of 
recovery from memantine and ketamine inhibition is not clear; one possibility is screening of 
surface potential ((Ascher and Nowak, 1988), but see (Zarei and Dani, 1994)) by Mg2+ (Isaev et 
al., 2012). However, the consistent and substantial acceleration by Mg2+ of recovery from 
memantine inhibition from GluN1/2A and GluN1/2B receptors is likely due to other mechanisms, 
as addressed below. Acceleration by Mg2+ of the time course of recovery of GluN1/2B receptors 
from ketamine inhibition is likely to result from Mg2+ potentiation of GluN1/2B receptor 
responses, which increases Popen (Paoletti et al., 1995) and therefore should accelerate the time 
course of recovery from inhibition; potentiation of GluN1/2B receptors by Mg2+ should also 
partially contribute to acceleration of the time course of recovery of GluN1/2B receptors from 
memantine inhibition. 
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Figure 14 Mg2+ accelerates recovery from memantine inhibition of GluN1/2A and GluN1/2B 
receptor 
 
A, representative current traces used for measuring the time course of recovery from 
memantine inhibition of GluN1/2A receptors in 1 mM Mg2+. Receptors were activated by 1 mM 
glutamate (black bars). Memantine (pink bars) was applied at the indicated concentrations. Traces 
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are from the same cell. B, representative current traces illustrating memantine concentration 
dependence of recovery from memantine inhibition for GluN1/2A – GluN1/2D receptors (Ba-Bd) 
in 1 mM Mg2+. Current traces show recovery from memantine (pink bars) inhibition in the 
continuous presence of glutamate (black bars) for GluN1/2A receptors (Ba; from cell used for 
panel A), or from similar experiments for GluN1/2B – GluN1/2D receptors (Bb-Bd). Pairs of 
traces at the indicated memantine concentrations are aligned at the time of memantine removal 
and scaled to the change in current amplitude during recovery from inhibition. C, representative 
current traces illustrate the effect of Mg2+ on recovery from 100 μM memantine inhibition of 
GluN1/2A – GluN1/2D receptors (Ca-Cd) in the continuous presence of glutamate. Pairs of traces 
in 0 Mg2+ (red traces, replotted from corresponding traces in Figure 12Ba-Bd) or 1 mM Mg2+ (pink 
traces, replotted from corresponding traces in Ba-Bd above) are aligned at the time of memantine 
removal, and scaled to the change in current amplitude during recovery from inhibition. D, Mean 
values of 𝜏w of recovery from memantine inhibition for indicated NMDAR subtype, Mg2+ 
concentration, and memantine concentration. Note the change in y-axis scale between GluN1/2A 
– GluN1/2B and GluN1/2C – GluN1/2D. Comparisons within NMDAR subtype and Mg2+ 
concentration were made by repeated measures one-way ANOVA with Tukey's post hoc analysis 
(* indicates p < 0.05; ** indicates p < 0.01; and *** indicates p < 0.001). Comparisons of the same 
memantine concentrations in 0 and 1 mM Mg2+ were made by two-tailed Student's t-test with 
Bonferroni correction for multiple comparisons (# indicates p < 0.05; ## indicates p < 0.01). n = 5 
– 7 cells in each group.  
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Figure 15 Mg2+ accelerates recovery from ketamine inhibition from GluN1/2B receptors 
 
A, representative current traces used for measuring the time course of recovery from 
ketamine inhibition of GluN1/2A receptors in 1 mM Mg2+. Receptors where activated by 1 mM 
glutamate (black bars). Ketamine (light blue bars) was applied at the indicated concentrations. 
Traces are from the same cell. B, representative current traces illustrating ketamine concentration 
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independence of recovery from ketamine inhibition for GluN1/2A – GluN1/2D receptors (Ba-Bd) 
in 1 mM Mg2+. Current traces show recovery from ketamine (light blue bars) inhibition in the 
continuous presence of glutamate (black bars) for GluN1/2A receptors (Ba; from cell used for 
panel A), or from similar experiments for GluN1/2B – GluN1/2D receptors (Bb-Bd). Pairs of 
traces at the indicated ketamine concentrations are aligned at the time of ketamine removal and 
scaled to the change in current amplitude during recovery from inhibition. C, representative current 
traces illustrate the effect of Mg2+ on recovery from 100 μM ketamine inhibition of GluN1/2A – 
GluN1/2D receptors (Ca-Cd) in the continuous presence of glutamate. Pairs of traces in 0 Mg2+ 
(blue traces, replotted from corresponding traces in Figure 13Ba-Bd) or 1 mM Mg2+ (light blue 
traces, replotted from corresponding traces in Ba-Bd above) are aligned at the time of ketamine 
removal, and scaled to the change in current amplitude during recovery from inhibition. D, mean 
values of 𝜏 or 𝜏w of recovery from ketamine inhibition for indicated NMDAR subtype, Mg2+ 
concentration, and ketamine concentration. Note the change in y-axis scale between GluN1/2A – 
GluN1/2B and GluN1/2C – GluN1/2D. Comparisons within NMDAR subtype and Mg2+ 
concentration were made by repeated measures one-way ANOVA with Tukey's post hoc analysis 
(* indicates p < 0.05). Comparisons of the same ketamine concentrations in 0 or 1 mM Mg2+ were 
made by Student's t-test with Bonferroni correction for multiple comparisons (# indicates p < 0.05). 
n = 4 – 7 cells in each group.  
 Recovery from memantine SSI represents the slow component of recovery from 
memantine inhibition 
Dependence of recovery from inhibition on memantine concentration is surprising if 
inhibition results from interaction of memantine with a single site. Concentration dependence of 
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the time course of drug binding (and thus of inhibition) is expected, since binding occurs in the 
presence of a varying drug concentration. In contrast, concentration dependence of drug unbinding 
kinetics (and thus recovery from inhibition) is atypical, since unbinding always occurs at the same 
drug concentration ([drug] = 0). Memantine concentration dependence of recovery from inhibition 
was proposed to reflect an ability of memantine to interact with two sites (Sobolevsky and 
Koshelev, 1998). However, the hypothesis that the site responsible for SSI (Blanpied et al., 1997, 
Chen and Lipton, 2005, Kotermanski et al., 2009) is involved in the memantine concentration 
dependence of recovery from inhibition has not been tested. Consistent with this hypothesis, 
memantine, but not ketamine, exhibits both SSI (Kotermanski et al., 2009) and strong 
concentration dependence of recovery from inhibition (data presented above). Previous data 
suggest that, paradoxically, the memantine SSI IC50 (~100 μM; (Blanpied et al., 1997, 
Kotermanski et al., 2009)) is much higher than the memantine IC50 for deep site inhibition (~1 μM; 
(Glasgow et al., 2017)), but the time course of recovery from memantine SSI is relatively slow 
(Kotermanski et al., 2009, Blanpied et al., 1997). High IC50 with slow recovery from inhibition is 
atypical because the speed of recovery of channel blockers generally increases as IC50 increases 
(Parsons et al., 2007b). Thus, we hypothesized that the slow component of recovery from 
memantine inhibition, which increases in relative amplitude as memantine concentration 
increased, reflects recovery from memantine SSI. We next evaluated this hypothesis by examining 
the time course of recovery from memantine SSI in 0 Mg2+.  
To assess memantine SSI, we used the SSI protocol described in Methods (see Figure 16A-
B), which is similar to protocols used previously (Blanpied et al., 1997, Kotermanski et al., 2009, 
Sobolevsky and Koshelev, 1998). We used 100 μM memantine, which is near the previously 
estimated memantine SSI IC50 (80-180 μM (Blanpied et al., 1997, Kotermanski et al., 2009)). As 
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shown in Figure 14, the effects of Mg2+ on the time course of recovery from memantine inhibition 
are similar for GluN1/2A and GluN1/2B receptors and are similar for GluN1/2C and GluN1/2D 
receptors. We therefore examined NMDAR subtype dependence of memantine SSI here by 
comparing data from GluN1/2A and GluN1/2C receptors, first in 0 Mg2+ and later in 1 mM Mg2+. 
We focus exclusively on memantine SSI because we previously showed that ketamine does not 
exhibit significant SSI (Kotermanski et al., 2009). 
 
 
Figure 16 Recovery from memantine SSI represents the slow component of recovery from 
memantine inhibition 
A-D, left, Representative current traces illustrate the memantine SSI protocol for 
GluN1/2A (A,C) or GluN1/2C (B,D) receptors in 0 Mg2+. APV was present during memantine 
application only in C and D. Traces are from separate cells. A-D, center, Pairs of traces compare 
control (Icontrol; black) and SSI (ISSI; red) currents aligned at the time of glutamate applications. A-
D, right, Plot of ISSI/Icontrol of the example traces shown at left and center. Gray boxes in A and B 
center indicate the window over which the minimum ISSI/Icontrol was measured for GluN1/2A (A) 
and for GluN1/2C receptors (B). Red lines in A and B right show single exponential fits to the 
time course of recovery from SSI.  
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In 0 Mg2+, we observed that 100 μM memantine induced robust SSI of GluN1/2C as well 
as GluN1/2A receptors. The minimum ISSI/Icontrol was slightly but significantly (p = 0.035) lower 
for GluN1/2C (0.44 ± 0.03) than for GluN1/2A receptors (0.56 ± 0.03; Figure 16A-B; Figure 17G). 
These data suggest that the potency of memantine SSI for GluN1/2A and GluN1/2C receptors is 
similar. The SSI protocol involves a 30-s application of 100 μM memantine in control solution. If 
our control solution contained a low concentration of contaminating glutamate, it may have 
permitted some memantine block to occur through open channels that we then misinterpreted as 
SSI. To control for this possibility, we repeated the SSI protocol while coapplying with memantine 
a competitive antagonist of glutamate binding (50 μM APV; Figure 16C-D). If a portion of the SSI 
we observed were due to memantine block of open NMDARs activated by contaminating 
glutamate, then coapplication of APV with memantine should increase the minimum ISSI/Icontrol 
(bring the minimum ISSI/Icontrol closer to 1, indicating less SSI). In contrast, when 50 μM APV was 
coapplied with 100 μM memantine, the minimum ISSI/Icontrol was not increased, but slightly 
decreased for GluN1/2A receptors (Figure 16C; minimum ISSI/Icontrol: memantine, 0.56 ± 0.03; 
memantine + APV, 0.42 ± 0.02, p = 0.01) and was indistinguishable for GluN1/2C receptors 
(Figure 16D; minimum ISSI/Icontrol: memantine, 0.44 ± 0.03; memantine + APV, 0.49 ± 0.03; p = 
0.84). To determine whether complete unbinding of APV occurred during the 1 s wash following 
application of memantine and APV, we repeated the SSI protocol using a 30 s application of 50 
μM APV alone (with no memantine). We observed no “SSI” using only 50 μM APV with 
GluN1/2A or GluN1/2C receptors (data not shown; minimum ISSI/Icontrol: GluN1/2A, 1.02 ± 0.02; 
GluN1/2C, 1.04 ± 0.01). Thus, glutamate contamination of control solutions did not result in 
artefactual inhibition by memantine of open NMDARs. We conclude that SSI reflects a 
mechanism of memantine access to both GluN1/2A and GluN1/2C NMDARs distinct from 
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conventional open channel block, consistent with previous reports using neuronal NMDARs 
(Blanpied et al., 1997, Sobolevsky and Koshelev, 1998). The remaining SSI experiments were 
conducted without coapplication of APV. 
 
Figure 17 Mg2+ does not compete with memantine for association with the second site 
 
(A-D, left) Representative current traces illustrate the memantine SSI protocol for 
GluN1/2A (A,C) or GluN1/2C (B,D) receptors in 1 mM Mg2+ (A,B) or with the Modified Mg2+ 
SSI protocol (C,D), where 1 mM Mg2+ was present only during memantine application. Traces are 
from separate cells. (A-D, center) Pairs of traces compare control (Icontrol; black) and SSI (ISSI; pink 
and dark red) currents aligned at the time of glutamate applications. (A-D, right) Plot of ISSI/Icontrol 
of the example traces shown at left and center. (E,F) Representative current traces illustrate the 
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effect of Mg2+ on ISSI for GluN1/2A (E) and GluN1/2C receptors (F). Traces in E are replotted 
from Figure 16A and 17A, middle; traces in F are replotted from Figure 16B and 17B, middle. 
Traces are aligned at the time of glutamate applications and scaled to the current amplitude of the 
steady-state response. (G) Mean minimum ISSI/Icontrol values measured during the window indicated 
by gray boxes in Figure 16A,B, right. 1 Mod indicates the Modified Mg2+ SSI protocol shown in 
C and D. *** indicate p < 0.001 by one-way ANOVA with Tukey's post hoc analysis. n = 4 – 6 
cells in each group.  
 
 
Figure 18 Deep site mutation eliminates memantine SSI 
 
(A-C, left) Representative current traces illustrate the memantine SSI protocol for 
GluN1(N616R)/2A (A,C) or GluN1(N616R)/2C (B) receptors with 100 M memantine (A,B) or 
with 500 M memantine (C). Traces are from separate cells. (A-C, center) Pairs of traces compare 
control current (Icontrol; black) and current during SSI (ISSI; red) aligned at the time of glutamate 
applications. (A-C, right) Plot of ISSI/Icontrol of the example traces shown at left and center. (D) 
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Mean minimum ISSI/Icontrol values measured during the time window indicated by gray boxes in 
Figure 16A,B, right. Mean values of the minimum ISSI/Icontrol for wild-type (WT) GluN1/2A and 
GluN1/2C receptors are replotted from Figure 17G. *** indicate p < 0.001 by one-way ANOVA 
with Tukey's post hoc analysis. n = 5 – 6 cells in each group. 
Despite similar memantine SSI potency for GluN1/2A and GluN1/2C receptors, the time 
course of recovery from SSI appeared to be faster for GluN1/2A than for GluN1/2C receptors. To 
quantify the time course of recovery from SSI we measured the 𝜏recovery SSI (see Methods). We 
found that the time course of recovery from SSI was ~3-fold faster for GluN1/2A than for 
GluN1/2C receptors (𝜏recovery SSI: GluN1/2A, 5.51 ± 0.33 s; GluN1/2C, 17.1 ± 1.4 s; p < 0.0001). 
It is unclear why the time course of recovery from SSI is faster for GluN1/2A than for GluN1/2C 
receptors. Possible explanations include dependence on NMDAR properties that differ between 
GluN1/2A and GluN1/2C receptors, such as Popen, gating kinetics or desensitization (Glasgow et 
al., 2015, Paoletti et al., 2013). As we hypothesized, the time course of recovery from SSI for 
GluN1/2A and GluN1/2C receptors is strikingly similar to the 𝜏slow of recovery from inhibition by 
100 μM memantine in 0 Mg2+, which also exhibits ~3-fold difference between GluN1/2A and 
GluN1/2C receptors (Table 1). Indeed, the 𝜏recovery SSI was indistinguishable from the 𝜏slow of 
recovery from inhibition by 100 μM memantine for GluN1/2A and GluN1/2C receptors (Table 1; 
𝜏recovery SSI vs. 𝜏slow of recovery from inhibition by 100 μM memantine: GluN1/2A, p = 0.99; 
GluN1/2C, p = 0.31). These data strongly support our hypothesis that the slow component of 
recovery from memantine inhibition, which becomes more prominent as memantine concentration 
increases (Figure 12; Table 1), reflects recovery from SSI. 
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Figure 19 SSI requires memantine transit from the second site to the deep site 
 
(A-F, left) Representative current traces illustrate the memantine SSI protocols in 0 Mg2+ 
for GluN1/2A (A,C,E) or GluN1/2C receptors (B,D,F) receptors. SSI protocols were performed at 
-65 mV (A,B), at +35 mV (C,D), or at -65 mV with a voltage jump to +35 mV from 0.5 s before 
to 0.5 s after memantine application (Vm Jump; E,F). Traces for GluN1/2A receptors (A,C,E) are 
from the same cell, and traces for GluN1/2C receptors (B,D,F) are from the same cell; mean data 
include cells where not all protocols were performed in the same cell. (A-F, center) Pairs of traces 
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compare control (Icontrol; black) and SSI (ISSI; red) currents aligned at the time of glutamate 
applications. (A-F, right) Plot of ISSI/Icontrol of the example traces shown at left and center. (G) 
Mean minimum ISSI/Icontrol values during the time window indicated by gray boxes in Figure 
16A,B, right. *** indicate p < 0.001 by one-way ANOVA with Tukey's post hoc analysis. n = 4 – 
6 cells in each group. Mean values of the minimum ISSI/Icontrol for -65 mV in G are replotted from 
Figure 17G.  
 Mg2+ does not compete with memantine for association with the second site 
Acceleration by Mg2+ of recovery from memantine inhibition (Figure 14; Table 1) could 
result from reduction by Mg2+ of the slow component of recovery from memantine inhibition for 
which SSI is responsible. Therefore, we next determined directly whether Mg2+ disrupts 
memantine SSI using the SSI protocol in the continuous presence of 1 mM Mg2+. We found that 
in 1 mM Mg2+, the minimum ISSI/Icontrol of GluN1/2A, but not of GluN1/2C receptors was 
significantly increased (Figure 17A,B,E-G). One possible explanation for these data is that Mg2+ 
competes with memantine for association with the second site of GluN1/2A receptors, but not for 
association with the second site of GluN1/2C receptors. To test this hypothesis more directly, we 
used a modified Mg2+ SSI protocol in which we coapplied 1 mM Mg2+ only during the application 
of 100 M memantine (Modified Mg2+; Figure 17C-D). If Mg2+ competes with memantine for 
association with the second site of GluN1/2A receptors, then the minimum ISSI/Icontrol should 
increase when measured using the Modified Mg2+ SSI protocol. Strikingly, we found that the 
minimum ISSI/Icontrol measured using the Modified Mg
2+ SSI protocol was indistinguishable from 
the minimum ISSI/Icontrol measured in 0 Mg
2+ for GluN1/2A receptors (and, not surprisingly, for 
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GluN1/2C receptors) (Figure 17C-D,G). These data suggest that Mg2+ does not compete with 
memantine for association with the second site. 
If Mg2+ does not compete for association with the second site, how else might 1 mM Mg2+ 
reduce memantine SSI and accelerate recovery from memantine inhibition of GluN1/2A and 
GluN1/2B receptors, but not of GluN1/2C and GluN1/2D receptors? Interestingly, the NMDAR 
subtype dependence of Mg2+ IC50 (Kuner and Schoepfer, 1996, Monyer et al., 1994) results in a 
similar pattern of Mg2+ occupation of the deep site in 1 mM Mg2+: there is much greater Mg2+ 
occupation of the deep site of GluN1/2A and GluN1/2B receptors than of GluN1/2C or GluN1/2D 
receptors. We therefore considered the hypothesis that Mg2+ competition with memantine for 
association with the deep site reduces memantine SSI of GluN1/2A receptors. This hypothesis 
suggests that memantine SSI may require transit of memantine from the second site to the deep 
site.  
 SSI requires memantine transit from the second site to the deep site 
If memantine SSI requires transit of memantine from the second site to the deep site, then 
elimination of deep site binding by memantine should also eliminate memantine SSI. To test this 
prediction, we determined whether mutating the GluN1 N-site asparagine residue, which is critical 
to deep site binding by channel blockers, affects memantine SSI. We mutated the GluN1 N-site to 
an arginine (GluN1(N616R)), which greatly increases the memantine IC50 (Chen and Lipton, 2005, 
Kashiwagi et al., 2002). 
We measured the minimum ISSI/Icontrol for GluN1(N616R)/2A and GluN1(N616R)/2C 
receptors (Figure 18A-B,D) using the SSI protocol as shown in Figure 16A-B. Strikingly, we found 
that SSI was completely abolished in GluN1(N616R)/2A and in GluN1(N616R)/2C receptors. We 
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also performed the SSI protocol with 500 M memantine, a concentration that nearly saturates SSI 
in native NMDARs and in wild-type GluN1/2A receptors (Blanpied et al., 1997, Kotermanski et 
al., 2009). Even with 500 M memantine, SSI was absent in GluN1(N616R)/2A receptors (Figure 
18C-D). These data are consistent with the hypothesis that memantine association with the second 
site does not inhibit NMDARs, and that SSI requires transit of memantine from the second to the 
deep site. Inhibition would occur exclusively after memantine transits to the deep site, explaining 
why SSI was abolished by mutation of the deep site (Figure 18), and was reduced by Mg2+ 
occupation of the deep site (Figure 17). 
We cannot rule out that the possibility that the GluN1(N616R) deep site mutation also may 
indirectly affect association of memantine with the second site. To further test our hypothesis that 
memantine SSI requires transit from the second site to the deep site in wild-type NMDARs, we 
next took advantage of the Vm dependence of memantine inhibition at the deep site (Blanpied et 
al., 1997, Bresink et al., 1996, Frankiewicz et al., 1996, Chen and Lipton, 1997). If SSI occurs via 
memantine transit from the second site to the deep site, then SSI should significantly decrease at 
depolarized voltage. SSI previously was found to be Vm-dependent, although less Vm-dependent 
than inhibition at the deep site (Blanpied et al., 1997). However, the previous experiments were 
interpreted assuming that occupation of the second site was sufficient to inhibit NMDAR 
responses. If SSI requires memantine transit from the second site to the deep site, then Vm 
dependence of SSI could result from the Vm dependence of dissociation from the deep site. In this 
case, occupation of the second site could exhibit negligible or no Vm dependence. We therefore 
determined whether occupation of the second site differed at -65 mV and 35 mV by comparing in 
0 Mg2+ the results of three SSI protocols: (a) a protocol performed entirely at -65 mV (Figure 19A-
B); (b) a protocol performed entirely at 35 mV (Figure 19C-D); (c) a protocol in which 100 M 
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memantine was applied at 35 mV, but the rest of the protocol was performed at -65 mV (Vm Jump; 
Figure 19E-F). Experiments were performed using both GluN1/2A and GluN1/2C receptors; 
results described below apply to both NMDAR subtypes. 
We found that when the entire SSI protocol was performed at 35 mV (protocol (b); Figure 
19C-D,G), the minimum ISSI/Icontrol was significantly greater (reflecting weaker inhibition) than 
when the entire protocol was performed at -65 mV (protocol (a); Figure 19A-B,G), confirming 
that memantine SSI is Vm-dependent. However, when memantine was applied at 35 mV and the 
minimum ISSI/Icontrol measured at -65 mV (protocol (c); Figure 19E-G), the minimum ISSI/Icontrol 
was indistinguishable from the minimum ISSI/Icontrol at -65 mV, but was significantly less (reflecting 
greater inhibition) than the minimum ISSI/Icontrol at 35 mV. These results show that memantine 
association with the second site is voltage-independent, but that subsequent SSI depends on 
voltage. Protocol (c) (Figure 19E-F) demonstrates that when applied at 35 mV, memantine 
associated with the second site; protocol (b) (Figure 19C-D) demonstrates that memantine 
occupation of the second site did not result in NMDAR response inhibition. Thus, SSI is Vm-
dependent, but only insofar as inhibition requires occupation of the deep site via memantine transit 
from the second site to the deep site.  
 
3.5 Discussion 
This study was initiated to investigate the effects of Mg2+ on the time course of recovery 
from inhibition by memantine and ketamine of the four main diheteromeric NMDAR subtypes, 
GluN1/2A – GluN1/2D receptors. Our results provide several new insights into mechanisms of 
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memantine and ketamine inhibition in the absence and presence of Mg2+. We found that in 0 Mg2+, 
the time course of recovery from memantine inhibition is ~2- to 10-fold slower following 
inhibition by 100 M than following inhibition by 1 M memantine (Figure 12; Figure 14D). The 
time course of recovery from ketamine inhibition, in contrast, demonstrated minimal dependence 
on ketamine concentration (Figure 13; Figure 16D). These data are consistent with the hypotheses 
that memantine inhibits via the deep site and via SSI, whereas ketamine inhibits via the deep site, 
but not via SSI (Blanpied et al., 1997, Chen and Lipton, 2005, Johnson et al., 2015, Kotermanski 
et al., 2009, Parsons et al., 2007b, Sobolevsky and Koshelev, 1998). The concentration dependence 
of recovery from memantine inhibition and the minimal concentration dependence of recovery 
from ketamine inhibition were maintained in 1 mM Mg2+ (Figure 14A-B,D; Figure 15A-B,D). We 
demonstrated that 1 mM Mg2+ accelerates recovery from memantine and ketamine inhibition in an 
NMDAR subtype-dependent manner (Figure 14C-D; Figure 15C-D). We inferred that Mg2+ 
accelerates recovery from memantine inhibition of GluN1/2A and GluN1/2B receptors by 
reducing SSI, a form of inhibition from which recovery is surprisingly slow (Figure 16A-B). In 
addition, it is likely that Mg2+ accelerates recovery from both memantine and ketamine inhibition 
of GluN1/2B receptors as a result of a Mg2+-induced increase in Popen (Paoletti et al., 1995). We 
showed that Mg2+ reduces memantine SSI, but not as a result of Mg2+ competition for association 
with the second site (Figure 17). To test the alternative hypothesis that Mg2+ reduces memantine 
SSI by competing for binding to the deep site, we mutated the GluN1 asparagine essential to 
formation of the deep site. We found that mutation of the deep site also eliminated SSI (Figure 
18). Examination of the Vm dependence of SSI and of memantine association with the second site 
further supported the conclusion that memantine occupation of the second site does not result in 
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NMDAR inhibition (Figure 19); inhibition only occurs after memantine transits from the second 
site to the deep site. 
 Determinants of the time course of recovery of NMDAR inhibition by memantine 
Our finding that the time course of recovery from memantine inhibition depends strongly 
on the memantine concentration used to induce inhibition is inconsistent with previous studies that 
reported little or no concentration dependence (Frankiewicz et al., 1996, Gilling et al., 2009, 
Gilling et al., 2007, Parsons et al., 1993, Parsons et al., 1995). However, several previous studies 
did report an increase in the amplitude of the slow component of recovery from memantine 
inhibition with increasing drug concentration (Sobolevsky and Koshelev, 1998). We also saw an 
increase in the amplitude of the slow component of recovery from memantine inhibition. However, 
overall, we saw a greater dependence of recovery from inhibition on memantine concentration 
than has been reported previously. We believe our examination of single NMDAR subtypes and 
several aspects of our experimental conditions explain most of the differences between our results 
and those of previous studies. 
We were able to study single NMDAR subtypes because our experiments were conducted 
in a heterologous expression system as opposed to neurons (Frankiewicz et al., 1996, Gilling et 
al., 2007, Parsons et al., 1993, Parsons et al., 1995, Sobolevsky and Koshelev, 1998, Blanpied et 
al., 1997), which contain a heterogeneous population of NMDAR subtypes, including 
triheteromeric NMDARs (Glasgow et al., 2015, Paoletti et al., 2013, Al-Hallaq et al., 2007, Luo 
et al., 1997). As the time course of recovery from inhibition differed greatly across NMDAR 
subtypes (Figure 12B; Figure 14D; Table 1), the presence of multiple NMDAR subtypes could 
alter interpretation of measurements obtained from neurons. Nevertheless, we see clear 
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concentration dependence of the time course of recovery from memantine inhibition across 
NMDAR subtypes, which is consistent with previous observations in neurons (Sobolevsky and 
Koshelev, 1998). 
In addition, several of our experimental conditions may have facilitated observation of 
concentration-dependent recovery from memantine inhibition by permitting us to observe fast 
recovery from deep site inhibition by memantine. Concentration dependence of the time course of 
recovery from memantine inhibition can be detected only if recovery from deep site inhibition is 
much faster than recovery from SSI. The rapid component of recovery from inhibition was much 
faster than the slow component under our experimental conditions because of our use of: (a) 
solutions that promoted high NMDAR Popen, (b) a perfusion system that permitted rapid 
elimination of memantine from the extracellular solution, and (c) use of tsA201 cells, which are 
more compact than neurons, permitting nearly simultaneous solution exchange around the entire 
cell, and recording of currents that are not slowed by neurite cable properties. Our use of solutions 
that increased NMDAR Popen was important because recovery from memantine inhibition at the 
deep site can occur only when the channel is open; increasing Popen therefore accelerates recovery 
from memantine inhibition at the deep site. NMDAR Popen was increased by our use of a saturating 
concentration of the full agonist glutamate, rather than a low or intermediate concentration of the 
partial agonist NMDA or aspartate (Traynelis et al., 2010a) used in most other studies. To prevent 
NMDAR current rundown, thereby also maintaining a relatively high Popen, we included ATP in 
the intracellular solution (Tong and Jahr, 1994); ATP was not present in the intracellular solutions 
used in most other studies cited above. We also included 10 μM EDTA in our extracellular solution 
to chelate contaminating Zn2+, which inhibits GluN1/2A receptors (Paoletti et al., 1997). Our fast 
perfusion system was capable of rapid solution exchange (see Methods), which should not be rate-
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limiting for components with time constants slower than ~0.15 s. Probably resulting from our use 
of high Popen conditions and a relatively rapid perfusion system, our 𝜏fast values for recovery from 
memantine inhibition were ~5- to 20-fold faster than previously reported values (Bresink et al., 
1996, Gilling et al., 2009, Gilling et al., 2007, Sobolevsky and Koshelev, 1998). Thus, we 
hypothesize that we observed especially strong concentration dependence of recovery from 
memantine inhibition because our conditions encouraged fast recovery from memantine inhibition 
at the deep site, which is the dominant binding site at low memantine concentrations. Nevertheless, 
our measured 𝜏fast values probably were limited by the speed of solution exchange, especially at 
higher drug concentrations (see Methods), a conclusion supported by the slightly faster 𝜏’s 
recorded using outside-out patches (Parsons et al., 2008a).  
The identity and concentration of intracellular permeant cations affect the Vm dependence, 
microscopic binding rate, and potency, but not the microscopic unbinding rate, of NMDAR 
channel blockers including Mg2+ (Ruppersberg et al., 1994, Antonov and Johnson, 1999), 
memantine (Chen and Lipton, 1997, Parsons et al., 1999), and ketamine (MacDonald et al., 1991). 
Since recovery from inhibition depends upon the microscopic unbinding rate of the channel 
blocker and the NMDAR Popen, we do not expect our use of non-physiological intracellular Cs
+ 
strongly impacted measurements of recovery from inhibition by memantine or ketamine. However, 
it is possible that the identity of the intracellular cation affects the development or Vm dependence 
of SSI. It will be important in future studies to determine how physiological intracellular K+, which 
speeds the microscopic binding rates of NMDAR channel blockers compared to Cs+, affects SSI. 
The time course of recovery from inhibition by memantine was adequately fit by double 
exponential functions, which we used to characterize phenomenologically the speed of recovery 
from inhibition. However, recovery from inhibition is expected to contain many kinetic 
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components, most of which cannot be resolved by exponential fits of whole-cell data. We 
determined that at least two separable processes were involved in recovery from memantine 
inhibition: recovery from deep site inhibition and recovery from SSI. Both processes should 
exhibit multiple kinetic components. The time course of the more rapid process, recovery from 
deep site inhibition, in principle depends on the kinetics of all channel gating transitions. However, 
because open channel blockers like memantine can unbind only when the channel is open, the Popen 
of blocked channels is of primary importance. The Popen of a blocked channel depends both on its 
intrinsic gating properties, and on any modifications of gating properties that result from channel 
occupation by the blocker. The NMDAR subtype dependence of Popen is probably the predominant 
determinant of the strong NMDAR subtype dependence of the time course of recovery from 
inhibition observed for both memantine and ketamine. Channel occupation by a blocker can result 
in either an increase or a decrease in the Popen of blocked channels compared to the Popen of 
unblocked channels. In the extreme case of a sequential (or foot-in-the-door) blocker, the blocker 
prevents channel closure (see, e.g. (Costa and Albuquerque, 1994, Vorobjev and Sharonova, 1994, 
Benveniste and Mayer, 1995, Sobolevsky, 1999, Sobolevsky et al., 1999, Antonov and Johnson, 
1996, Paganelli and Popescu, 2015, Koshelev and Khodorov, 1995)). Memantine and ketamine, 
in contrast, are trapping channel blockers, which permit channel closure while blocking the 
channel. Channel occupation by trapping channel blockers nevertheless can affect channel gating 
(e.g. (Blanpied et al., 1997, Blanpied et al., 2005, Dilmore and Johnson, 1998, Glasgow et al., 
2017, Sobolevskii and Khodorov, 2002, Sobolevsky, 1999, Sobolevsky et al., 1999)). Thus, the 
complex time course of recovery from inhibition at the deep site depends both on the intrinsic 
gating properties of the NMDAR subtype under study, and on the specific effects of a blocker on 
channel gating.  
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We identified recovery from SSI as the slower process involved in recovery from 
memantine inhibition based on multiple lines of evidence: (1) recovery from inhibition by 
memantine but not ketamine became slower at higher drug concentrations close to the memantine 
SSI IC50, and memantine but not ketamine exhibits SSI; (2) the effect of Mg
2+ on the time course 
of recovery from memantine inhibition and on memantine SSI exhibited the same NMDAR 
subtype dependence; (3) the slow component of recovery from memantine inhibition became more 
prominent at the higher memantine concentrations required to induce SSI; (4) the directly-
measured 𝜏recovery SSI was nearly identical to the 𝜏slow of recovery from inhibition by 100 μM 
memantine for both GluN1/2A and GluN1/2C receptors. Because SSI involves transit of 
memantine from the second site to the deep site, recovery from SSI is also likely to exhibit a 
complex time course of recovery. Importantly, association of memantine with the second site does 
not require NMDAR activation (Figure 16). Thus, models of NMDAR inhibition by memantine in 
which memantine access to both of two sites requires channel activation (Sobolevsky and 
Koshelev, 1998, Sobolevsky, 1999) are inconsistent with the data presented here. 
 
 Mg2+ accelerates recovery from memantine and ketamine inhibition via multiple 
mechanisms 
We found that extracellular Mg2+ accelerated recovery from memantine and ketamine 
inhibition, but with distinct NMDAR subtype dependence (Figure 14D; Figure 15D). Mg2+ 
accelerated recovery from ketamine inhibition only from GluN1/2B receptors, which also exhibit 
Mg2+-induced potentiation via an increase in Popen (Paoletti et al., 1995). Therefore, Mg
2+ 
potentiation alone may underlie Mg2+-induced acceleration of recovery from ketamine inhibition 
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from GluN1/2B receptors. Mg2+ potentiation likely also partially underlies Mg2+-induced 
acceleration of recovery from memantine inhibition of GluN1/2B receptors. However, because 
Mg2+ accelerated recovery from memantine inhibition of GluN1/2A as well as GluN1/2B 
receptors, we concluded that Mg2+ affects recovery from memantine and ketamine inhibition via 
distinct mechanisms. Our memantine SSI results (Figures 16-19) suggest that Mg2+ accelerates 
recovery from memantine inhibition because Mg2+ occupation of the deep site interferes with 
memantine transit from the second site to the deep site. As a result, the slow component of recovery 
from memantine inhibition, which reflects the time course of recovery from SSI, is reduced. 
Therefore, we propose that Mg2+ accelerates recovery from inhibition at two separate sites: (1) the 
site at which Mg2+ binds to GluN1/2B receptors to induce potentiation, and (2) the deep channel 
blocking site of GluN1/2A and GluN1/2B receptors.  
Mg2+ recently was demonstrated to accelerate recovery from inhibition by MK-801, 
another NMDAR channel blocker, of cultured cortical neurons (McKay et al., 2013). Mg2+-
induced acceleration of recovery from MK-801 inhibition likely results in part from Mg2+ 
potentiation of neuronally expressed GluN1/2B receptors. It is unclear whether MK-801 also 
associates with the same second site as memantine, and can transit to the deep site. MK-801 can 
inhibit NMDARs from the intracellular solution (Rodríguez-Moreno and Paulsen, 2008, Berretta 
and Jones, 1996, Bouvier et al., 2015) as well as the extracellular solution, suggesting that, like 
memantine, MK-801 may be able to inhibit via multiple sites or routes. Unlike MK-801, 
intracellular memantine was found not to inhibit NMDARs (Parsons et al., 2008b). However, 
intracellular memantine was tested only at 30 μM, a concentration much lower than the 
intracellular MK-801 concentration typically used to inhibit NMDARs. The ability of Mg2+ to 
induce phenomenologically similar effects on the time course of recovery from inhibition by two 
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channel blockers suggests that multiple mechanisms of inhibition may be common among 
NMDAR channel blockers. 
 Mechanism of memantine second site inhibition 
In previous studies, two experimental observations were ascribed to the ability of 
memantine to associate with two sites: (1) the time course of recovery from memantine inhibition 
depended on the concentration of memantine used to inhibit the NMDAR response; (2) exposure 
to memantine in the absence of agonist resulted in inhibition of a subsequent NMDAR response 
activated by agonist application shortly after removal of memantine (Blanpied et al., 1997, Chen 
and Lipton, 2005, Kotermanski et al., 2009, Sobolevsky and Koshelev, 1998). Our data support 
the hypothesis that memantine’s ability to associate with two sites results in concentration 
dependence of recovery from memantine inhibition. The memantine IC50 is lower at the deep site 
than the second site, but recovery from memantine inhibition is faster from the deep site than the 
second site; increasing memantine concentration therefore increases association with the second 
site and slows recovery from inhibition. We found in addition that Mg2+ accelerates recovery from 
memantine inhibition and reduces memantine SSI in an NMDAR subtype-dependent manner. Both 
phenomena result from competition between Mg2+ and memantine, although surprisingly, not 
competition for association with the second site. Instead, competition between Mg2+ and 
memantine for binding to the deep site interferes with transit of memantine from the second site 
to the deep site. These phenomena can be explained by the hypothesis that memantine can associate 
with, but does not cause inhibition at, the second site; inhibition from the second site requires 
memantine transit to the deep site. Since memantine can associate with the second site of 
unactivated NMDARs, but deep site access requires channel opening, transit from the second site 
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to the deep site likely requires channel opening. If second site to deep site transit is slow enough, 
it may be possible to observe development of inhibition as memantine transit takes place. We 
propose that the initial phase of SSI development that was particularly clear with GluN1/2C 
receptors (e.g., Figure 16B and D, right; initial period of decreasing ISSI/Icontrol) may represent the 
transit of memantine from the second site to the deep site. 
Numerous NMDAR channel blocking antagonists other than memantine have been found 
to exhibit two distinct binding sites or modes, including: ketamine (Orser et al., 1997); some 
derivatives of adamantane (Antonov and Johnson, 1996); tetraethylammonium, MRZ 2/178, and 
9-aminoacridine (Sobolevsky, 1999, Sobolevsky et al., 1999); amantadine and some derivatives 
of phencylcyclohexyl derivatives (Bolshakov et al., 2003); bupivacaine (Paganelli and Popescu, 
2015). However, in each of these studies, the drug was found to inhibit NMDARs when occupying 
either of the two sites, suggesting mechanisms of action that differ from SSI by memantine. 
Where might the second site be located? Our data are not inconsistent with the hypothesis 
that the second site is located near the external entrance to the NMDAR channel, as previously 
proposed (Blanpied et al., 1997, Chen and Lipton, 2005, Sobolevsky and Koshelev, 1998, 
Kotermanski et al., 2009). However, the paradoxical combination of high IC50 with very slow 
recovery from SSI suggests the second site may not be a traditional receptor binding site. An 
alternative possibility is that the second site represents a pool or reservoir of memantine that builds 
up during memantine application in the absence of agonists, and slowly depletes after memantine 
washout. Memantine SSI then would occur when memantine transits from the second site reservoir 
to the deep site. Due to memantine’s lipophilicity (Chew et al., 2008, del Rio-Sancho et al., 2012, 
Zambrano et al., 2018), plausible locations of a memantine second site reservoir include the 
intracellular compartment or the membrane (Blanpied et al., 1997). As discussed above, there is 
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evidence that memantine does not inhibit from the intracellular compartment (Parsons et al., 
2008b). However, the intracellular memantine concentration may reach much higher levels during 
the SSI protocol than the concentration previously tested. Determination of the location and the 
nature of the second site will require further investigation.  
Full understanding of the complex effects of Mg2+ and of SSI on properties of memantine 
inhibition of NMDARs will require further investigation. For example, the therapeutic potential of 
targeting the second site remains to be determined. Although the memantine SSI IC50 is much 
higher than the estimated memantine concentration in the brain at therapeutic doses (0.5-1 μM 
(Parsons et al., 2007b)), SSI is an indirect measure of memantine association with a second site. 
Due to these necessarily indirect measurements, there may be yet undiscovered additional 
consequences of memantine association with a second site at lower concentrations. For example, 
there could be a rapid component of memantine dissociation from the second site that we did not 
observe because of the 1-s wash following memantine application in our SSI protocol. If this is 
the case, memantine may associate with the second site at concentrations lower than those used 
here. Thus, it will be important to further evaluate the implications of SSI. In addition to the 
influence of Mg2+ on SSI, physiological concentrations of Mg2+ impart selectivity of memantine 
or ketamine for GluN2C- and GluN2D-containing NMDARs that may be of high clinical 
significance (Khlestova et al., 2016, Povysheva and Johnson, 2016). Our demonstration that Mg2+ 
accelerates recovery of GluN1/2A and GluN1/2B receptors from memantine inhibition, and 
GluN1/2B receptors from ketamine inhibition, reveals that Mg2+ has NMDAR subtype-selective 
effects on drug kinetics as well as on IC50. Insights into NMDAR inhibition by memantine and 
ketamine, in addition to advancing knowledge of two clinically useful drugs, may help elucidate 
broad mechanisms of NMDAR inhibition. 
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4.0 Inhibition of NMDA Receptors through a Membrane-to-Channel Path 
4.1 Summary 
N-methyl-D-aspartate receptors (NMDARs) are transmembrane proteins that are activated 
by the neurotransmitter glutamate and are found at most excitatory vertebrate synapses. NMDAR 
channel blockers, an antagonist class of broad pharmacological and clinical significance, inhibit 
by occluding the NMDAR ion channel. A vast literature demonstrates that NMDAR channel 
blockers, including MK-801, phencyclidine, ketamine, and the Alzheimer’s disease drug 
memantine, act as open-channel blockers: they can bind and unbind only when the NMDAR 
channel is open. Here we reveal that numerous NMDAR open channel blockers can enter the open 
channel through two routes: the well-known path from extracellular solution to channel through 
the ion channel gate, and a previously undescribed path from plasma membrane to channel through 
a gated fenestration. We term inhibition via the latter path membrane-to-channel inhibition (MCI). 
MCI has previously been demonstrated for voltage-gated Na+ and K+ channels, and may be an 
inhibitory mechanism of very broad significance. 
4.2 Introduction 
N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors (iGluRs) 
present at most excitatory synapses in the mammalian brain. Among iGluRs, NMDARs exhibit 
unique features such as slow deactivation kinetics and high permeability to calcium (Traynelis et 
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al., 2010b, Paoletti et al., 2013, Glasgow et al., 2015). Calcium influx through NMDARs activates 
a multitude of intracellular signaling pathways that can give rise to synaptic plasticity, and 
ultimately contribute to learning and memory (e.g. (Li and Tsien, 2009)). On the other hand, 
aberrant activation of NMDARs can be pathological and is implicated in Alzheimer’s disease, 
schizophrenia, and many other neurological and neuropsychiatric disorders (Lau and Tymianski, 
2010, Zhou and Sheng, 2013). NMDARs are heterotetramers typically composed of two obligatory 
GluN1 and two GluN2(A-D) subunits and/or GluN3(A-B) subunits. NMDARs can assemble as 
diheteromers (e.g. GluN1/2A) or triheteromers (e.g. GluN1/2A/2B) (Traynelis et al., 2010b). Each 
subunit has three transmembrane helices (M1, M2, M4) and a pore-lining reentrant loop (M2) that 
lines the NMDAR channel. NMDAR antagonism has been extensively studied for therapeutic 
purposes, as well as to understand receptor structure and function. NMDAR open-channel blockers 
examined for therapeutic use include memantine, magnesium (Mg2+), ketamine, MK-801, 
dextrorphan, and phencyclidine (PCP). These entities can access the pore through the permeation 
pathway and bind at the “deep site” located at the tips of the M2 regions (Kashiwagi et al., 2002, 
Chen and Lipton, 2005, Kotermanski et al., 2009, Glasgow et al., 2018). Memantine has been 
particularly successful among open-channel blockers: it is FDA-approved for the management of 
Alzheimer’s disease and is being investigated for treatment of other pathological conditions (Yang 
et al., 2013).  
Interestingly, inhibition by memantine has also been observed following exposure of 
NMDARs to memantine in the absence of agonist, producing “second site inhibition” (SSI) 
(Blanpied et al., 1997, Glasgow et al., 2018, Kotermanski et al., 2009, Sobolevsky et al., 1998, 
Chen and Lipton, 2005). Previous studies have suggested that memantine binds to a second site 
superficial to the pore that exhibits weak apparent Vm dependence and is accessible when 
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NMDARs are closed (Blanpied et al., 1997, Chen and Lipton, 2005, Glasgow et al., 2018, 
Kotermanski et al., 2009, Sobolevsky et al., 1998) (but see (Sobolevsky and Koshelev, 1998)). 
Glasgow et al. concluded that that an intact and unoccupied deep site is important for SSI, and 
found that during SSI, memantine occupancy of the second site is not sufficient for inhibition 
(Glasgow et al., 2018). This supports a mechanism for SSI that involves second site binding and 
SSI as two distinct processes. The authors hypothesized that memantine occupies the second site 
and then travels to the deep site, where it produces inhibition. This hypothesis suggests that SSI is 
a misnomer; the second site does not produce inhibition, but rather sequesters memantine that can 
relocate to the deep site.  
Previous work has suggested that some NMDAR modulators may access binding sites on 
the NMDAR by first partitioning into the plasma membrane (Paganelli and Popescu, 2015, Song 
et al., 2018, Orser et al., 1997, Moring et al., 1994, Korinek et al., 2015). Drug access to the pore 
through the membrane is a well-established mechanism in voltage gated sodium channels (Navs) 
and is a common mechanism of local anesthetic action (Jorgensen et al., 2016, Gamal El-Din et 
al., 2018, Kaczmarski and Corry, 2014, Hille, 1977, Catterall and Swanson, 2015, Lirk et al., 2014, 
Boiteux et al., 2014b). In this work we first reveal that numerous NMDAR inhibitors in addition 
to memantine exhibit SSI, suggesting that SSI may be a broadly used mechanism. We then present 
electrophysiological and computational experiments to test the hypothesis that the plasma 
membrane is the second “site” involved in SSI. We conclude that drugs participating in SSI travel 
from the membrane to the deep site upon NMDAR activation through a membrane-facing 
fenestration. Based on the findings detailed here, we have renamed this phenomenon “membrane-
to-channel inhibition” (MCI) and will refer to it as MCI throughout this work.  
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4.3 Methods 
 Cell culture and transfection 
Experiments were performed on the tsA201 cell line (The European Collection of 
Authenticated Cell Cultures), a variant of the HEK 293 cell line. tsA201 cells were maintained as 
previously described in DMEM supplemented with 10% fetal bovine serum and 1% GlutaMAX 
(Thermo Fisher Scientific) (Glasgow and Johnson, 2014). 1 × 105 cells/dish were plated on 15 mm 
glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 mg/ml, BD 
Biosciences) in 35 mm petri dishes. 12–24 h after plating, cells were transiently co-transfected 
using FuGENE6 Transfection Reagent (Promega) with mammalian expression plasmids that 
contained cDNAs encoding enhanced green fluorescent protein (EGFP in pRK7) for identification 
of transfected cells, the rat GluN1-1a subunit (hereafter GluN1; GenBank X63255 in pcDNA3.1), 
and the rat GluN2A subunit (GenBank M91561 in pcDNA1). For some experiments cells were 
transfected with GluN1 and EGFP:pIRES:GluN2A (a generous gift from Dr. Kasper Hansen 
(Hansen, unpublished)), which was constructed by inserting EGFP in pIRES (Clontech) under 
transcriptional control of the CMV promoter, and rat GluN2A cDNA (GenBank D13211) after the 
IRES sequence. Site-directed mutagenesis was performed on cDNAs encoding GluN1 and 
GluN2A subunit genes in ampicillin resistance-encoding plasmids (pcDNA 3.1 or pcDNA1) using 
the Stratagene Quik-Change XL sited-directed mutagenesis kit. Mutagenized NMDAR subunit 
cDNAs from isolated colonies were sequenced from 100–200 bases upstream to 100–200 bases 
downstream of each mutation (University of Pittsburgh Genomics and Proteomics Core 
Laboratories). cDNA ratios used in transfection were 1:1:1 (EGFP, GluN1, and GluN2A) and 1:1 
(GluN1 and EGFP:pIRES:GluN2A). Following transfection, the competitive NMDAR 
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antagonist D,L-2-amino-5-phosphonopentanoate (200 μM) was added to the media to prevent 
NMDAR-mediated cell death. 
 Solutions 
The extracellular bath solution contained (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, 10 HEPES, 
0.1 glycine, 0.01 EDTA. Osmolality raised to 290 ± 10 mOsm with sucrose. Extracellular solution 
pH was balanced to 7.2 ± 0.05 or 9.0 ± 0.1 with NaOH and to 6.3 ± 0.05 with HCl as indicated. L-
glutamate, memantine, D-APV, MK-801, PCP, dextrorphan, and RL-208 (Leiva et al., 2018) were 
added where indicated. Voltage clamp recordings were obtained from transfected tsA201 cells 12–
24 h after transfection. Pipettes were pulled from borosilicate capillary tubing (Sutter Instruments) 
on a Sutter Instruments-Flaming Brown P-97 microelectrode puller and polished with a heated 
glass filament to a resistance of 2–5 ΜΩ. Whole-cell recordings were made from cells expressing 
eGFP identified by epifluorescence illumination on an inverted Zeiss Axiovert microscope. Cells 
were held at a Vm of −65 mV (corrected for a liquid junction potential of −6 mV) unless otherwise 
indicated. Whole-cell currents were amplified using an Axopatch 200B patch-clamp amplifier 
(Molecular Devices), low-pass filtered at 5 kHz and sampled with a Digidata 1440A at 10 or 
20 kHz in pClamp10 (Molecular Devices). Series resistance was compensated 80–90% with the 
prediction and correction circuitry in all experiments. Solutions were delivered to cells using a 
previously described ten-barrel fast perfusion system (Glasgow et al., 2017).  
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 Analysis 
All data were analyzed with Clampfit 10.7 (Molecular Devices), Origin 16 or GraphPad 
Prism 7. The fractional response after MCI (IMCI/IControl) was measured by taking the ratio of IMCI to 
the average of IControl1 and IControl2 with a point-by-point ratio of time-series IMCI/IControl, where 
IControl = ((IControl1 + IControl2)/2) (Iacobucci and Popescu, 2017b). Each current was aligned to the 
time of glutamate application. We measured the minimum IMCI/IControl as the mean of 
IMCI/IControl over a 30 ms window centered on the minimum ratio value. MCI measurements were 
excluded if IControl2 did not recover to at least 80% of IControl1. Cells with peak NMDAR 
currents > 2.5 nA were excluded from analysis. 
 Modeling and molecular dynamics simulations 
A molecular dynamics (MD)-optimized model structure of the GluN1/2A NMDAR TMD 
in lipid bilayer and water with the ion channel closed was taken from our previous work (Mesbahi-
Vasey et al., 2017). The full simulated system had 10159 water molecules, 108 DMPC membrane 
lipid molecules, and 534 protein residues, resulting in a total of 43850 atoms. All MD simulations 
were performed using AMBER (Case, 2018) package for molecular modeling with Amber 
FF12SB force-field for protein atoms (Hornak et al., 2006), TIP3P water, Lipid14 force field for 
lipid (Kukol, 2009) and GAFF force field parameters for memantine (developed using 
Antechamber module of AMBER). All simulations were performed with initial minimization of 
the systems using steepest descent algorithm, followed by constrained protein MD at room 
temperature maintained with Langevin thermostat (Berendsen et al., 1984), 1 atm pressure 
maintained with the Berendsen barostat and long range electrostatics accounted for with Particle 
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Mesh Ewald with cut off a 10A.Simulations were implemented in AMBER. The integration step 
was 1 fs. To develop an open channel model a set of 10 steered MD simulations was performed 
(<1 ns each) using harmonic constrains applied to the SYTANLAAF sequence region of all M3 
helixes. The constrains were designed to gradually increased the distance between M3 helixes at 
the channel gate until the channel filled with water. The protocol was similar to the one used to 
produce an open AMPA model (Yelshanskaya et al., 2017). The program HOLE (Smart et al., 
1996) was used to identify possible fenestrations. Memantine docking was performed using 
AutoDock Vina (Trott and Olson, 2010).  
 Statistics 
Statistical tests were performed in GraphPad Prism 7. We used one-way ANOVA with 
Tukey's post hoc analysis and t-tests where indicated. All error bars indicate ± standard error of 
the mean (SEM). Current traces for presentation were refiltered offline in Clampfit 10.7 at 50 Hz. 
4.4 Results 
  Numerous compounds participate in MCI 
We first confirmed that memantine displayed MCI consistent with previous reports. MCI 
was measured using the following protocol: (a) 1 mM glutamate (Glu) was applied for 20 s, and 
control current before MCI (IControl1) was measured (see below); (b) normal extracellular solution 
was applied for 10 s to allow full deactivation of receptors; (c) memantine in the absence of Glu 
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was applied for 30 s; (d) memantine was washed away by a 1 s application of normal extracellular 
solution; (e) 1 mM Glu was reapplied for 20-30 s and current during MCI (IMCI) was measured; (f) 
normal extracellular solution was applied for 41 s; (g) 1 mM Glu was reapplied for 20 s and control 
current after MCI (IControl2) was measured. The minimum fractional response after MCI 
(IMCI/IControl) was measured by taking the ratio of IMCI to the average of IControl1 and IControl2 with a 
point-by-point ratio of IMCI/IControl, where IControl = ((IControl1 + IControl2)/2) (Iacobucci and Popescu, 
2017b). The 30-s duration of memantine application was chosen based on evidence suggesting that 
memantine in the membrane reaches an equilibrium before 30 s of application. Kotermanski et al., 
2009, demonstrated that the extent of MCI remains constant with memantine applications 30 s – 4 
min. The duration of the wash after memantine application was also carefully chosen. Memantine 
unbinds from the membrane with a time constant of ~ 2 s (Kotermanski et al., 2009). Therefore, a 
1-s wash allows visualization of significant MCI before much memantine leaves the membrane. 
We are confident that MCI results from occupancy of a second site rather than incomplete wash-
off of drug from the cell for several reasons: (1) the 1 s wash is >30-fold longer than the time 
constant, 𝜏 of solution exchange (27 ms) (Glasgow et al., 2017); (2) the control MCI performed 
with D-APV, in which APV alone is applied and washed off to be sure APV is gone when 
glutamate is applied supports the idea that wash-off is complete (Glasgow et al., 2018) (3) 
ketamine does not show MCI at 500 M (>500x its traditional IC50) with a 0.4 s wash under the 
same conditions (Kotermanski et al., 2009). Therefore, ketamine serves as a negative control to 
confirm that full solution exchange occurs. We performed MCI experiments with 100 μM 
memantine at pH 7.2 and found that IMCI/IControl values (IMCI/IControl = 0.502 ± 0.123) were consistent 
with those reported in Glasgow et al. (2018). We then explored whether other NMDAR channel 
blockers exhibit MCI. We investigated several additional open-channel blockers: PCP, 
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dextrorphan, MK-801, and novel compound RL-208 (Leiva et al., 2018). Each drug displayed MCI 
(Figure 20), suggesting that MCI is a broadly applicable mechanism of NMDAR channel blocker 
action. It should be noted that the concentrations used in Figure 20 are many times the drugs’ 
traditional (ion conduction pathway) IC50s. However, the ability of numerous open channel 
blockers to produce MCI is entirely novel and suggests that our current understanding of NMDAR 
mechanisms of inhibition require expansion. We sought to first build upon the current 
understanding of memantine MCI to better understand the general MCI phenomenon. 
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Figure 20 Multiple NMDAR inhibitors exhibit MCI 
 
A, chemical structures of compounds examined electrophysiologically using the MCI 
protocol. B – D, MCI with 10 μM PCP (B), 50 μM Dextrorphan (Dex) (C), 20 μM RL-208 (D) in 
tsA201 cells. The MCI protocol in B-D consists of the following sequence of solution application: 
Control (5 s); Glu (20 s); Control (10 s); Drug (e.g. PCP) (30 s); Control (1 s); Glu (20-60 s); 
Control (41 s); Glu (20 s); Control (5 s). Modified MCI protocol with APV present during MK-
801 application, as well as1 s before MK-801 application and 0.2 seconds after, in tsA201 cells 
(E) and neurons (F). G, Plot of IMCI/IControl for the indicated compounds. 
 Memantine MCI depends on the pH during memantine application 
Memantine is mostly charged at physiological pH due to protonation of its nitrogen (pKa 
= 10.3). Computational experiments suggest that charged memantine can reside in the membrane 
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(Chew et al., 2008). However, even at physiological pH, memantine is present in equilibrium 
between charged and uncharged forms. A parsimonious explanation for a voltage-independent 
second site that houses many different molecules (Figure 20), is that the second site is fairly 
nonspecific. One target of nonspecific molecular association is the plasma membrane. We 
postulated that, if the second site were the membrane, increasing the concentration of uncharged 
memantine (more hydrophobic form) would increase memantine partitioning into the membrane 
and increase MCI. We increased the concentration of uncharged memantine present during MCI 
by raising the pH of the memantine-containing solution. A similar approach has been used in the 
study of anesthetics, in which increases in drug solution pH were used to increase drug diffusion 
into the membrane (Perez-Isidoro et al., 2014, Chernoff and Strichartz, 1990). When memantine 
is applied at pH 9, cells experience a concentration of uncharged memantine ~50X higher than at 
pH 7.2 (with 100 M total memantine, from 80 nM uncharged memantine at pH 7.2 to 5 M 
uncharged memantine at pH 9, Figure 21A). We avoided raising pH above 9 due to the lack of 
receptor characterization at such a high pH (Traynelis and Cull-Candy, 1991, Vyklicky et al., 1990, 
Traynelis and Cull-Candy, 1990, Traynelis et al., 1995, Banke et al., 2005, Erreger and Traynelis, 
2008, Kussius and Popescu, 2009). We found that memantine MCI produced by 100 μM 
memantine at pH 9 was significantly greater than MCI at pH 7.2 (IMCI/IControl: pH 7.2 = 0.48 ± 0.36; 
pH 9 = 0.12 ± 0.005, p<0.001, Figure 21C). However, we were concerned that increased pH could 
affect MCI through mechanisms apart from increasing the concentration of uncharged memantine. 
In particular, GluN1/2A receptors are over 50% inhibited by protons at pH 7.2, and proton 
inhibition is substantially lessened at pH 9 (Traynelis and Cull-Candy, 1990). To further explore 
the effect of memantine solution pH on MCI, we performed experiments in which the cell was 
exposed to pH 9 only during memantine application, and Glu and control solutions were 
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maintained at pH 7.2 (“pH 9 jump”, Figure 21E). We also examined the effect of decreasing 
[uncharged memantine] in 100 μM memantine solution by performing the MCI protocol with 
memantine applied at pH 6.3 (“pH 6.3 jump”). To reduce responses from proton-activated currents 
during pH changes we performed pH jump experiments in the continuous presence of 20 μM 
amiloride (Waldmann et al., 1997). Similar to MCI experiments performed entirely at pH 9, the 
pH 9 jump experiments showed significantly increased MCI with 100 μM memantine relative to 
experiments at pH 7.2 (IMCI/IControl pH 9 jump = 0.25 ± 0.017, p = 0.002). Next, we examined MCI 
with 100 μM at pH 6.3, where uncharged memantine is about 0.01% of the total memantine 
concentration in solution. We saw significantly reduced MCI produced by 100 μM memantine in 
the pH 6.3 jump protocol compared to int pH 7.2 (IMCI/IControl pH 6.3 jump = 0.835 ± 0.327, p < 
0.001). We then wanted to measure the IC50 of memantine MCI with memantine solution applied 
at different pH’s using pH 7.2, pH 6.3 jump, and pH 9 jump protocols. We first performed pH 9 
and 6.3 jump control experiments to examine whether amiloride and pH changes alone affected 
our measurement of IMCI/IControl. We found that average IMCI/IControl for pH 9 jump control 
experiments was 0.906 ± .0541, suggesting that pH changes may slightly influence our 
measurement of MCI during the pH 9 jump protocol. We normalized all pH 9 jump IMCI/IControl 
values to the average values of pH 9 jump control experiments. pH 6.3 jump control IMCI/IControl  
as 0.931 ± 0.079. We then measured the IC50 of memantine MCI at pH 7.2 (Figure 21G,I; 80.7 ± 
15.5 μM), and at pH 9 (Figure 21H,I; IC50= 5.43 ± 0.75 μM, p < 0.0001). by applying various 
concentrations of memantine during MCI protocols. To obtain the pH 6.3 jump IC50 we fit the 
logistic equation to IMCI/IControl values from pH 6.3 jump MCI experiments using 100 μM and 300 
μM memantine. We chose not to examine higher [memantine] because of the possibility of 
nonspecific effects of memantine with concentrations >300 μM. The pH 6.3 jump MCI IC50 was 
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significantly different from the pH 7.2 MCI (877 ± 17 μM, p < 0.0001). Figure 22 shows that the 
memantine MCI IC50 decreased with increasing memantine solution pH. This suggests that 
[uncharged memantine] is correlated with IMCI/IControl, and further, that uncharged memantine 
mediates MCI. 
 
 
Figure 21 Memantine MCI is pH-dependent 
 
A, Expected amount of charged and uncharged memantine at pH 6.3, 7.2, and 9. B – D, 
Data from MCI protocol performed at pH 7.2 (B) and 9 (D) with 100 μM memantine. E – F, Data 
from pH 9 jump protocol (E) and pH 6.3 jump protocol (F) with 100 μM memantine. Colored lines 
in B,C,E,F indicate the pH’s used in the protocol. G – H, Plot of memantine MCI IC50 at pH 7.2 
(G) and pH 9 jump (H). I, comparison of MCI IC50 at pH 6.3, 7.2, and 9. ****, P<0.00001 
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 Memantine exhibits reservoir-like behavior 
How many molecules can occupy the second site at once? Do drugs that participate in MCI 
bind to a specific site in the membrane region that holds one or two molecules? Many binding sites 
of well-known drugs are specific: they stabilize the binding of drug molecules through interactions 
with the drug’s structure. However, nonspecific binding sites also exist. Many molecules interact 
nonspecifically with the membrane, for example. Often, large quantities of hydrophobic molecules 
can accumulate in membranes and reside there. We previously demonstrated that MCI is Vm-
dependent: MCI is prominent at -65 mV but nearly abolished at 35 mV (Glasgow et al., 2018). 
Based on the Vm dependence of MCI, we devised an experiment to further probe the characteristics 
of the second site. We reasoned that including two 500 ms voltage jumps during recovery from 
MCI (during the Glu application immediately after removal of Mem) would causes memantine to 
quickly unbind from the deep site (Rammes et al., 2008). If the second site houses one or several 
molecules, increasing the rate of unbinding from the deep site would result in altered MCI time 
course of unbinding when compared to a typical MCI protocol if the second site housed just one 
or several molecules .We performed an MCI protocol with two 500 ms Vm jumps to 50 mV during 
recovery from MCI and measured IMCI/IControl 100 ms after the second jump (Figure 22). We 
compared this measurement to IMCI/IControl at the same timepoint in control MCI experiments 
performed entirely at -65 mV. We performed these experiments with memantine applied at pH 9 
(in both control and Vm jump conditions), where MCI was more extensive, to allow clear 
observation of decreases in IMCI/IControl. IMCI/IControl did not differ between Vm jump and control 
protocols (Vm jump = 0.38 ± 0.026; control = 0.43 ± 0.019, p = 0.14), indicating no significant 
alteration in the time course of recovery from MCI due to the two Vm jumps to 50 mV. The block 
quickly returns to near-control levels when Vm is returned to -65 mV. This observation suggests 
 122 
that memantine can repeatedly bind to the deep site throughout recovery from MCI. We conclude 
that the second site can house a reservoir of memantine and is not a “traditional” binding site that 
binds one or several molecules (as assumed in (Kotermanski et al., 2009, Blanpied et al., 1997, 
Sobolevsky and Koshelev, 1998, Sobolevsky et al., 1998)). Further, it suggests that [memantine] 
at the second site is largely undisturbed by Vm changes, consistent with our previous observation 
(Glasgow et al., 2018). This is in contrast with inhibition resulting from the MCI protocol, which 
occurs at the deep site and is Vm-dependent. A parsimonious explanation for these data is that the 
second site represents a reservoir of memantine in the plasma membrane. There is extensive 
precedent hydrophobic and amphipathic molecules associating with the plasma membrane. For 
example, many local anesthetics act by first partitioning into the membrane (Boiteux et al., 2014b, 
Hille, 1977, Jorgensen et al., 2016). 
 
Figure 22 MCI exhibits reservoir-like behavior 
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A, Left, MCI arising from 100 μM memantine at pH 9 with two 500 ms Vm steps to 50 mV 
during recovery from MCI; Right, overlay of MCI trace highlighting the Vm steps to 50 mV. B, 
MCI with 100 μM memantine at pH 9 without Vm steps. C, IMCI/IControl measured at the timepoint 
corresponding to 200 ms after the second Vm step back to -65 mV.  
 MK-801 MCI kinetics are concentration-dependent 
Because drugs that participate in MCI are also NMDAR open-channel blockers, we 
hypothesized that access to the deep site in MCI is gated and occurs only in activated NMDARs. 
We wanted to develop an experiment to further test this hypothesis. As shown in Figure 20A-E, 
we observed a pronounced pre-inhibition peak immediately following agonist application with 
each drug tested. The presence of pre-inhibition peaks suggests that deep site binding via MCI 
occurs only in agonist-bound NMDARs. We further examined the pre-inhibition peaks apparent 
with memantine, PCP, dextrorphan, RL-208, and MK-801 MCI protocols and noted that the time 
course of MCI onset (𝜏M) varied between channel blockers (e.g. 1 μM MK-801 = 995.5 ± 134.9 
ms; 100 μM memantine = 85.1 ± 6.02 ms). Interestingly, GluN1/2C receptors show a more defined 
pre-inhibition peak and slower onset of memantine MCI than GluN1/2A receptors (Glasgow et al., 
2018). This could reflect dependence of MCI onset kinetics on NMDAR open probability (Popen), 
again suggesting that blocker transit from membrane to the deep site requires NMDAR activation.  
If MCI requires channel opening, we would predict that 𝜏M would vary with [drug] applied 
during MCI. This is also consistent with deep site inhibition through the MCI route occurring only 
in agonist-bound receptors. The pre-inhibition peak with memantine often was very small and 𝜏M 
was difficult to measure, possibly because 𝜏M is similar to the time course of NMDAR activation. 
Therefore, we performed MCI experiments with 1 μM and 10 μM MK-801 and examined whether 
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𝜏 varied with MK-801 concentration. (Figure 23). At both concentrations we observed a defined 
pre-inhibition peak and a time-dependent increase in inhibition. Fitting a single exponential curve 
to the current decay immediately following the pre-inhibition peak of IMCI/IControl allowed 
measurement of 𝜏M. 𝜏 was significantly different with 1 and 10 μM MK-801 (995.5 ± 134.9 ms 
and 312.0 ± 59.44 ms, respectively; p = 0.002). Concentration dependence of 𝜏M is consistent with 
the idea that MK-801 transits from the membrane to the deep site after channel opening, and that 
the membrane [MK-801] depends on the previous [MK-801] in solution. Concentration 
dependence of 𝜏 is inconsistent with the idea that MK-801 binds to a discrete “second site”, since 
the rate of transit from a binding site should not depend on the previous [MK-801]. These results 
thus provide evidence against the second site binging one or several molecules and also suggests 
that MCI is state-dependent, with inhibition occurring only when NMDARs are active. 
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Figure 23 MK-801 MCI characteristics depend on [MK-801] applied during MCI 
 
A,B, MCI protocol with 1 μM (A) and 10 μM (B) MK-801. In A and B, a Vm step to 30 
mV was performed for ≤20 s during the second Glu application to facilitate rapid MK-801 
unbinding from the deep site. C, IMCI/IControl with 1 μM and 10 μM MK-801. D, 𝜏 of MCI onset 
with 1 μM and 10 μM MK-801. 
 Modeling NMDAR fenestrations 
The above experiment evidence indicates that MCI requires transit of channel blockers 
from the membrane to the deep site after NMDARs are activated. Thus, there must be a path or 
fenestration in the NMDAR TMR through which channel blockers can pass only when NMDAR 
channels are in the open state. To find such a path, we first developed an open channel state of the 
NMDAR TMD using steered molecular dynamics (SMD) simulations. We started with a 
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previously developed closed NMDAR TMD structure that was equilibrated in water and DMPC 
lipid bilayer using MD simulations (Mesbahi-Vasey et al., 2017). To develop an open channel 
structure in lipid and water we used an SMD protocol previously used to model the AMPA receptor 
TMD in the open state (Yelshanskaya et al., 2017). The simulated open channel structure in water 
and lipid is shown in Figure 24A. Next, we identified all continuous paths from lipid to the ion 
channel in both closed and open TMD NMDAR structures using the pore predicting program 
HOLE (Smart et al., 1996). We found one lipid to ion channel path (fenestration) in GluN1/2A 
receptors that is unique to the open structure (Figure 24B). We further confirmed that memantine 
can traverse this open structure fenestration by performing multiple position molecular docking of 
the memantine molecule along this path (Figure 24C). Docking resulted in small negative energy 
values (-1.2 kcal/mol) indicating that memantine fits in the fenestration but does not bind with 
high affinity, consistent with a path rather than a binding site. Fenestration-lining residues are 
shown in Figure 24D.  
We identified a methionine residue (GluN2A(M630)) that lines the fenestration and forms 
a constriction (Figure 24D-F). To examine how mutation of GluN2A(M630) may influence the 
constricted region, we performed in silico mutagenesis followed by molecular dynamics 
simulations. In silico, the GluN2A(M630A) and GluN2A(M630W) mutations influenced the 
radius of the fenestration near the GluN2A(630) position. Increasing residue size 
(GluN2A(M630W) mutation) decreased the radius of the fenestration, while decreasing residue 
size (GluN2A(M630A) mutation) increased the radius of the fenestration (Figure 24E-H). We 
hypothesize that increasing the radius of the fenestration may increase the rate of memantine transit 
from the membrane to the channel, while decreasing the fenestration radius may have an opposite 
effect.   
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Figure 24 Simulations of NMDAR TMD reveal a state-dependent fenestration 
 
A, Simulated open NMDAR TMD model in lipid bilayer and water. Protein is shown in 
green in cartoon representation; lipid tails are grey wireframe; lipid head groups are spheres 
(carbon in cyan, oxygen in red, phosphorus in orange); water channel is shown as a solid blue 
surface and bulk water in blue wireframe isosurface. B, Fenestration through the open GluN1/2A 
TMD between the lipid bilayer and the channel center identified using HOLE is shown as a solid 
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surface. The largest regions of the fenestration are shown in blue, intermediate regions are in green, 
and most constricted regions are in red. C, Memantine is shown docked at the entrance of the 
fenestration that leads from membrane to ion channel. D. Top view of the fenestration (B) shown 
as an orange line. Residues lining the pore are shown in yellow stick representation. E. Fenestration 
radius at different points along the fenestration (“fenestration position”) is shown for WT 
GluN1/2A (yellow line), GluN1/2A(M630A) (blue) and GluN1/2A(M630W) (red line). F-H, The 
portion of the fenestration near position 630 of GluN2A, with the residue at position 630 identified 
and shown as stick models, is shown for WT GluN1/2A (F), GluN1/2A(M630A) (G), and 
GluN1/2A(M630W) (H) receptors.   
 Mutation of GluN2A(M630) specifically alters MCI 
We performed site-directed mutagenesis to alter residues predicted to line the fenestration 
identified through molecular dynamics simulations (Figure 24). We compared at pH 7.2 MCI by 
100 μM memantine of WT and mutant NMDARs. We found that mutation of the putative 
fenestration-lining methionine identified in our NMDAR TMD simulations, GluN2A(M630), 
specifically modulates MCI. We first increased the size of the residue by mutating GluN2A(M630) 
to tryptophan, which our simulations predicted would narrow the fenestration. Consistent with that 
prediction, GluN1/2A(M630W) receptors showed decreased memantine MCI (IMCI/IControl = 0.717 
± 0.0225) relative to WT (IMCI/IControl = 0.483 ± 0.362). We next examined MCI of 
GluN1/2A(M630A) receptors to test the prediction of our simulations that the mutation of 
GluN2A(M630) to a smaller alanine would increase the size of the fenestration.”. Indeed, 
GluN1/2A(M630A) receptors showed increased MCI by 100 M memantine (IMCI/IControl = 0.254 
± 0.0113) relative to WT (IMCI/IControl = 0.272 ±0.0138) (Figure 25). Given the importance of the 
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deep site in MCI, we examined whether changes in MCI could be explained by potential alterations 
in memantine affinity for the deep site. We measured the traditional IC50 for memantine inhibition 
of GluN1/2A(M630W) and GluN1/2A(M630A) receptors by coapplying memantine and 
glutamate to permit memantine access to the deep site from the extracellular solution. We found 
that the traditional memantine IC50s of GluN1/2A(M630W) (1.489 ± 0.203 μM) and 
GluN1/2A(M630A) (1.524 ± 0.0696 μM) were not different from wildtype (1.709 ± 0.0638 μM, 
p > 0.05 by one-way ANOVA) (Figure 25). These results suggest that the membrane-to-channel 
path used by memantine during MCI is specifically altered in GluN1/2A(M630A) and 
GluN1/2A(M630W) receptors, strongly support the prediction of our simulations. 
 
 
Figure 25 Fenestration-lining mutations alter MCI 
 
A-D, The GluN2A(M630W) mutation reduced MCI (A, C), but did not affect traditional 
memantine IC50 (D). The GluN2A(M630A) mutation increased MCI (B,C) but had no effect on 
traditional memantine IC50 (D). These findings support the hypothesis that GluN2A(M630) 
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mutations specifically affects MCI by modifying the membrane to channel path. ***, p < 0.0001 
by one-way ANOVA. 
 Mutation of additional fenestration lining residues 
Based on the computational simulations of the fenestration, we examined MCI in receptors 
in which additional putative fenestration-lining residues were mutated to tryptophan. 
GluN1/2A(A570W), GluN1/2A(I571W), GluN1/2A(M630W)(A570W) and 
GluN1/2A(M630W)(I571W) (Figure 26). GluN1/2A(A570W) showed increased MCI compared 
to WT (IMCI/IControl = 0.272 ± 0.0138), but showed reduced traditional memantine IC50 (0.933 ± 
0.144 μM). Thus, the increased MCI seen in GluN1/2A(A570W) receptors could be caused by 
increased affinity of memantine at the deep site rather than a specific effect on the MCI pathway. 
GluN1/2A(M630W)(I571W) receptors showed no current. GluN1/N2A(M630W)(A570W) 
showed IMCI/IControl similar to WT (0.559 ± 0.0790).  
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Figure 26 Mutation of additional fenestration-lining residues 
A, Minimum IMCI/IControl of NMDARs containing the indicated WT or mutated GluN2A in 
response to 100 M MCI at pH 7.2. GluN1/2A(M630W)(I571W) receptors were also examined 
and showed no current in 3/3 cells. Only GluN1/2A(A570W) shows MCI that differed from WT. 
B, Traditional memantine IC50 of receptors containing WT GluN1/2A or GluN21/2A(A570W).   
4.5  Discussion 
We report here a systematic investigation of MCI, a little-explored route of NMDAR 
inhibition. MCI occurs when drugs first associate with the plasma membrane and then, after 
NMDAR activation, travel through a hydrophobic path to access the deep site. Using 
electrophysiological and computational methods we found that the plasma membrane is important 
for MCI and can house many molecules, unlike a traditional binding site. The logarithm of the 
partition coefficient of memantine (logP) is ~3.2 (Mealing et al., 1999), which indicates that the 
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uncharged form of memantine is >1000-fold more soluble in octanol than water. This suggests that 
uncharged memantine resides preferentially in the membrane, and is consistent with data 
indicating that the membrane is a reservoir of uncharged memantine. 
 Knowledge of receptor modulation through lipophilic pathways has existed for decades, 
and is well established in many ion channels, but has never been demonstrated for NMDARs. 
Hydrophobic fenestrations provide access by local anesthetics to their binding sites on VGSCs 
(Hille, 1977, Boiteux et al., 2014b, Catterall and Swanson, 2015, Lirk et al., 2014, Gamal El-Din 
et al., 2018). Interestingly, permanently charged local anesthetics seem unable to act through the 
hydrophobic pathway (Hille, 1977). Pore access through fenestrations also occurs in voltage gated 
potassium channels (Wrobel et al., 2016, Jorgensen et al., 2016) and may occur in voltage gated-
calcium channels (Wu et al., 2018). Finally, several NMDAR modulators in addition to memantine 
have been proposed to travel through hydrophobic pathways, though the nature of these pathways 
remains unclear (Paganelli and Popescu, 2015, Korinek et al., 2015, Moring et al., 1994, Orser et 
al., 1997). Here, we present mechanistic and structural insight into the fenestration responsible for 
MCI. 
In the present study, we found that MCI is exhibited by many channel blockers including 
memantine, PCP, dextrorphan, MK-801, and RL-208. However, it is possible that not all NMDAR 
channel blockers act through fenestrations: ketamine produces little-to-no MCI despite its high 
lipophilicity (Glasgow et al., 2018, Johnson et al., 2015, Kotermanski et al., 2009, Parsons et al., 
2007a). Memantine transitions between the charged and uncharged forms with protonation and 
deprotonation of its amine group, and altering pH alters the ratio of charged to uncharged 
memantine. We examined whether we could alter MCI by changing the pH of the memantine-
containing solution. Solution pH has been used to modulate drug protonation in work with VGSCs 
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and local anesthetics (Schwarz et al., 1977) (Chernoff and Strichartz, 1990). We observed changes 
in MCI correlated with the amount of uncharged memantine in solution. This supports the 
hypothesis that MCI requires entry of uncharged memantine into the membrane. However, it is 
important to note that changes of extracellular pH may influence NMDARs as well as [uncharged 
memantine]. pH modulates NMDAR responses and may also affect the structure of lipid 
membranes (Leung et al., 2013, Traynelis et al., 1995). We attempted to minimize the effects of 
pH change on NMDARs with our pH jump protocol by activating NMDARs only at pH 7.2, and 
by normalizing values of pH 9 jump MCI experiments to control pH 9 jump experiments. In the 
pH jump MCI protocols used, pH is returned to 7.2 1 s before glutamate application, providing 
ample time to reverse any effects of pH change on NMDARs or the membrane. However, we 
cannot exclude the possibility that pH change affects MCI by a mechanism separate from altering 
memantine accumulation. For example, it is possible that changes in amino acid charges due to 
changing pH can modulate memantine travel through the fenestration.  
We took advantage of the Vm dependence of memantine MCI to examine whether the 
plasma membrane housed few or many memantine molecules during MCI. We expected that, if 
the second site binds just one or several memantine molecules, IMCI/IControl after the second Vm 
jump would be different from IMCI/IControl in control experiments because the memantine molecules 
producing MCI would be forced out of the deep site. We observed that IMCI/IControl at 200 ms after 
the second Vm jump did not differ from control. The membrane seemed to continuously re-supply 
memantine for inhibition at the deep site, suggesting that the second site houses a reservoir of 
memantine. This observation is consistent with the hypothesis that the second site is the membrane.  
Next, we explored the state-dependence of MCI. We found that MCI occurs only after 
agonist is applied and shows drug concentration dependence. We used two MK-801 concentrations 
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to determine whether the time course of MCI onset depends on the concentration of previously-
applied drug. The time course of MCI onset with the [MK-801] applied during MCI. The 
dependence of the time course of MCI development on [MK-801] in solution suggests that drug 
transfer through the fenestration occurs only in open receptors (Figure 23). 
Using structural molecular modeling of the NMDAR TMD, we identified a fenestration 
present only in the modeled open state of the NMDAR channel (Figure 24). We observed a 
constriction in the fenestration formed by residue M630 in the GluN2A subunit and found that 
mutation of GluN2A(M630) alters MCI (Figure 25). GluN1/2A(M630W) and GluN1/2A(M630A) 
receptors displayed alterations in MCI without changes in traditional memantine IC50. It is possible 
that GluN2A(M630) mutations alter travel of memantine from the membrane to the deep site 
through a mechanism other than direct disruption of the fenestration. However, these data suggest 
that GluN2A(M630) lines the fenestration, and further support the conclusion that MCI and 
traditional deep site block occur through separate pathways. Molecular dynamics simulations of 
in silico mutations at GluN2A(M630) support electrophysiological data (Figure 24). We then 
mutated additional residues predicted to line the fenestration (Figure 26). We found that only 
mutation of GluN2A(M630) alters MCI without changing traditional memantine IC50. A recent 
paper by Song et al., 2018, suggested that the closed NMDAR contains tunnels through which 
lipids or small molecules may be able to access the receptor. It is unlikely that fenestrations in 
closed NMDARs allow transit of channel blockers, which can access the deep site only when the 
NMDAR is open. Figure 27 illustrates the two methods of NMDAR block by memantine, which 
are likely relevant to other NMDAR open channel blockers.  
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Figure 27 Schematic of the two routes of memantine access to its NMDAR channel blocking 
site 
A, Traditional route. Charged memantine can access the deep site only when agonists 
(Ago) bind and the channel opens. B, Newly discovered route. Uncharged memantine enters the 
membrane and can access its blocking site through gated fenestrations only when agonists bind 
and the channel opens. 
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5.0 General Discussion 
The work presented in this dissertation focuses largely on the characteristics of the 
NMDAR TMD and its many critical roles in receptor function. With my coauthors and 
collaborators, I explored the roles of a conserved tryptophan residue in the GluN1, GluN2A, and 
GluN2B M2 regions (Chapter 2). We revealed that the roles of the conserved tryptophan are 
subtype-dependent. The GluN1(W608C) mutation dramatically slowed deactivation in 
GluN1(W608C)/2A receptors and was found to interact with the nearby GluN2A(S632) position 
to influence deactivation kinetics (Figure 9). GluN2B(W607C)-containing receptors show 
enhanced voltage-independent potentiation by Mg2+ (Figure 11). Even at saturating concentrations, 
Mg2+ inhibited GluN2B(W607C)-containing receptors only ~50%, suggesting that significant 
Mg2+ permeation occurs through GluN2B(W607C)-containing receptors (Figure 11). In GluN1/2A 
receptors, the GluN2A(W606C) mutation did not affect Mg2+ IC50, while mutation of a residue 
predicted to be nearby, GluN1(M634), increased Mg2+ IC50 (Figure 10) The GluN1(M634) and 
GluN2A(W606) sites interact functionally, though it is unclear whether the residues are physically 
proximal. The results of Chapter 2 suggest that intersubunit interactions in the TMD are critical 
for both gating and Mg2+ block of NMDARs, and that the role of the conserved M2 tryptophan 
varies in GluN1, GluN2A, and GluN2B subunits. 
Chapter 3 began with an investigation of the effects of Mg2+ on recovery from inhibition 
by memantine and ketamine of GluN1/2A, GluN1/2B, GluN1/2C, and GluN1/2D receptors. We 
found that the time course of recovery from memantine and ketamine inhibition depended on the 
concentration of blocker applied (prior to recovery from block) and on the NMDAR subtype 
studied (Figures 12-15). In GluN1/2A and GluN1/2B receptors, Mg2+ caused substantial 
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acceleration of memantine unbinding. We then explored the possibility that the concentration-
dependence of memantine unbinding was due to binding of memantine at a second site distinct 
from binding at the deep site (Figures 16-19). We termed this “second site inhibition” (SSI), meant 
to refer to a mechanism distinct from diffusion of extracellular memantine into the pore and 
binding at the deep site. We found that the time course of recovery from SSI in GluN1/2A and 
GluN1/2C receptors was strikingly similar to the slow time constant of recovery from memantine 
inhibition (Figure 16). We also found that Mg2+ disrupted SSI of GluN1/2A but not GluN1/2C 
receptors, paralleling the effects of Mg2+ on the slow time constant of memantine recovery from 
inhibition in GluN1/2A and GluN1/2C receptors (Figure 17). These data suggest that the slow 
component of recovery from memantine inhibition is due to SSI. Experiments suggested that Mg2+ 
does not compete with memantine for occupancy of the second site, but rather inhibits GluN1/2A 
SSI by occupying the deep site. Thus, we proposed that, although memantine occupancy of a 
second site is necessary for SSI, memantine occupancy of the second site is not in itself inhibitory. 
This hypothesis implies that SSI is a misnomer, for inhibition does not occur at the second site. 
Instead, our data suggested that memantine gives rise to SSI by associating with a non-inhibitory 
second site (distinct from the deep site) and transitioning to the deep site upon receptor activation. 
Memantine occupancy of the second site was found to be largely voltage-independent, while SSI 
was Vm-dependent (Figure 19). Accordingly, disruption of the highly Vm-dependent deep site with 
the GluN1(N616R) mutation in GluN1/2A and GluN1/2C receptors abolished SSI (Figure 18). 
In Chapter 4 we reveal that memantine SSI arises through memantine association with the 
membrane and transit through a fenestration to reach the NMDAR pore. We renamed SSI 
membrane-to-channel inhibition (MCI) to more accurately describe the inhibitory mechanism. 
Two experiments led to us to initially hypothesize that the plasma membrane is the second site of 
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memantine association. Manipulation of the pH of the memantine solution applied during MCI 
suggested that the uncharged form of memantine mediates MCI (Figure 21). Additionally, we 
observed reservoir-like behavior of the second site consistent with memantine accumulation in the 
membrane (Figure 22). Using molecular dynamics simulations of an open NMDAR TMD model 
we identified a fenestration that leads from the plasma membrane to the NMDAR pore (Figure 
24). Mutation of a residue predicted to line the fenestration, GluN2A(M630), to alanine 
(GluN2A(M630A)) caused increased MCI, while the GluN2A(M630W) mutation resulted in 
decreased MCI (Figure 25). Importantly, changes in MCI in GluN1/2A(M630A) and 
GluN1/2A(M630W) receptors were not accompanied by changes in memantine affinity for the 
deep site measured using an open-channel block protocol. Molecular dynamics simulations of 
GluN1/2A(M630A) receptors showed increased fenestration size near the GluN2A(M630) 
position compared to WT GluN1/2A receptors, while GluN1/2A(M630W) receptors showed 
decreased fenestration size near the GluN2A(M630) position (Figure 24). Compared to WT 
GluN1/2A receptors, GluN1/2A(M630A) and GluN1/2A(M630W) receptors also had increased 
and decreased fenestration diameter, respectively, at the intersection of the fenestration and the ion 
channel. 
In addition to the discovery that memantine can travel from the membrane to the NMDAR 
deep site through a fenestration, we showed that open channel blockers besides memantine display 
MCI. PCP, MK-801, dextrorphan, and RL-208 caused NMDAR inhibition in response to the MCI 
protocol (Figure 20). Therefore, PCP, MK-801, dextrorphan and RL-208 may travel from the 
membrane to the pore through the same fenestration proposed to be involved in memantine MCI. 
Ion channel inhibition by transit of drugs from membrane to channel via fenestrations has been 
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demonstrated for voltage-gated Na+ and K+ channels and may also be an inhibitory mechanism of 
broad significance in NMDARs. 
5.1 The Role of a Conserved Tryptophan in the TMD 
The conserved tryptophan in the M2 region of the TMD was previously explored by several 
groups. Williams et al. found that the GluN1(W608L) mutation did not affect Mg2+ block in 
GluN1(W608L)/2B receptors (Williams et al., 1998, Kashiwagi et al., 1997), although 
GluN1(W608) interacts with the GluN2A S/L site to influence Mg2+ IC50 (Siegler Retchless et al., 
2012). GluN1(W608L)/2B receptors showed decreased potentiation by spermine and decreased 
proton inhibition (Kashiwagi et al., 1997). The homologous mutation in GluN2B 
(GluN2B(W607L)) increased spermine potentiation without affecting proton inhibition. 
Modulation of spermine potentiation by GluN1(W608) and GluN2B(W607) mutations in 
GluN1/2B receptors is intriguing because spermine potentiation stems from spermine binding in 
the NTD, far from the M2 region (Mony et al., 2011). Potentiation of GluN2B-containing receptors 
by Mg2+ and spermine are thought to be mechanistically similar (Paoletti et al., 1995, Mony et al., 
2011). Therefore, our observation that GluN2B(W607C)-containing receptors show increased 
potentiation by Mg2+ is consistent with the increased spermine potentiation seen in 
GluN2B(W607L)-containing receptors (Kashiwagi et al., 1997). The consistent influence of a 
GluN2B M2 residue on an NTD-mediated form of NMDAR potentiation underscores the 
importance of long-range allosteric effects in NMDARs.   
Consistent with the results of Chapter 2, previous publications demonstrate that the 
conserved M2 tryptophan regulates NMDAR permeation and block in a subunit-specific manner. 
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GluN1/2B(W607L) and GluN1/2A(W606L) receptors showed increased permeability to the 
polyamine derivative N1-dansyl-spermine and to Mg2+, while GluN1(W608L)/2B receptors 
displayed N1-dansyl-spermine and Mg2+ permeability similar to WT GluN1/2B receptors 
(Kashiwagi et al., 1997, Williams et al., 1998). GluN1/2A(W606L) receptors showed Mg2+ 
permeability similar to GluN1/2B(W607L) receptors. Interestingly, GluN1/2B(W607L) receptors 
showed drastically increased Mg2+ IC50 in GluN1/2A(W606L) receptors at -70 mV was only 
slightly altered (Williams et al., 1998). This suggests that Vm-dependent Mg
2+ block and 
permeation may be regulated differently in GluN1/2A and GluN1/2B receptors.  
The conserved M2 tryptophan is also involved in NMDAR gating. GluN1(W608C)/2A 
receptors show drastically slowed deactivation kinetics, suggesting that GluN1(W608) is an 
important determinant of receptor gating. Buck et al., showed that mutation of a tryptophan three 
residues C-terminal to GluN1(W608) (GluN1(W611)) alters receptor Popen (Buck et al., 2000). 
Like GluN1(W608), GluN1(W611) faces the GluN2 M3 region in the neighboring subunit. 
Together, these data suggest that the conformation of the GluN1 M2 – GluN2 M3 interface changes 
during receptor gating. Additionally, the observation that GluN1(W608L)/2B receptors show 
reduced proton sensitivity and spermine potentiation suggest that GluN1(W608) is important for 
regulation of gating (Kashiwagi et al., 1997). 
5.2 Importance of the Deep Site in MCI 
A conclusion of chapter 3 is that memantine MCI occurs through occupancy of a non-
inhibitory site and subsequent translocation to the deep site. An important finding used to support 
this argument is the observation that Mg2+ inhibited MCI when applied throughout the MCI 
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protocol, but not when applied just during memantine application (“modified Mg2+ protocol,” 
Figure 17). Similar experiments by Sobolevsky et al. examined the influence of Mg2+ present only 
during memantine application on NMDAR inhibition in an MCI-like protocol (Sobolevsky et al., 
1998). In contrast to our results, Sobolevsky et al. found that co-application of Mg2+ and 
memantine during an MCI protocol greatly reduced inhibition (Sobolevsky et al., 1998). However, 
Sobolevsky et al. observed a dramatic decrease in NMDAR inhibition by an MCI-like protocol 
with inclusion of APV during memantine application, suggesting that significant open channel 
block occurred during memantine application in their MCI-like protocols. APV was not present 
during co-application of memantine and Mg2+, which likely allowed Mg2+ binding to the deep site.  
Mg2+ was found to increase the speed of memantine unbinding from GluN1/2A receptors 
(Figure 14) and subsequent experiments in Chapters 3 and 4 suggested that Mg2+ eliminates the 
slow component of memantine unblock by interfering with memantine MCI. The speed of MK-
801 unbinding from NMDARs also increases in the presence of Mg2+, though increased MK-801 
unbinding may be caused by Mg2+ prevention of subsequent re-binding of MK-801 (McKay et al., 
2013).  
Our data suggest that MCI requires an intact and unoccupied deep site. MCI was abolished 
in GluN1(N616R)/2A receptors, which show dramatically decreased sensitivity to open channel 
block by memantine. Kotermanski et al. examined MCI in GluN1(N616Q) mutants and found that 
MCI was unchanged (Kotermanski et al., 2009). However, the GluN1(N616Q) mutation reduces 
memantine IC50 only 2-6 fold (Chen and Lipton, 2005, Kotermanski and Johnson, 2009), while 
the GluN1(N616R) mutation reduces memantine IC50 >40-fold (Kashiwagi et al., 2002, Chen and 
Lipton, 2005). At concentrations used to test MCI in Kotermanski et al. (100 and 500 μM 
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memantine), a several-fold decrease in memantine potency at the deep site would likely not alter 
MCI.  
5.3 Memantine MCI Relative to MCI of Other Compounds 
Does MCI potency depend only on traditional channel block potency and pKa? The open-
channel block IC50 of MK-801 is 15 nM, that of PCP is 0.82 μM, and that of dextrorphan is 1.3 
μM, and that of memantine is 4.4 at pH 7.6 (Dravid et al., 2007). Based on Figure 20 we can 
conclude that 10 μM MK-801 produced ~90% MCI, 10 μM PCP produced ~60% MCI, 50 μM 
dextrorphan produced ~45% MCI. From examination of Figure 21G we determine that 100 μM 
memantine produced ~45% MCI and estimate that ~1 mM memantine is necessary to produce 
~90% MCI. Using these values we can conclude that the approximate MCI IC50 is 23X greater 
than the open channel block IC50 for memantine, 12X greater for PCP and 38X greater for 
dextrorphan. Therefore, PCP MCI is slightly more potent than memantine and dextrorphan MCI, 
relative to the open channel block IC50 of each drug. To compare the relative MCI potency of  MK-
801 and memantine, we can compare the drug concentration that produces ~90% MCI with the 
open channel block IC50. The concentration of MK-801 that produces 90% MCI is 667X greater 
than the open channel block IC50 for MK-801. The concentration of memantine that produces 90% 
MCI is 227X greater than open channel block IC50.227 for memantine. Therefore, memantine MCI 
is more potent than MK-801 MCI, relative to each drug’s open channel block potency. 
Do the expected MCI potencies (PCP < memantine < dextrorphan < MK-801) correlate 
with the amount of uncharged drug in solution? The pKas of drugs dictate the fraction of uncharged 
drug in solution in a pH-dependent way. The pKas of MK-801 (8.5), PCP (8.5) and dextrorphan 
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(9.2) are all more acidic than that of memantine (10.3) (Dravid et al., 2007). This means that, at 
physiological pH, each of these compounds contains a greater proportion of uncharged molecules 
in solution than does memantine. The ranking of drug pKa (memantine > dextrorphan > PCP = 
MK-801) does not correlate with the ranking of drug MCI potency relative to open channel block 
potency. This suggests that MCI potency depends on something in addition to open channel block 
potency and pKa. 
5.4 Comparison of MCI with Fenestration-Dependent Modulation of Other Channels 
Numerous channels have been proposed to allow pore access through fenestrations. 
Perhaps the most well-known example is voltage gated sodium (NaV) channels. A hydrophobic 
route of access to the NaV channel pore was proposed to be important for the action of local 
anesthetics on NaV channels over 40 years ago (Hille, 1977). NaV channels have closed, open, and 
inactivated states. While an obvious mechanism of drug access to the pore is through open-channel 
entry, some uncharged drugs can access the closed channel through fenestrations (Hille, 1977, 
Payandeh et al., 2012, Payandeh et al., 2011, Montini et al., 2018, Gamal El-Din et al., 2018). This 
allows for “tonic block,” or block of resting NaV channels. Resting block seems to occur only with 
uncharged drugs: charged molecules are unable to produce tonic block of resting channels 
(Strichartz, 1973, Payandeh et al., 2012, Payandeh et al., 2011). NMDAR and NaV channel 
fenestrations may be similar in that only uncharged molecules can travel through them. 
Crystal structures of prokaryotic voltage gated sodium channels from Arcobacter butzleri 
(NavAb) and Magnetococcus marinus (NavM) have allowed visualization of lateral fenestrations 
leading from the membrane to the NaV pore (Payandeh et al., 2011, Payandeh et al., 2012, Lenaeus 
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et al., 2017, Sula et al., 2017). Prokaryotic sodium channels are thought to be good models for 
human (Sula et al., 2017) and other eukaryotic NaVs (Bagneris et al., 2014). Comparisons of 
prokaryotic NaV channel structures in the closed, open and inactivated states suggest that 
fenestrations change shape with the activation state of the channel, which may give rise to state-
dependent fenestration access (Montini et al., 2018, Payandeh et al., 2012). Mutation of a 
phenylalanine residue (NavAb(F203)) to alanine or tryptophan resulted in bidirectional 
modulation of fenestration size in molecular modeling simulations (Gamal El-Din et al., 2018). 
The NavAb(F203A) mutation increased fenestration size, along with tonic block of NavAb by 
local anesthetics, while the NavAb(F203W) mutation decreased fenestration size and tonic block. 
These results suggest that a change in a single residue can alter the passage of molecules through 
an NavAb channel fenestration. The results from Gamal El-Din et al. (2018) also remarkably 
parallel the increased memantine MCI and broadened fenestration we observed in 
GluN1/2A(M630A) receptors, and decreased MCI and narrowed fenestration we observed in 
GluN1/2A(M630W) receptors (Figures 24,25).  
In NaV channels, the size and lipophilicity of drugs influence fenestration-dependent block. 
Drug lipophilicity is correlated with degree of tonic block (Li et al., 1999). Size also restricts 
molecular passage through fenestrations in NavAbs, which tolerate a maximum molecular width 
the width of a benzene ring (Boiteux et al., 2014a, Kaczmarski and Corry, 2014, Buyan et al., 
2018). Interestingly, ketamine does not display significant MCI (Kotermanski et al., 2009) despite 
being more lipophilic than other molecules that participate in MCI (Mealing et al., 1999). One 
possibility is that ketamine participates in MCI, but leaves the membrane too quickly for us to 
observe using our MCI protocol. The MCI protocol used includes a 1-s wash following removal 
of channel blocking drug, which requires that drugs remain in the membrane for >1 second to 
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allow observation of MCI. Most of the molecules shown to display MCI are substantially larger 
than a benzene ring. Therefore, NMDAR fenestrations are likely larger or more flexible than 
NavAb fenestrations. We have not systematically determined the maximal dimensions of 
molecules able to participate in MCI but doing so may yield important insight into the NMDAR 
fenestration. 
Computational studies based on crystal structures suggest that potassium channels also 
have fenestrations. Molecular dynamics simulations showed that the voltage-gated channel Kv1.2, 
the G protein-gated inward rectifying channel GIRK2 (Kir3.2), and the human two-pore domain 
TWIK-1 (K2P1.1) have lateral fenestrations (Jorgensen et al., 2016). Molecular dynamics 
simulations suggest that fenestrations in Kv1.2 and Kir3.2 are unable to pass molecules larger than 
water. However, the TWIK-1 channel fenestrations were larger and allowed entry of lipids. The 
crystal structure of the TREK-2 channel (K2P10.2) showed norfluoxetine bound within a 
fenestration, suggesting that fenestrations may include important drug binding sites in addition to 
allowing drug passage (Dong et al., 2015). Fenestrations are state-dependent in TREK-2, apparent 
in the “down state” and absent in the “up state” (Dong et al., 2015). Like TREK-2 channels, 
NMDARs seem to show state-dependent membrane-to-channel access allowing a complete path 
from the membrane to the pore only in the activated state.  
Most clinically useful local anesthetic molecules pass from the extracellular region into the 
membrane phase and/or intracellular space to reach their binding sites. Unlike in NMDARs, open 
channel blockers of NaVs enter the pore from the intracellular solution. Uncharged molecules 
typically enter the membrane phase more readily than charged molecules, and NaV channels can 
be inhibited by uncharged molecules binding in the pore region. However, NaV channel inhibition 
by the charged form of a local anesthetic molecule is often more potent than inhibition by the same 
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molecule in the uncharged form (Buyan et al., 2018). Many local anesthetics contain a protonatable 
amine group and have pKa ~7, suggesting that a near-equal proportion of molecules exist in both 
charged and uncharged states near physiological pH. This allows the uncharged form of molecules 
to pass through the membrane, take on a proton within the cytoplasm, and exhibit high-affinity 
block of NaV channels (Buyan et al., 2018). To explain the Vm dependence of inhibition in MCI, 
we hypothesized that uncharged memantine accepts a proton after travelling through the 
fenestration and entering the open NMDAR pore. Protonation of uncharged memantine is likely 
mediated by H3O
+ molecules in the pore region. It is unclear how the rate of protonation may affect 
MCI by memantine and other molecules. The time course of MCI may depend not only on 
memantine transit through the fenestration but also on protonation. 
5.5 MCI and Block from the Intracellular Solution 
Numerous studies use intracellular MK-801 to inhibit NMDARs on the MK-801 filled cell 
(e.g. (Bender et al., 2006, Brasier and Feldman, 2008, Corlew et al., 2007)). Intracellular MK-801 
has been hypothesized to reach the deep site through either direct diffusion into the pore from the 
intracellular space or through diffusion into the extracellular space followed by typical open-
channel block. Diffusion from the intracellular space to the deep site is unlikely because MK-801 
is too large (~ 7.2 Å) (Chang and Kuo, 2008) to access the deep site from the intracellular solution 
(Amin et al., 2018, Villarroel et al., 1995, Kuner et al., 1996, Wollmuth et al., 1996). Evidence 
suggests that intracellular MK-801 does not block NMDARs on the filled cell by first diffusing 
into the extracellular space (Lavzin et al., 2012). It is tempting to speculate that block by 
intracellular MK-801 occurs through entry into the membrane and transit to the deep site through 
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NMDAR fenestrations. Interestingly, a very high concentration of intracellular MK-801 is required 
to achieve block of NMDARs. Similarly, intracellular memantine does not block NMDARs at up 
to 30 M (Parsons et al., 2008b), though our unpublished data suggest that significant block by 
intracellular memantine occurs at concentrations of 1 mM and larger. If block by intracellular 
memantine and MK-801 occurs through the fenestration responsible for MCI, it is unclear why 
much larger concentrations of drug are needed to produce block from the intracellular space than 
from the extracellular space. A potential explanation for this is that drug entry into the membrane 
from the intracellular space is much slower than entry from the extracellular space. Differing lipid 
content between the inner and outer leaflets,  or the existence of a barrier between the intracellular 
solution and the membrane inner leaflet, could be responsible for slowing entry into membrane 
from the intracellular space. Additional studies into differences in MCI when drug is applied to 
the intracellular versus extracellular spaces are required to better understand MCI. 
5.6 Physiological Role of MCI 
Is MCI a therapeutically relevant mechanism? Memantine is typically administered orally 
and absorbed in the gastrointestinal tract (Jarvis and Figgitt, 2003). Concentrations of memantine 
found in cerebrospinal fluid (CSF) of patients taking oral memantine are typically sub-micromolar 
(Kornhuber and Quack, 1995). At physiological pH, these concentrations would not be expected 
to result in significant MCI with the experimental setup and protocols used in Chapter 4. However, 
memantine has a fairly long half-life (60 – 100 hours) (Jarvis and Figgitt, 2003). Assuming that 1 
μM memantine is present in the blood, ~ 0.1% of that, or 1 nM, is expected to be uncharged. 
Because uncharged memantine has a high partition coefficient (logP = 3.2 (Mealing et al., 1999)), 
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>99% of uncharged memantine will reside in the membrane rather than in aqueous solution after 
reaching equilibrium. Despite the observation that cells exposed to memantine for 30 s – 4 m show 
similar MCI, it is possible that 4 min is not enough to reach equilibrium. Over hours of continued 
exposure to memantine, membranes in vivo may accumulate a higher concentration of memantine 
than in our experiments. Additionally, physiological conditions are much different from conditions 
in whole-cell patch-clamp recordings. For example, in our recordings cells are internally perfused, 
whereas neurons in vivo contain a complex intracellular milieu that could influence MCI. 
Another important factor in considering the physiological relevance of MCI is the presence 
of ~ 1 mM Mg2+ extracellularly. Continuous Mg2+ presence occludes MCI in GluN1/2A receptors 
in the experimental setup we used (Figure 17). However, this may not be the case under natural 
conditions. In neurons, action potentials cause brief removal of resting Mg2+ block. With 
memantine present in the membrane and NMDARs open, MCI may allow for memantine to 
occupy the deep site before Mg2+ block recurs. Thus, some NMDARs that would normally be 
blocked by Mg2+ would instead be blocked by memantine. Therefore, a drug that participates in 
MCI may compete more effectively with Mg2+ than a drug that exhibits only open channel block.  
Additionally, while the physiological role for memantine MCI is unknown, MCI may be a 
therapeutically relevant mechanism of NMDAR inhibition by compounds we have not yet 
examined. As discussed, PCP shows a greater MCI potency relative to open channel block IC50 
than other compounds tested. Study of additional compounds may reveal molecules with even 
greater relative propensity to participate in MCI. These drugs may prove to be therapeutically 
useful due, in part, to their MCI mechanism. 
Finally, drugs that participate in MCI may have unique therapeutically relevant 
characteristics in addition to their involvement in MCI. For example, the long-lived biological 
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availability of memantine may cause memantine accumulation in intracellular compartments 
(“acid trapping”). This has been shown to regulate the lipid composition of the plasma membrane 
(Honegger et al., 1993). Further, some molecules subject to acid trapping can become packaged 
into synaptic vesicles and may be released at axon terminals (Tucker et al., 2015).  
5.7 Future Directions 
 The conserved tryptophan in the TMD M2 region 
We demonstrated that GluN2B(W607C)-containing receptors show increased potentiation 
by Mg2+ and assumed that this was due to potentiation of receptors through an NTD and exon 5-
dependent mechanism. However, it is worthwhile to examine whether GluN2B(W607C)-
containing receptors show enhanced Mg2+ potentiation when combined with exon 5-lacking 
GluN1 subunits. If indeed the GluN2B(W607C) mutation dramatically influences NTD-dependent 
properties, it would be interesting to explore the mechanisms linking changes in this residue to the 
NTD.  
The experiments that indicated crosslinking between GluN1(W608C) and 
GluN2A(S632C) were not quantitative and gave minimal insight into the frequency of residue 
crosslinking. Although Western blots showed greater relative diheteromer signal in the 
GluN1(W608C)/2A(S632C) lane compared to the WT GluN1/2A lane, and mass spectrometry 
experiments confirmed that crosslinking between GluN1(W608C) and GluN2A(S632C) occurs, it 
is unclear how much of the diheteromer band is due to crosslinking between the introduced 
cysteines. Therefore, to gather data about the frequency of this crosslink, Western blots of cysteine 
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single mutants (GluN1(W608C)/2A and GluN1/2A(S632C)) should also be performed. If the 
diheteromer signal apparent in WT GluN1/2A receptors arises from disulfide crosslinking of 
intracellular proteins at endogenous cysteines, receptors containing mutations at endogenous 
cysteines may show stronger relative diheteromer signal stronger than WT GluN1/2A receptors. 
If the diheteromer band in the GluN1(W608C)/2A(S632C) lane includes substantial protein due 
to crosslinking between these two residues, we would expect that the GluN1(W608C)/2A(S632C) 
lane would show a significantly larger diheteromer to GluN1 monomer ratio than the sum of the 
diheteromer to monomer ratios in GluN1(W608C)/2A, GluN1/2A(S632C) receptors. 
The work in Chapter 2 began with the observation that the tryptophan residue at position 
GluN1(W608) is conserved not only within NMDAR GluN2 subunits, but also within other 
structurally and evolutionarily related channels. We discovered that mutation of the conserved M2 
tryptophan in the GluN1 and GluN2B subunits drastically affects NMDAR gating and block by 
Mg2+. Investigating the effects of mutating the conserved tryptophan in related channels may yield 
further insight into the structural and functional importance of maintaining a tryptophan residue at 
this location. 
 MCI 
Direct exploration of the relationship between membrane accumulation of molecules and 
MCI could link molecule reservoirs in the membrane to NMDAR inhibition. We attempted to 
visualize changes in membrane fluidity associated with application of high memantine 
concentrations to provide further evidence that the membrane provides a reservoir of memantine 
in MCI. Unfortunately, due to technical difficulties, these experiments did not yield interpretable 
results. However, imaging memantine accumulation in the membrane, along with analyzing the 
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time course of memantine accumulation, may strengthen the hypothesis that the membrane serves 
as a drug reservoir in MCI. Additionally, although our experiments suggest that the uncharged 
form of memantine mediates MCI, it is unclear whether charged memantine also plays a role in 
MCI. To explore whether charged memantine contributes to MCI our collaborator Dr. Santiago 
Vazquez synthesized for us a permanently charged version of memantine (trimethylmemantine). 
Trimethylmemantine is structurally identical to memantine apart from the addition of three methyl 
groups at the protonatable amine in memantine. Examining whether trimethylmemantine exhibits 
pH-dependent MCI may lend insight into whether charged memantine is involved in MCI.  
A more complete characterization of MCI dependence on NMDAR subtype and drug 
characteristics may reveal important information about pore-accessible fenestrations in NMDARs. 
Further experiments should be carried out with the drugs shown to participate in MCI, and MCI 
by additional molecules should be examined. We have shown that the GluN2A(M630) residue 
influences memantine MCI. Examining MCI by MK-801, PCP, dextrorphan and RL-208 in 
GluN1/2A(M630A) and GluN1/2A(M630W) receptors is a potential next step in exploring 
whether these drugs interact with the proposed fenestration in a manner similar to memantine. The 
subtype-dependence of the MCI pathway also warrants further exploration. Whether GluN1/2B 
and GluN1/2D receptors exhibit memantine MCI has not been directly tested. Additionally, it is 
unclear whether all receptor subtypes tolerate MCI by the same molecules. Examination of an 
alignment of the GluN2A-D subunit TMDs provides a logical starting point for exploring the 
structural causes of potential subtype-dependent differences in MCI (Figure 28). Finally, based on 
our hypothesis that MCI involves drug accumulation in the membrane and subsequent transit to 
the pore, MCI is likely to vary with agonist concentration and membrane composition. A detailed 
characterization of MCI will improve and expand our understanding of NMDAR inhibition.  
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Figure 28 Sequence alignment of GluN2 TMDs 
Sequence alignment of the TMDs of the rattus norvegicus GluN2A-D subunits. Residues 
highlighted in yellow indicate positions predicted to line the GluN1/2A fenestration that are 
conserved between subunits. Residues highlighted in blue indicate positions predicted to line the 
GluN1/2A fenestration that are not fully conserved between subunits. Residues highlighted in blue 
may give rise to subtype-specific changes in MCI. Figure adapted from Siegler Retchless et al., 
2012. 
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